CA1268458A - Quinolizinone compound, processes for preparation thereof and pharmaceutical composition comprising the same - Google Patents
Quinolizinone compound, processes for preparation thereof and pharmaceutical composition comprising the sameInfo
- Publication number
- CA1268458A CA1268458A CA000491534A CA491534A CA1268458A CA 1268458 A CA1268458 A CA 1268458A CA 000491534 A CA000491534 A CA 000491534A CA 491534 A CA491534 A CA 491534A CA 1268458 A CA1268458 A CA 1268458A
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- salt
- quinolizin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
ABSTRACT
Quinolizinone compounds of the formula:
Quinolizinone compounds of the formula:
Description
~L268~51~
QUINOLIZINONE COMPOUND, PROCESSES FOR
PREPARATION THEREOF AND PHARMACEUTICAL
COMPOSITION COMPRISING THE SAIYE
. - .
; This invention relates to quinolizinone compound and a salt thereof. More particularly, it relates to a new quinolizinone compound and a pharmaceutically acceptable salt thereof which have inhibitory activities on allergy and ulcer,;to processes for preparation thereof, and to a pharmaceutical composition comprising the same.
Accordingly, one object of this invention is to provide the new and useful quinolizinone compound and a pharmaceutically acceptable salt thereof.
Another object of this invention is to provide processes for preparation of said quinolizinone compound and the salt thereof. ~ ;
.
A further object of this invention is to provide :~ :
~.
. -- : :
:~
- ~ :,,:
lZ68~58 a pharmaceutical composition comprising, as an active ingredient, said quinolizinone compound o~ the pharmaceutically acceptable salt thereof.
Still further object of this invention is to provide a therapeutical method for treatment of allergic disease and ulcer in human be:ing and animals.
The quinolizinone compound of this invention can be represented by the following formula (I) :
O (I) wherein Rl is carboxy! amidated carboxy, cyano, thiocarbamoyl or tetrazolyl group;
R7 is hydrogen or aryl;
R2 is hydrogen, hydro~y, lower alkyl or lower alkoxy;
R3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, carboxy, protected carboxy, lower alkenyloxy, aryl which may have suitable substituent(s), arylthio, aroyl, ar(lower)-alkyl, arenesulfonyl, arylamino which may ha~e a suitable substituent or aryloxy; and ;~ R2 and R3 can be located at any place on the 3`~` quinolizinone ring and can be linked together to form -CH2CH2CH2-, -C~=CH- or -CH=CH-CH=CH-.
According to this invention, the object compound (I) can be prepared by the processes as illustrated by the following schemes.
6~
Process 1 :
, 7 Elimination of R2 R R3 the carboxy 2 7 3 \ \ / protective R R R
4 sroup ~
R ~ ~ N ~ COOH
O O
(II) (Ia) or a salt thereof or a salt thereof Process 2 :
~ COOH ,~ ~1 (Ia) (Ib) or its reactive derivative or a salt thereof at the carboxy group or a salt thereof : ` :
Process 3 :
:, :
; R2 R7 R3 R2 R7 R3 ~ ~ CONH .- ~ ~ C~N
: ~
(Ic) (Id) ~ or a salt thereof or a salt thereof : 3:5 . .
..
-.
- . :
Process 4 :
~ ~ C=N Hydrogen s~lfide ~ C-NH
5~ N ~ ~ . ~ ~ N~ ~ 11 2 O O
(Id) (Ie) or a salt thereof or a salt thereof 10Process 5 ~
__ C-N ~ t ~ ~ - N
O - O
(Id) (If) : or a salt thereof or a salt thereof Process 6 :
, .
QUINOLIZINONE COMPOUND, PROCESSES FOR
PREPARATION THEREOF AND PHARMACEUTICAL
COMPOSITION COMPRISING THE SAIYE
. - .
; This invention relates to quinolizinone compound and a salt thereof. More particularly, it relates to a new quinolizinone compound and a pharmaceutically acceptable salt thereof which have inhibitory activities on allergy and ulcer,;to processes for preparation thereof, and to a pharmaceutical composition comprising the same.
Accordingly, one object of this invention is to provide the new and useful quinolizinone compound and a pharmaceutically acceptable salt thereof.
Another object of this invention is to provide processes for preparation of said quinolizinone compound and the salt thereof. ~ ;
.
A further object of this invention is to provide :~ :
~.
. -- : :
:~
- ~ :,,:
lZ68~58 a pharmaceutical composition comprising, as an active ingredient, said quinolizinone compound o~ the pharmaceutically acceptable salt thereof.
Still further object of this invention is to provide a therapeutical method for treatment of allergic disease and ulcer in human be:ing and animals.
The quinolizinone compound of this invention can be represented by the following formula (I) :
O (I) wherein Rl is carboxy! amidated carboxy, cyano, thiocarbamoyl or tetrazolyl group;
R7 is hydrogen or aryl;
R2 is hydrogen, hydro~y, lower alkyl or lower alkoxy;
R3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, carboxy, protected carboxy, lower alkenyloxy, aryl which may have suitable substituent(s), arylthio, aroyl, ar(lower)-alkyl, arenesulfonyl, arylamino which may ha~e a suitable substituent or aryloxy; and ;~ R2 and R3 can be located at any place on the 3`~` quinolizinone ring and can be linked together to form -CH2CH2CH2-, -C~=CH- or -CH=CH-CH=CH-.
According to this invention, the object compound (I) can be prepared by the processes as illustrated by the following schemes.
6~
Process 1 :
, 7 Elimination of R2 R R3 the carboxy 2 7 3 \ \ / protective R R R
4 sroup ~
R ~ ~ N ~ COOH
O O
(II) (Ia) or a salt thereof or a salt thereof Process 2 :
~ COOH ,~ ~1 (Ia) (Ib) or its reactive derivative or a salt thereof at the carboxy group or a salt thereof : ` :
Process 3 :
:, :
; R2 R7 R3 R2 R7 R3 ~ ~ CONH .- ~ ~ C~N
: ~
(Ic) (Id) ~ or a salt thereof or a salt thereof : 3:5 . .
..
-.
- . :
Process 4 :
~ ~ C=N Hydrogen s~lfide ~ C-NH
5~ N ~ ~ . ~ ~ N~ ~ 11 2 O O
(Id) (Ie) or a salt thereof or a salt thereof 10Process 5 ~
__ C-N ~ t ~ ~ - N
O - O
(Id) (If) : or a salt thereof or a salt thereof Process 6 :
, .
2 7 3 Elimlnation of R R /Ra the carboxyR2 R7 COOH
1 protectiva gro~p :
` (Ig) (Ih) .`~. 25 or a salt thereof or a salt thereof ~ whexein R2, R3 and R7 are each as defined above, :~ Ra is amidated carboxy, and ~. 3U~ R4 and R3~are each protected carboxy.
:: Among the starting compounds~n the present ~ invention, the compound (II) can be prepared by the : processes which are illustrated:in the following ~ 35 schemes. :
: .
:.. .;~.. :.: - ~
Process A ~
2 - 4 ~ 5 10(III) (V) or a salt thereof or a salt thereof Process A - (2) :
: 15 2 R
R ~ Ring closure R ~
N ~ R6 reaction~ N ~ R4 - R4 ~ R5 O
R4 (IIa) (V) or a salt thereof or a salt thereof : Process B - (1) :
~ .
:~
1 protectiva gro~p :
` (Ig) (Ih) .`~. 25 or a salt thereof or a salt thereof ~ whexein R2, R3 and R7 are each as defined above, :~ Ra is amidated carboxy, and ~. 3U~ R4 and R3~are each protected carboxy.
:: Among the starting compounds~n the present ~ invention, the compound (II) can be prepared by the : processes which are illustrated:in the following ~ 35 schemes. :
: .
:.. .;~.. :.: - ~
Process A ~
2 - 4 ~ 5 10(III) (V) or a salt thereof or a salt thereof Process A - (2) :
: 15 2 R
R ~ Ring closure R ~
N ~ R6 reaction~ N ~ R4 - R4 ~ R5 O
R4 (IIa) (V) or a salt thereof or a salt thereof : Process B - (1) :
~ .
:~
3~ CH ~ ~ H
(IIIc) (~c) ~5 or a sa7t: theFeof or a salt thereof ': ~
: - . .
~: , , ~ ~ .. ..
~Z63~4S8 Process B - ~2) :
-C CH~ ~
/ H~Ring closure \\ ~ R6reaction CH ~ ~ ~
~ ~ ~ R4 J
R4 ~ R5 R4 (IIh) ~c) or a salt thereof or a salt thereof Process C ~
R R
- ~ CH ) (IV) ~ (CH ) :~ N 2 n . __~N ~ 2 n R ~ R5 (IIIa) ~4 or- a salt thereof (Va) or a salt thereof Process C - (2) :
: ~ (CH2)n ,G~ Ring closure ~
(CH2)n r = ~ ~ R4 R4 ~ 5 O
R
R (IIb):
or a salt thereof : (Va) or a salt thereof ..
Process D - tl) :
(IIIc) (~c) ~5 or a sa7t: theFeof or a salt thereof ': ~
: - . .
~: , , ~ ~ .. ..
~Z63~4S8 Process B - ~2) :
-C CH~ ~
/ H~Ring closure \\ ~ R6reaction CH ~ ~ ~
~ ~ ~ R4 J
R4 ~ R5 R4 (IIh) ~c) or a salt thereof or a salt thereof Process C ~
R R
- ~ CH ) (IV) ~ (CH ) :~ N 2 n . __~N ~ 2 n R ~ R5 (IIIa) ~4 or- a salt thereof (Va) or a salt thereof Process C - (2) :
: ~ (CH2)n ,G~ Ring closure ~
(CH2)n r = ~ ~ R4 R4 ~ 5 O
R
R (IIb):
or a salt thereof : (Va) or a salt thereof ..
Process D - tl) :
4/~==~ 5 ~ R4 (Iva) N ~
2 ~ R5 (IIIb) (Vb) 10or a salt thereof or a salt thereof Process D - t2) :
~ 4 Ring closure ~N ~ R reactiOn ~ N
R4 ~ R5 O
(IIc) H
or a salt thereof (Vb) or a salt thereof .:
Process E :
~ :;
R6 Introduction of R~
- :the hydroxy ~
prote-c~iv~gro:up Rg ~ ~ ~ :
30HO ~N ~ R4 ~ ' ~N ~ R4 ~ O
(XId) (IIe) or a salt thereof or a salt thereof :' :
':
- ~ - . ' . : , , . :
.. . ...
:
:...: -s~
Process F :
.
~ F~
~ ~ ~ Oxidation R4 ~ ~ ~ R4 . O
(IIf) (IIg) or a salt thereo or a salt thereof Process G :
, Introduction of the hydroxy ~ protective group ~N~cH2oH ~:H20R8 ` 20 (IIId) (IIIe) : or a salt thereof or a salt thereof , .
Process H : ~ ~
: :;
: 25 Elimination of 8 the hydroxy OR :: pro~ective ~ :~OH
~ ; group ~N~ R ~ ~R4 ~ ~
~ ~: :
, :
:~ or a salt thereof : or a salt thereof ~ 35 i : ~
~ :: :
,.: : : :
. .
. :: ., : . . - : :. , , ~ -. .
Processl S Oxidation SO2 . ~ ~ ~ R4 O O
(IIj) (IIk) -- , or a salt thereof or a salt thereof (to be continued to the next page.) ~;
: :
3~ :
: :
: : :
_.
' :.~
, . .
~Ei8~
wherein R2, R- and R are each as defined above, R is lower al~oxy, R6 is hydrogen, protected hydroxy, lower alkyl, lower alkoxy, carboxy, protected carboxy, lower alkenyloxy, aryl which may have suitable substituent(s), arylthio, aroyl, ar(lower)-alkyl, arenesulfonyl, arylamino which may have a suitable substituent or aryloxy, R8 is hydroxy protective group, R9 is protected hydroxy and n is 1 or 2.
Suitable pharmaceutically acceptable salts of the object compounds (I) are conventional non-toxic salt and include an acid addition salt such as an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenasulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, nitrate, phosphate, ~tc.),~or a salt with an amino acid (e.g. arginine, aspartic acid, glutamic ~; acid, etc.), or a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, ; 25 magnesium salt, etc.?, an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine ~ -salt, pyridine salt, picoline saltj dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), or the like.
3~
In the above and subsequent descriptions of the present speci~ication, suitable examples and illustrations of the various definitions which the present invention include within the scope thereof are explained in detail as follows.
.: :
:
"., , ' ~: ., ., : : ,, , -. - : .:
9 ~ 34S~
The term "lower" is intended to mean 1 to 6 carbon atoms, unless otherwise indicated.
Suitable "lower alkyl" and "lower alkyl" moiety in "ar(lower)alkyl" may include straight or branched one, having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl or ~he like.
Suitable "lower alkoxy" may include methoxy, ~0 ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pen~yloxy, hexyloxy, and the like, preferably one having 1 to 4 carbon atom(s).
Suitable "lower alkenyloxy" may include vinyloxy, l-propenyloxy, allyloxy, l-butenyloxy, 2-butenyloxy, 2-pentenyloxy, and the like, preferably ones having 2 to 4 carbon atoms.
Suitable-"protected carboxy" may include esterified carboxy wherein "esterified carboxy" can be referred to the ones as mentioned below.
Suitable examples of the ester moiety of an esterified carboxy may be the ones such as lower alkyl ester (e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, l-cyclopropylethyl ester, etc.) which may have at least one suitable substituent(s), for example, lower alkanoyloxy(lower)-~0; alkyl ester [e.g~ acetoxymethyl es~er, propionyloxy-~ methyl ester, butyryIoxymethyl ester, valer~loxymethyl ;~ ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, l(or 2)-~cetoxyethyl ester, l(or Z or 3)-acetoxypropyl ester, l(or 2 or 3 or 4)-acetoxybutyl ester, l(or 2)-propionyloxyethyl ester, I(or 2 or 3)-propionyloxypropyl 8~
ester, l(or 2)-butyryloxyethyl ester, l(or 2)-isobutyryloxyethyl ester, l(or 2)-pivaloyloxyethyl ester, l(or 2)-hexanoyloxyethyl ester, isobutyryloxy-methyl ester, 2-ethylbutyryloxymethyl ester, 3,3-dimethylbutyryloxymethyl ester, l(or 2)-pentanoyloxyethyl ester, etc.] lower alkanesulfonyl(lower)alkyl ester (e.g.
2-mesylethyl ester, etc.), mono(or di or tri)-halo(lower)alkyl ester (e.g.
2- odoethyl ester, 2,2,2-trichloroethyl ester, etc.), lower alkoxycarbonyloxy(lower)alkyl ester (e.g.
methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, 2-methoxycarbonyloxyethyl ester, l-ethoxycarbonyl-oxyethyl ester, l-isopropoxycarbonyloxyethyl ester, etc.), phthalidylidene(lower)alkyl ester, or - 15 (5-lo~er alkyl-2-oxo-1,3-dioxol-4-yl)(lower)alkyl ester [e.g. (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester, (S-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-propyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, etc.];
lower alkenyl ester (e.g. vinyl ester, allyl ester, etc.);
lower alkynyl ester (e.g. ethynyl ester, propynyl ester, etc.);
ar(lower)alkyl ester which may have at least one suitable substituent(s) (e.g. benzyl ester, 4-; 25 methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxyben~yl ester, 4-hydroxy-3,5-di-tert-butylbenzyl ester, etc.);
aryl ester which may have at least one suitable substituent(s) (e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, ; mesityl ester, cumenyl ester, etc.);
phthalidyl ester; and the like.
:, Preferable examples of the esteri~ied caxboxy .. ..
, .
: .:
. .. . ..
:, :
.
. .:: .: . .
z~s~
as mentioned above may include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarb~nyl, isobutoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, tert-pentyloxy-carbonyl, hexyloxycarbonyl, l-cyclopropylethoxycarbonyl, etc.).
Suitable "amidated carboxy" may include amide (-CONH2) which may have suitable substituent(s) on the nitrogen atom, wherein said substituent(s) may in~lude heterocyclic group which may have suitable substituent(s), aryl which may have suitable substituent(s) as mentioned below, and the like.
"Heterocyclic group" as mentioned above means, in detail, saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one hetero-atom such as an oxygen, sulfur, nitrogen atom and the like.
And, especially preferably heterocyclic group may be heterocyclic group such as unsaturated 3 to 8-membered more preferably 5 or 6-membered heteromonocyclic group containing l to 4-nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyrid~l and its N-oxide, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-l,Z,4-triazolyl, lH-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. lH-tetrazolyl, 2H-tetrazolyl, etc.), triazinyl (e.g.
1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, etc.), etc.;
saturated 3 to 8-membered (more preferably 5 or 6-membered)heteromonocyclic group containing l to 4 ` nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.;
::
:~68~S8 unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.;
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, syndonyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6-membered)heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g. 1,2,3-thiadia~olyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to ~
sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;
; unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydrodithiinyl, ~ 30 dihydrodithionyl, etc.;
unsaturated condensed heterocyclic group containing : 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for e~ample, benzothiazolyl, benzothiadiazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 to 6-mem~ered) heteromonocyclic group containing an oxygen . .
. :: ' :.: :
: -. . .
.:
~ :
~:61~4S8 atom, for example, furyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6-meFmbered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;
unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc. and the like, wherein said "heterocyclic group" may have one or more suitable substituent(s) such as halogen (e.g., chlorine, bromine, iodine or fluorine), lower alkyl (e.g., methyl, ethyl, propyl, etc.) as stated above, amino, or the like.
Suitable "protected hydroxy" may include a hydroxy group protected by a conventional hydroxy-protectiva group, for example, lower alkyl (e.g. methyl, ethyl, propyl, n-butyl, etc.), lower alkenyl (a.g. vinyl, allyl, etc.), ar(lower)alkyl such as mono- or di- or triphenyl(lower)alkyl (e.g. benzyl, benzhydryl, trityl, etc.), etc., trisubstituted silyl such as tri(lower)-alkylsilyl (e.g. trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, diisopropylmethylsilyl, etc ), triarylsilyl (e.g.
triphenylsilyl, etc.), triar(lower)alkylsilyl (e.g.
tribenzylsilyl, etc.), etc., and the like.
~:;
Suitable "aryl" may include phenyl, tolyl, xylyl, cumenyl, naphthyl, biphenylyl, and the like, which may have one or more suitable substituent(s) such as amino, nitro, halogen (e.g. fluorine, chlorine, bromine, iodine, etc.), lower alkoxy as exemplified above, carboxy, a protected carboxy group as exemplified above, hydroxy, and the like.
';
13 1 126Ei~58 Suitable "aryl" moiety in the terms "arylthio", "ar(lower)alkyl" and "arylamino" can be referred to the ones as exemplified above.
Suitable "aroyl" may include benzoyl, toluoyl, naphthoyl, and the like.
Suitable "arenesulfonyl" may include benzenesulfonyl, p-toluenesulfonyl, and the like.
The aforesaid "arylamino" may have a suitable substituent such as lower alkyl (e.g. methyl, ethyl, etc.) on the nitrogen atom, and the like.
Suitable "aryloxy" may include phenoxy, tolyloxy, and the like.
Suitable "hydroxy protective group" can be referred to the ones as exemplified above.
Preferable "amidated carboxy" may be carbamoyl, pyridylamido, pyrimidinylamido which may have lower alkyl, pyrazinylamido, phenylamido which may have ~ hydroxy, thiazolylamido, triazinylamido, triazolylamido `~ 25 which may have amino, pyridazinylamido which may have halogen, or tetrazolylamido, or the like.
The processes for preparing the object compounds (I) of the present invention are ~xplained in detail in the following.
Process 1 :
-- .. _ . .
The object compound (Ia) or a salt thereof can be ~;
- :
.~.,., ' ~ ~
`' , ~, ', '~ ' ~2~
prepared by subjecting the compound (II) or a salt thereof to elimination reaction of the carboxy protective group.
Suitable salt of the compound (II) can be referred to the acid addition salt exemplified for the compound (I) and suitable salt of the compound (Ia) can be referred to the ones as exemplified for the compound (I).
In the present elimination reaction, all conventional methods used in the elimination reaction of the carboxy protective group, for example, hydrolysis, reduction, elimination using Lewis acid, etc. are applicable.
When the carboxy protective group is an ester, it can be eliminated by hydrolysis or elimination using Lewis acid.
The hydrolysis is preferably carried out in the presence of a base or an acid.
Suitable base may include, for example, an inorganic base such as alkali metal hydroxide (e~g. sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.y. magnesium hydroxide, calcium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g. magnesium carbonate, calcium carbonate, etc.), alkali metal bicarbonate (e.g. sodium bicarbonate, potassium bicarbonate, etc.), alkali metal acetate (e.g. sodium acetate, potassium acetate, etc.), alkaline earth metal phosphate (e.g. magnesium phosphate, calcium phosphate, etc.), alkali metal hydrogen phosphate (e.g. disodium hydrogen phosphate, dipotassium hydrogen phosphate, etc.), or the like, and an organic base such as trialkylamine (e.g. trimethylamine, triethylamine~ etc.), picoline, N-methylpyrrolidine, N-methylmorpholine, I,5-diazabicyclo[4,3,0]non-5-one, , : : . ~,:, .
~ 15 -~8~S8 1,4-diazabicyclo[2,2,2]octane, 1,5-diazabicyclo-[5,4,0]undecene-5 or the like. The hydrolysis using a base is often carried out in water or a hydrophilic organic solvent or a mixed solvent thereof.
Suitable acid may include an organic acid (e.g.
formic acid, acetic acid, propionic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.).
The presPnt hydrolysis is usually carried out in an organic solvent, water or a mixed solvent thereof.
The reaction temperature is not critical, and it may suitable be selected in accordance with the kind of the carboxy protectiva group and the elimination method.
The elimination using Lewis acid is preferable to eliminate substituted or unsubstituted ar(lower)-alkyl ester and carried out by reacting the compound (II) or a salt thereof with Lewis acid such as boron trihalide te.g. boron trichloride, boron trifluoride, etc.), titanium tetrahalide (e.g. titanium tetra-chloride, titanium tetrabromide, etc.), tin tetrahalide (e.g. tin tetrachloride, tin tetrabromide etc.), aluminum halide (e.g. aluminum chloride, aluminum bromide, etc.), trihaloacetic acid (e.g. trichloro-acetic acid, trifluoroacetic acid, etc.) or the like.This elimination reaction is preferably carried out in the presence of cation trapping agents (e.g.
anisole, phenol, etc.) and is usually carried out in a solvent such as nitroalkane (e.g. nitromethane, 3~ nitroethane, etc.), alkylene halide (e.g. methylene chloride, ethylene chloride, e~c.), diethyl ether, carbon disulfide or any other solvent which does not adversely affect the reaction. These solvents may be used as a mixture thereof.
:
~- . : ~ , . : .. ,, ~ ,. . : . . . .. ..
- ' ~
` ,. ' ;:, ~' ~ ' ,' : -.; :: .. ~,. :
- 16 ~ 84S~
The reduction elimination can be applied preferably for elimination of the protective group such as halo(lower)-alkyl (e.g. 2-iodoethyl, 2,2,2-trichloroethyl, etc.) ester, ar(lower)alkyl (e.g. benzyl, etc.) ester or the like.
The reduction method applicable for the elimination reaction may include, for example, reduction by using a combination of a metal (e.g. zinc, zinc amal~am, etc.) or a salt of chromium compound (e.g. chromous chloride, chromous acetate, etc.) and an organic or an inorganic acid (e.g. acetic acid, propionic acid, hydrochloric acid, etc.); and conventional catalytic reduction in the presence of a conventional metallic catalyst (e.g.
palladium carbon, Raney nickel, etc.).
The reaction temperature is not critical, and the reaction is usually carried out under cooling, at ambient temperature or under warming.
The present elimination reaction of the carboxy protective group includes, within its scope, the case that another protected carboxy are converted into free carboxy during the reaction or the post-treating step of - the present process.
;:
; Process 2 :
The object compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or its reactive derivative at the carboxy group or a salt thereof to amidation reaction.
Suitable salt of the compound (Ib) can be referred to the salt exemplified for the compound (I).
The amidating agent to be used in the present amidation reaction may include amine which may have suitable substituent(s) such as heterocyclic group which may have suitable substituent(s) or aryl which may have su:Ltable substituent(s) on the nitrogen atom.
,.
..:
- ~ : , . . .
' '~
: . . .
. : ,. ~
Suitable reactive derivative at the carboxy group of the compound (Ia) may include an acid halide, an acid anhydride, an activated ester, and the like.
The suitable example ma~ be an acid chloride, an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulforous acid, thio-sulfuric acid, sulfuric acid, alkylcarbonic acid,aliphatic carboxylic acid (e~g. pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid or trichloroacetic acid, etc.) or aromatic carboxylic acid (e.g. benzoic acid, etc.); a symmetrical acid anhydride;
or an acitvated ester (e.g. cyanomethyl ester, methoxy-methyl ester, dimethyliminomethyl [(CH3)2~=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, ; pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.), or an ester with a N-hydroxy compound (e.g. N,N-dimethylhydroxylamine, l-hydroxy-2-( lH)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, l-hydroxy-6-chloro-lH-benzotriazole, etc.), and the like.
When the compound (Ia) is used in a free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, l,l'-carbonyldi-imidazole, thionyl chloride, oxalyl chloride, lower alkoxycarbonyl halide [e.g. ethyl chloroformate, isobutyl :, , : ` . -- 18 ~ 1 Z ~ 8 ~ 8 chloro~ormate, etc.], l-(p-chlorobenzenesulfonyloxy)-6-chloro-lH-benzotriazole, or the like.
The reaction is usually carried out in a conventional solvent such as water, acetone, dio~ane, chloroform, methylene chloride,ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. Among these solvents, hydrophilic solvents may be used in a mixture with water.
The reaction in the presence of a condensing agent is usually carried out in an anhydrous, but not critical conditions.
The reaction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), an alkali metal bicarbonate (e.g. sodium bicarbonate, potassium bicarbonate, etc.), tri(lower)alkylamine (e.g.
trimethylamine, triethylamine etc.), pyridine or its derivative (e.g. picoline, lutidine, 4-dimethylaminopyridine, etc.), or the like. In case that the base or the condensing agent to be used is in liquid t it can be used also as a solvent.
The reaction temperature is not critical, and the reaction is usually carried out under heating or under warming, preferably under heating.
Process 3 :
The object compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof .
.. . ~ : ~ . ., :
,. . :
-: .
' ' ' ,,,~ ~ ,- '. ' `' :' . -.
~68q~S~
to dehydration reaction.
The dehydrating agent to be used in this dehvdration ; reaction may include phosphory] chloride, thionyl chloride, phosphorus pentoxide, phosphorus pentachloride,phosphorus pentabromide and the like.
The present reaction is usually carried out in a solvent such as dioxane, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydro-furan, pyridine, aceto-nitrile, dimethylfoxmamide or any other solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or heating.
Process 4 :
The object compound (Ie) or a salt thereof can be ~0 prepared by reacting the compound (Id) or a salt thereof with hydrogen sulfide.
The present reaction is usually carried out in a solvent such as dioxane, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydrouran, pyridine, aceto-nitrile, dimethylformamide or any other solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or heating.
Process 5 :
The object compound (If~ or a salt thereof can be prepared by subjecting the compound (Id~ or a salt thereof ~`
- 20 - ~ ~68~
to the formation reaction of a tetrazole group.
Suitable salt of the compound ~If) and (Id) can be referred to the acid addition salt exemplified for the compound (I) The agent to be used in the pres~nt reaction may include conventional ones such as combination of alkali metal azide (e.g., potassium azide, sodium azide etc.) and ammonium halide (e.g. ammoni~ chloride), or the like.
The present reaction is usually carried out in a solvent such as dioxane, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydrofuran, pyridine, acetonitrile, dimethylformamide or any other solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the reaction is usually carried out under warming or heating.
Process 6 :
The compound ~Ih) or a salt thereof can be prepared by subjecting the compound (Ig) or a salt thereof to elimination reaction of the carboxy protective group.
Suitable salts of the compounds (Ig) and (Ih) can be referred to the salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process 1 as mentioned above, and therefore the reaction modes and conditions (e.g. reaction temperature, solvent, etc.) are referred to those of Process 1.
Process A ~
~ , .
The compound (V) or a salt thereof can be prepared by reacting the compound (III) or a salt thereof with the compound (IV).
Suitable salts of the compounds(III) and (V) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be preferably carried out in the presence of alkyl lithium (e.g., n-butyl lithium), ~5 lithium dii.sopropylamide, alkalimetal aIkoxide (e.g., sodium methoxide, sodium ethoxide etc.) and the like.
-.:, ., , , : - ., :; : . , - -: - . .. .
:., .. ... :. .. :
, , : ~ :
The present reaction is usually carried out in a solvent such as acetone, dioxane, acetonitrile, dimethylformamide, benzene, hexane, chloroform, methylene chloride, ethylene chloride, ~etrahydrofuran, ethyl acetate, or any other so:Lvent which does not adversely affect the reaction.
The reaction temperature ls not critical and the reaction is usually carried out: under cooling, at ambient temperature or under heating.
Process A - (2) :
The compound (IIa) or a salt thereof can be prepared by subjecting the compound (V) or a salt thereof to ring closure reaction.
Suitable salt of the compound (V) can be referred to the acid addition salt exemplified for the compound (I).
The present reaction may preferably be carried out in the presence of a suitable agent such as the mixture of diphenyl and diphenylether, which is used as heating medium.
The reaction temperature is not critical and the reaction is usually carried out under heating.
Process B ~
The compound (Vc) or a salt thereof can be prepared by reacting the compound (IIIc) or a salt thereof with the compound (IV).
Suitable salts of the compounds (Vc) and (IIIc) can be referred to the acid addition salts exemplified for the compound (I~.
::~
:, ~..., ~ -,~
- 22 ~ ~2684S~
The present reaction can be carried out in a similax manner to that of Process A ~ as mentioned above.
Process B - (2) :
_ _ _ The compound (IIh) or a salt thereof can be prepared by subjecting the compound (Vc) or a salt thereof to ring closure reaction.
Suitable salts of the compound (IIh) and (Vc) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process A - (2) as mentioned above.
Process C - (1) :
The compound (Va) or a salt thereof can be prepared by reacting the compound (IIIa) or a salt thereof with the compound (IV).
Suitable salts of the compound (IIIa) and (Va) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process A - (1) as mentioned above.
Process C - (2) :
; .
The compound (IIb) or a salt thereof can be prepared ~0~ by subjecting the compound (Va) or a salt thereof to ring closure reaction.
Suitable salts of the compound (IIb) and (Va) can be referred to t:he acid addition salts exemplifed for the ~5~ compound (I).
:.~
:' . ' ~ , :. -~ . : ,., :
.
~68~S~i3 The present reaction can be carried out in a similar manner to that of Process A - (2) as mentioned above.
Process D ~
The compound (Vb) or a salt thereof can be prepared by reacting the compound (IIIb) or a salt thereof with the compound (IVa).
Suitable salts of the compounds (IIIb~ and (Vb) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process A - (1) as mentioned above.
Process D - (2) :
.
- 15 The compound (IIc) or a salt thereof can be prepared by subjecting the compound (Vb) or a salt thereof to ring closure reaction.
Suitable salts o the compounds (IIc) and (Vb) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a simllar manner to that of Process A - (2) as mentioned above.
Process E :
The object compound (IIe) or a salt thereof can be prepared by subjecting the compound (IId) or a salt thereof to introduction reaction of the hydroxy protective group.
Suitable salt of the compounds (IId) and (IIe) 3~ can be referred to the acid addition salts as exemplified for the compound (I).
In case that the protective group to be introduced are lower alkyl or lower alkenyl, the reaction can be carried out by reacting the compound (IId) with lower 3S alkylating agent or lower alkylating agent.
' ~ .
' .
: ,.'-: : . -..
- 24 ~ ~Z68~
The lower alkylating agent or lower alkenylating agent to be used in the present reaction may include conventional one such as mono(or di)lower alkyl sulfate (e.g. dimethyl sulfate, etc.), lower alkyl(lower)-alkanesulfonate (e.g. methyl methanesulfonate, etc.), halo(lower)alkane (e.g. bromomethane, iodomethane, iodoethane,iodobutane etc.), halo(lower)alk.ene (e.g.
iodopropene etc.) or the like.
When lower alkyl ester of an acid is used as a lower alkylating agent, the reaction is usually carried out in a solvent such as water, acetone, tetrahydrofuran, ethanol, ether, dimethylformamide or any other solvent which does not adversely influence the reaction.
The present reaction is preferably carried out in the present of a conventional base such as an inorganic base or an organic base.
The reaction temperature is not critical and the reaction is usually carried out under cooling to heating around boiling point of the solvent.
ZO
Process F :
The compound (IIg) or a salt thereof can be prepared by subjecting the compound (IIf) or a salt thereof to oxidation reaction.
Z5 Suitable salt of the compound (IIf) can be referred to the acid addition salt exempli~ied for the compound (I).
~uitable oxidizing agent to be used in this oxidation reaction may include conventional ones such as 2,3-dichloro-5,6-dicyano-1,4-benzoquinone ~DDQ), : ~a and the like.
The present o~idation is carried out with solvent such as benzene, toluene, chloroform, methylene chloride, carbon tetrachloride, diethyl ether, dimethylformamide or any other solvent which does not adversely affect ~5~ the reaction, and the solvent is optionally selected .
- -~.: - - . ~ -:,. : - ~ : . :
.: ~: ~. -, :,.. i. , .
: -, :
.. .. - ~, - 25 - ~ ~6~5~
according to a kind of oxidizing a~ent to be used.
The reaction temperature of the oxidation reaction oftthis process is not critical, and the reaction is carried out under coolin~, at ambient temperature, under warming or under heating. The reaction temperature is optionally selected according to a kind of oxidizing agent to be used.
Process G :
The compound (IIIe) or a salt thereof can be prepared by subjecting the compound (IIId) or a salt thereof to introduction reaction of the hydroxy protective group.
The present reaction can be carried out in a conventional manner.
In case that the protective group to be introduced is a silyl group, the present reaction is carried out by reacting the compound (IIId) or a salt thereof with the compound of the formula :
Ra - X (VI) wherein Ra is a trisubstituted silyl and X is an acid residue.
.
Suitable acid residue may include halogen (e.g., chlorine, bromine; etc.) or the like.
The present reaction is preferably carried out in the presence or imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole.
~o The reaction is usually carried out in a conventional~
solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetatP, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
. .
.
.,..: .
.: ;~
:
' ~ , .
:
. .
:. , - ~ . ~ , ~, ,,...... , .. :
- , 25 1 ~ 2 6~ ~ S ~
The reaction temperature is not critical and the reaction is usually carried out under cooling, at ambient temperature or under warminy.
Process H :
The compound (IIi) or a salt thereof can be prepared ~y subjecting the compound (IIh) or a salt thereof to elimination reaction of the hydroxy protective group.
The present elimination reaction is carried out in accordance with a conventional method such as Process 1.
The present reactlon is preferably carried out in the presence of a mild reagent such as tetra-n-butylammonium fluoride.
The reac~ion is usually carried out in a con-ventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
The reaction temperature is not critical and the reaction is usually carried out under cooling, at ambient temperature or under warming.
- (to be continued to the next page.) :
:`
3~
: :
:' .. . : .
:- , -~2~ 58 ~roceSs I
The object compound (IIk) or a salt thereof can be prepared by oxidizing the compound (IIj) or a salt - thereof.
The oxidizing agent to be used in this reaction may include an inorganic peracid or a salt thereof (e.g. periodic acid, persulfuric acid, or sodium or potassium salt thereof, etc.), an organic peracid or a salt thereof (e.g. perbenzoic acid, m chloro-perbenzoic acid, performic acid, peracetic acid, chloroperacetic acid, trifluoroperacetic acid, or sodium or potassium salt thereof, etc.), ozone, hydrogen peroxide, urea-hydrogen peroxide, N-halosuccinimide (e.g. N-bromosuccinimide, N-chloro-succinimide, etc.), hypochlorite compound (e.g.
tert-butyl hypochlorite, etc.), permanganate (e.g.
potassium permanganate, etc.), or any other conventional oxidizing agent which can oxidide a sulfinyl group to a sulfonyl group.
The present reaction can also be carried out in the presence of a compound comprising Group Vb or VIb metal in the Periodic Table of elements, for example, tungstic acid, molybdic acid, vanadic acid, etc., or an alkali or an alkaline earth metal salt thereof.
The present oxidation reaction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, acetic acid, chloroform, methylene chloride, acetone, methanol, ethanol or a mixture thereof.
The reaction temperature is not critical and the reaction is preferably carried out under cooling to at ambient temperature.
. .
.
:
, :
'; ' ; : ': . : ' :
~ , " , ;8~
Particularly, the compounds (I) possessing the most potent antimicrobial activity can be represented by the following formula:
Ri R3 R2f~N ~1 wherein Rl, R2, R3 and R7 are each as defined above, and more particularly, Rl is tetrazolylamido, R2 and R7 are each hydrogen, and R3 is aryloxy or aroyl.
(to be continued to the next page.) , ~ ~ , .:
. 30 :
,~
:
:~
~: .. : ::. .: .
. . ~ : : :: . .
' 1'.', . . . .. , - . .
lZ684~
For the purpose of showing pharmaceutical utility of the quinolizinone compound (I), pharmaceutical test data thereof are illustrated in the following.
S [1] Test compound :
N-[5-(lH-Tetrazolyl)l-4H-quinolizin-4-one-3-carboxamide (hereinafter referred to as compound ~ ) ..
N-[5-(lH-Tetrazolyl)]-l-phenyl-4H-quinolizin-4-one-3-carboxamide (here:inafter referred to as compound ~ ) [2] Test :
(A) Inhibition on stress ulcer Test Method :
Sprague-Dawley rats weighing about 200 g were used.
Each animal was immobilized in a small cage and put in - a water bath allowing to respire. The temperature of the water bath kept at 22C. The test compound ~ and X were administered orally just before the immobilization.
Seven hours la~er, the animals were sacrificed ~nd their stomachs were removed. The stomach was then ; fixed with 2% formalin. The area of ulcers was measured for each animal. The mean area (mm2) in the test animals was compared with that in the control animals. ;
~ ~a :
`: :
.
.
.
:126~5~
Test Result :
" Ulcer index .
. Treatment No. -'2 . Inh.
1 19 Mean + S.E. .
~ ~ 19.2 + ~.8 Compound ~ 2 5 L~ 6.~ + 3.0 67 .7 _ _ . ~ ~ _ .
: Ulcer index : Treatment No. 2 . . Inh. %
mm Mean~+ S.E.
Control ~ ~ 48.4 + 3~3 ~ 1 10 . ~ . _ `~: Compound ~ : 2 ll :
3 3 8.4 ~ 1.9 83.7 3s ~ ~
~ r:
' ~
~ ' ` ' ,' '~ . . ..
. . ',1 : .
` . .
,~ . , ': '.
~Z~i8458 (B) Effect on passive cutaneous anaphylaxis (PCA).
~ Test Method Recipient animals for PCA reactions were female Sprague-Dawley rats, 7 weeks old, 180g-200g (Nihon Kurea).
Each experiment included 5 observations.
Five times crystallized ovalbumin (OVA) (Sigma Lot, 31F-8061) was used as antigen.
Female BDFl mice, 7 weeks old (Nihon Kurea~, were - given a primary injection (lefl foot pad, s.c.) of 100 mcg OVA in 0.05ml saline and after 20 days a booster injection by the same route. Blood was collected 28 - days after the primary injection and the sera were stored at -80C.
The animals were shared with an electric clipper in advance and prepared for Passive Cutaneous Anaphylaxis - (PCA) by injecting 0.05ml of mouse antiserum dilutions (1/16, 1/32) in each side of the dorsal skin.
They were then challenged 48 hours later with an intravenous injection of 1 ml of 0.5% Evans Blue containing
2 ~ R5 (IIIb) (Vb) 10or a salt thereof or a salt thereof Process D - t2) :
~ 4 Ring closure ~N ~ R reactiOn ~ N
R4 ~ R5 O
(IIc) H
or a salt thereof (Vb) or a salt thereof .:
Process E :
~ :;
R6 Introduction of R~
- :the hydroxy ~
prote-c~iv~gro:up Rg ~ ~ ~ :
30HO ~N ~ R4 ~ ' ~N ~ R4 ~ O
(XId) (IIe) or a salt thereof or a salt thereof :' :
':
- ~ - . ' . : , , . :
.. . ...
:
:...: -s~
Process F :
.
~ F~
~ ~ ~ Oxidation R4 ~ ~ ~ R4 . O
(IIf) (IIg) or a salt thereo or a salt thereof Process G :
, Introduction of the hydroxy ~ protective group ~N~cH2oH ~:H20R8 ` 20 (IIId) (IIIe) : or a salt thereof or a salt thereof , .
Process H : ~ ~
: :;
: 25 Elimination of 8 the hydroxy OR :: pro~ective ~ :~OH
~ ; group ~N~ R ~ ~R4 ~ ~
~ ~: :
, :
:~ or a salt thereof : or a salt thereof ~ 35 i : ~
~ :: :
,.: : : :
. .
. :: ., : . . - : :. , , ~ -. .
Processl S Oxidation SO2 . ~ ~ ~ R4 O O
(IIj) (IIk) -- , or a salt thereof or a salt thereof (to be continued to the next page.) ~;
: :
3~ :
: :
: : :
_.
' :.~
, . .
~Ei8~
wherein R2, R- and R are each as defined above, R is lower al~oxy, R6 is hydrogen, protected hydroxy, lower alkyl, lower alkoxy, carboxy, protected carboxy, lower alkenyloxy, aryl which may have suitable substituent(s), arylthio, aroyl, ar(lower)-alkyl, arenesulfonyl, arylamino which may have a suitable substituent or aryloxy, R8 is hydroxy protective group, R9 is protected hydroxy and n is 1 or 2.
Suitable pharmaceutically acceptable salts of the object compounds (I) are conventional non-toxic salt and include an acid addition salt such as an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenasulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, nitrate, phosphate, ~tc.),~or a salt with an amino acid (e.g. arginine, aspartic acid, glutamic ~; acid, etc.), or a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, ; 25 magnesium salt, etc.?, an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine ~ -salt, pyridine salt, picoline saltj dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), or the like.
3~
In the above and subsequent descriptions of the present speci~ication, suitable examples and illustrations of the various definitions which the present invention include within the scope thereof are explained in detail as follows.
.: :
:
"., , ' ~: ., ., : : ,, , -. - : .:
9 ~ 34S~
The term "lower" is intended to mean 1 to 6 carbon atoms, unless otherwise indicated.
Suitable "lower alkyl" and "lower alkyl" moiety in "ar(lower)alkyl" may include straight or branched one, having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl or ~he like.
Suitable "lower alkoxy" may include methoxy, ~0 ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pen~yloxy, hexyloxy, and the like, preferably one having 1 to 4 carbon atom(s).
Suitable "lower alkenyloxy" may include vinyloxy, l-propenyloxy, allyloxy, l-butenyloxy, 2-butenyloxy, 2-pentenyloxy, and the like, preferably ones having 2 to 4 carbon atoms.
Suitable-"protected carboxy" may include esterified carboxy wherein "esterified carboxy" can be referred to the ones as mentioned below.
Suitable examples of the ester moiety of an esterified carboxy may be the ones such as lower alkyl ester (e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, l-cyclopropylethyl ester, etc.) which may have at least one suitable substituent(s), for example, lower alkanoyloxy(lower)-~0; alkyl ester [e.g~ acetoxymethyl es~er, propionyloxy-~ methyl ester, butyryIoxymethyl ester, valer~loxymethyl ;~ ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, l(or 2)-~cetoxyethyl ester, l(or Z or 3)-acetoxypropyl ester, l(or 2 or 3 or 4)-acetoxybutyl ester, l(or 2)-propionyloxyethyl ester, I(or 2 or 3)-propionyloxypropyl 8~
ester, l(or 2)-butyryloxyethyl ester, l(or 2)-isobutyryloxyethyl ester, l(or 2)-pivaloyloxyethyl ester, l(or 2)-hexanoyloxyethyl ester, isobutyryloxy-methyl ester, 2-ethylbutyryloxymethyl ester, 3,3-dimethylbutyryloxymethyl ester, l(or 2)-pentanoyloxyethyl ester, etc.] lower alkanesulfonyl(lower)alkyl ester (e.g.
2-mesylethyl ester, etc.), mono(or di or tri)-halo(lower)alkyl ester (e.g.
2- odoethyl ester, 2,2,2-trichloroethyl ester, etc.), lower alkoxycarbonyloxy(lower)alkyl ester (e.g.
methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, 2-methoxycarbonyloxyethyl ester, l-ethoxycarbonyl-oxyethyl ester, l-isopropoxycarbonyloxyethyl ester, etc.), phthalidylidene(lower)alkyl ester, or - 15 (5-lo~er alkyl-2-oxo-1,3-dioxol-4-yl)(lower)alkyl ester [e.g. (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester, (S-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-propyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, etc.];
lower alkenyl ester (e.g. vinyl ester, allyl ester, etc.);
lower alkynyl ester (e.g. ethynyl ester, propynyl ester, etc.);
ar(lower)alkyl ester which may have at least one suitable substituent(s) (e.g. benzyl ester, 4-; 25 methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis(methoxyphenyl)methyl ester, 3,4-dimethoxyben~yl ester, 4-hydroxy-3,5-di-tert-butylbenzyl ester, etc.);
aryl ester which may have at least one suitable substituent(s) (e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, ; mesityl ester, cumenyl ester, etc.);
phthalidyl ester; and the like.
:, Preferable examples of the esteri~ied caxboxy .. ..
, .
: .:
. .. . ..
:, :
.
. .:: .: . .
z~s~
as mentioned above may include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarb~nyl, isobutoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, tert-pentyloxy-carbonyl, hexyloxycarbonyl, l-cyclopropylethoxycarbonyl, etc.).
Suitable "amidated carboxy" may include amide (-CONH2) which may have suitable substituent(s) on the nitrogen atom, wherein said substituent(s) may in~lude heterocyclic group which may have suitable substituent(s), aryl which may have suitable substituent(s) as mentioned below, and the like.
"Heterocyclic group" as mentioned above means, in detail, saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one hetero-atom such as an oxygen, sulfur, nitrogen atom and the like.
And, especially preferably heterocyclic group may be heterocyclic group such as unsaturated 3 to 8-membered more preferably 5 or 6-membered heteromonocyclic group containing l to 4-nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyrid~l and its N-oxide, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-l,Z,4-triazolyl, lH-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. lH-tetrazolyl, 2H-tetrazolyl, etc.), triazinyl (e.g.
1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, etc.), etc.;
saturated 3 to 8-membered (more preferably 5 or 6-membered)heteromonocyclic group containing l to 4 ` nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.;
::
:~68~S8 unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.;
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, syndonyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6-membered)heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g. 1,2,3-thiadia~olyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;
saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to ~
sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;
; unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydrodithiinyl, ~ 30 dihydrodithionyl, etc.;
unsaturated condensed heterocyclic group containing : 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for e~ample, benzothiazolyl, benzothiadiazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 to 6-mem~ered) heteromonocyclic group containing an oxygen . .
. :: ' :.: :
: -. . .
.:
~ :
~:61~4S8 atom, for example, furyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6-meFmbered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;
unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, benzoxathiinyl, etc. and the like, wherein said "heterocyclic group" may have one or more suitable substituent(s) such as halogen (e.g., chlorine, bromine, iodine or fluorine), lower alkyl (e.g., methyl, ethyl, propyl, etc.) as stated above, amino, or the like.
Suitable "protected hydroxy" may include a hydroxy group protected by a conventional hydroxy-protectiva group, for example, lower alkyl (e.g. methyl, ethyl, propyl, n-butyl, etc.), lower alkenyl (a.g. vinyl, allyl, etc.), ar(lower)alkyl such as mono- or di- or triphenyl(lower)alkyl (e.g. benzyl, benzhydryl, trityl, etc.), etc., trisubstituted silyl such as tri(lower)-alkylsilyl (e.g. trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, diisopropylmethylsilyl, etc ), triarylsilyl (e.g.
triphenylsilyl, etc.), triar(lower)alkylsilyl (e.g.
tribenzylsilyl, etc.), etc., and the like.
~:;
Suitable "aryl" may include phenyl, tolyl, xylyl, cumenyl, naphthyl, biphenylyl, and the like, which may have one or more suitable substituent(s) such as amino, nitro, halogen (e.g. fluorine, chlorine, bromine, iodine, etc.), lower alkoxy as exemplified above, carboxy, a protected carboxy group as exemplified above, hydroxy, and the like.
';
13 1 126Ei~58 Suitable "aryl" moiety in the terms "arylthio", "ar(lower)alkyl" and "arylamino" can be referred to the ones as exemplified above.
Suitable "aroyl" may include benzoyl, toluoyl, naphthoyl, and the like.
Suitable "arenesulfonyl" may include benzenesulfonyl, p-toluenesulfonyl, and the like.
The aforesaid "arylamino" may have a suitable substituent such as lower alkyl (e.g. methyl, ethyl, etc.) on the nitrogen atom, and the like.
Suitable "aryloxy" may include phenoxy, tolyloxy, and the like.
Suitable "hydroxy protective group" can be referred to the ones as exemplified above.
Preferable "amidated carboxy" may be carbamoyl, pyridylamido, pyrimidinylamido which may have lower alkyl, pyrazinylamido, phenylamido which may have ~ hydroxy, thiazolylamido, triazinylamido, triazolylamido `~ 25 which may have amino, pyridazinylamido which may have halogen, or tetrazolylamido, or the like.
The processes for preparing the object compounds (I) of the present invention are ~xplained in detail in the following.
Process 1 :
-- .. _ . .
The object compound (Ia) or a salt thereof can be ~;
- :
.~.,., ' ~ ~
`' , ~, ', '~ ' ~2~
prepared by subjecting the compound (II) or a salt thereof to elimination reaction of the carboxy protective group.
Suitable salt of the compound (II) can be referred to the acid addition salt exemplified for the compound (I) and suitable salt of the compound (Ia) can be referred to the ones as exemplified for the compound (I).
In the present elimination reaction, all conventional methods used in the elimination reaction of the carboxy protective group, for example, hydrolysis, reduction, elimination using Lewis acid, etc. are applicable.
When the carboxy protective group is an ester, it can be eliminated by hydrolysis or elimination using Lewis acid.
The hydrolysis is preferably carried out in the presence of a base or an acid.
Suitable base may include, for example, an inorganic base such as alkali metal hydroxide (e~g. sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.y. magnesium hydroxide, calcium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g. magnesium carbonate, calcium carbonate, etc.), alkali metal bicarbonate (e.g. sodium bicarbonate, potassium bicarbonate, etc.), alkali metal acetate (e.g. sodium acetate, potassium acetate, etc.), alkaline earth metal phosphate (e.g. magnesium phosphate, calcium phosphate, etc.), alkali metal hydrogen phosphate (e.g. disodium hydrogen phosphate, dipotassium hydrogen phosphate, etc.), or the like, and an organic base such as trialkylamine (e.g. trimethylamine, triethylamine~ etc.), picoline, N-methylpyrrolidine, N-methylmorpholine, I,5-diazabicyclo[4,3,0]non-5-one, , : : . ~,:, .
~ 15 -~8~S8 1,4-diazabicyclo[2,2,2]octane, 1,5-diazabicyclo-[5,4,0]undecene-5 or the like. The hydrolysis using a base is often carried out in water or a hydrophilic organic solvent or a mixed solvent thereof.
Suitable acid may include an organic acid (e.g.
formic acid, acetic acid, propionic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.).
The presPnt hydrolysis is usually carried out in an organic solvent, water or a mixed solvent thereof.
The reaction temperature is not critical, and it may suitable be selected in accordance with the kind of the carboxy protectiva group and the elimination method.
The elimination using Lewis acid is preferable to eliminate substituted or unsubstituted ar(lower)-alkyl ester and carried out by reacting the compound (II) or a salt thereof with Lewis acid such as boron trihalide te.g. boron trichloride, boron trifluoride, etc.), titanium tetrahalide (e.g. titanium tetra-chloride, titanium tetrabromide, etc.), tin tetrahalide (e.g. tin tetrachloride, tin tetrabromide etc.), aluminum halide (e.g. aluminum chloride, aluminum bromide, etc.), trihaloacetic acid (e.g. trichloro-acetic acid, trifluoroacetic acid, etc.) or the like.This elimination reaction is preferably carried out in the presence of cation trapping agents (e.g.
anisole, phenol, etc.) and is usually carried out in a solvent such as nitroalkane (e.g. nitromethane, 3~ nitroethane, etc.), alkylene halide (e.g. methylene chloride, ethylene chloride, e~c.), diethyl ether, carbon disulfide or any other solvent which does not adversely affect the reaction. These solvents may be used as a mixture thereof.
:
~- . : ~ , . : .. ,, ~ ,. . : . . . .. ..
- ' ~
` ,. ' ;:, ~' ~ ' ,' : -.; :: .. ~,. :
- 16 ~ 84S~
The reduction elimination can be applied preferably for elimination of the protective group such as halo(lower)-alkyl (e.g. 2-iodoethyl, 2,2,2-trichloroethyl, etc.) ester, ar(lower)alkyl (e.g. benzyl, etc.) ester or the like.
The reduction method applicable for the elimination reaction may include, for example, reduction by using a combination of a metal (e.g. zinc, zinc amal~am, etc.) or a salt of chromium compound (e.g. chromous chloride, chromous acetate, etc.) and an organic or an inorganic acid (e.g. acetic acid, propionic acid, hydrochloric acid, etc.); and conventional catalytic reduction in the presence of a conventional metallic catalyst (e.g.
palladium carbon, Raney nickel, etc.).
The reaction temperature is not critical, and the reaction is usually carried out under cooling, at ambient temperature or under warming.
The present elimination reaction of the carboxy protective group includes, within its scope, the case that another protected carboxy are converted into free carboxy during the reaction or the post-treating step of - the present process.
;:
; Process 2 :
The object compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or its reactive derivative at the carboxy group or a salt thereof to amidation reaction.
Suitable salt of the compound (Ib) can be referred to the salt exemplified for the compound (I).
The amidating agent to be used in the present amidation reaction may include amine which may have suitable substituent(s) such as heterocyclic group which may have suitable substituent(s) or aryl which may have su:Ltable substituent(s) on the nitrogen atom.
,.
..:
- ~ : , . . .
' '~
: . . .
. : ,. ~
Suitable reactive derivative at the carboxy group of the compound (Ia) may include an acid halide, an acid anhydride, an activated ester, and the like.
The suitable example ma~ be an acid chloride, an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulforous acid, thio-sulfuric acid, sulfuric acid, alkylcarbonic acid,aliphatic carboxylic acid (e~g. pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid or trichloroacetic acid, etc.) or aromatic carboxylic acid (e.g. benzoic acid, etc.); a symmetrical acid anhydride;
or an acitvated ester (e.g. cyanomethyl ester, methoxy-methyl ester, dimethyliminomethyl [(CH3)2~=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, ; pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.), or an ester with a N-hydroxy compound (e.g. N,N-dimethylhydroxylamine, l-hydroxy-2-( lH)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, l-hydroxy-6-chloro-lH-benzotriazole, etc.), and the like.
When the compound (Ia) is used in a free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, l,l'-carbonyldi-imidazole, thionyl chloride, oxalyl chloride, lower alkoxycarbonyl halide [e.g. ethyl chloroformate, isobutyl :, , : ` . -- 18 ~ 1 Z ~ 8 ~ 8 chloro~ormate, etc.], l-(p-chlorobenzenesulfonyloxy)-6-chloro-lH-benzotriazole, or the like.
The reaction is usually carried out in a conventional solvent such as water, acetone, dio~ane, chloroform, methylene chloride,ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. Among these solvents, hydrophilic solvents may be used in a mixture with water.
The reaction in the presence of a condensing agent is usually carried out in an anhydrous, but not critical conditions.
The reaction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), an alkali metal bicarbonate (e.g. sodium bicarbonate, potassium bicarbonate, etc.), tri(lower)alkylamine (e.g.
trimethylamine, triethylamine etc.), pyridine or its derivative (e.g. picoline, lutidine, 4-dimethylaminopyridine, etc.), or the like. In case that the base or the condensing agent to be used is in liquid t it can be used also as a solvent.
The reaction temperature is not critical, and the reaction is usually carried out under heating or under warming, preferably under heating.
Process 3 :
The object compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof .
.. . ~ : ~ . ., :
,. . :
-: .
' ' ' ,,,~ ~ ,- '. ' `' :' . -.
~68q~S~
to dehydration reaction.
The dehydrating agent to be used in this dehvdration ; reaction may include phosphory] chloride, thionyl chloride, phosphorus pentoxide, phosphorus pentachloride,phosphorus pentabromide and the like.
The present reaction is usually carried out in a solvent such as dioxane, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydro-furan, pyridine, aceto-nitrile, dimethylfoxmamide or any other solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or heating.
Process 4 :
The object compound (Ie) or a salt thereof can be ~0 prepared by reacting the compound (Id) or a salt thereof with hydrogen sulfide.
The present reaction is usually carried out in a solvent such as dioxane, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydrouran, pyridine, aceto-nitrile, dimethylformamide or any other solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or heating.
Process 5 :
The object compound (If~ or a salt thereof can be prepared by subjecting the compound (Id~ or a salt thereof ~`
- 20 - ~ ~68~
to the formation reaction of a tetrazole group.
Suitable salt of the compound ~If) and (Id) can be referred to the acid addition salt exemplified for the compound (I) The agent to be used in the pres~nt reaction may include conventional ones such as combination of alkali metal azide (e.g., potassium azide, sodium azide etc.) and ammonium halide (e.g. ammoni~ chloride), or the like.
The present reaction is usually carried out in a solvent such as dioxane, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydrofuran, pyridine, acetonitrile, dimethylformamide or any other solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the reaction is usually carried out under warming or heating.
Process 6 :
The compound ~Ih) or a salt thereof can be prepared by subjecting the compound (Ig) or a salt thereof to elimination reaction of the carboxy protective group.
Suitable salts of the compounds (Ig) and (Ih) can be referred to the salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process 1 as mentioned above, and therefore the reaction modes and conditions (e.g. reaction temperature, solvent, etc.) are referred to those of Process 1.
Process A ~
~ , .
The compound (V) or a salt thereof can be prepared by reacting the compound (III) or a salt thereof with the compound (IV).
Suitable salts of the compounds(III) and (V) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be preferably carried out in the presence of alkyl lithium (e.g., n-butyl lithium), ~5 lithium dii.sopropylamide, alkalimetal aIkoxide (e.g., sodium methoxide, sodium ethoxide etc.) and the like.
-.:, ., , , : - ., :; : . , - -: - . .. .
:., .. ... :. .. :
, , : ~ :
The present reaction is usually carried out in a solvent such as acetone, dioxane, acetonitrile, dimethylformamide, benzene, hexane, chloroform, methylene chloride, ethylene chloride, ~etrahydrofuran, ethyl acetate, or any other so:Lvent which does not adversely affect the reaction.
The reaction temperature ls not critical and the reaction is usually carried out: under cooling, at ambient temperature or under heating.
Process A - (2) :
The compound (IIa) or a salt thereof can be prepared by subjecting the compound (V) or a salt thereof to ring closure reaction.
Suitable salt of the compound (V) can be referred to the acid addition salt exemplified for the compound (I).
The present reaction may preferably be carried out in the presence of a suitable agent such as the mixture of diphenyl and diphenylether, which is used as heating medium.
The reaction temperature is not critical and the reaction is usually carried out under heating.
Process B ~
The compound (Vc) or a salt thereof can be prepared by reacting the compound (IIIc) or a salt thereof with the compound (IV).
Suitable salts of the compounds (Vc) and (IIIc) can be referred to the acid addition salts exemplified for the compound (I~.
::~
:, ~..., ~ -,~
- 22 ~ ~2684S~
The present reaction can be carried out in a similax manner to that of Process A ~ as mentioned above.
Process B - (2) :
_ _ _ The compound (IIh) or a salt thereof can be prepared by subjecting the compound (Vc) or a salt thereof to ring closure reaction.
Suitable salts of the compound (IIh) and (Vc) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process A - (2) as mentioned above.
Process C - (1) :
The compound (Va) or a salt thereof can be prepared by reacting the compound (IIIa) or a salt thereof with the compound (IV).
Suitable salts of the compound (IIIa) and (Va) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process A - (1) as mentioned above.
Process C - (2) :
; .
The compound (IIb) or a salt thereof can be prepared ~0~ by subjecting the compound (Va) or a salt thereof to ring closure reaction.
Suitable salts of the compound (IIb) and (Va) can be referred to t:he acid addition salts exemplifed for the ~5~ compound (I).
:.~
:' . ' ~ , :. -~ . : ,., :
.
~68~S~i3 The present reaction can be carried out in a similar manner to that of Process A - (2) as mentioned above.
Process D ~
The compound (Vb) or a salt thereof can be prepared by reacting the compound (IIIb) or a salt thereof with the compound (IVa).
Suitable salts of the compounds (IIIb~ and (Vb) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a similar manner to that of Process A - (1) as mentioned above.
Process D - (2) :
.
- 15 The compound (IIc) or a salt thereof can be prepared by subjecting the compound (Vb) or a salt thereof to ring closure reaction.
Suitable salts o the compounds (IIc) and (Vb) can be referred to the acid addition salts exemplified for the compound (I).
The present reaction can be carried out in a simllar manner to that of Process A - (2) as mentioned above.
Process E :
The object compound (IIe) or a salt thereof can be prepared by subjecting the compound (IId) or a salt thereof to introduction reaction of the hydroxy protective group.
Suitable salt of the compounds (IId) and (IIe) 3~ can be referred to the acid addition salts as exemplified for the compound (I).
In case that the protective group to be introduced are lower alkyl or lower alkenyl, the reaction can be carried out by reacting the compound (IId) with lower 3S alkylating agent or lower alkylating agent.
' ~ .
' .
: ,.'-: : . -..
- 24 ~ ~Z68~
The lower alkylating agent or lower alkenylating agent to be used in the present reaction may include conventional one such as mono(or di)lower alkyl sulfate (e.g. dimethyl sulfate, etc.), lower alkyl(lower)-alkanesulfonate (e.g. methyl methanesulfonate, etc.), halo(lower)alkane (e.g. bromomethane, iodomethane, iodoethane,iodobutane etc.), halo(lower)alk.ene (e.g.
iodopropene etc.) or the like.
When lower alkyl ester of an acid is used as a lower alkylating agent, the reaction is usually carried out in a solvent such as water, acetone, tetrahydrofuran, ethanol, ether, dimethylformamide or any other solvent which does not adversely influence the reaction.
The present reaction is preferably carried out in the present of a conventional base such as an inorganic base or an organic base.
The reaction temperature is not critical and the reaction is usually carried out under cooling to heating around boiling point of the solvent.
ZO
Process F :
The compound (IIg) or a salt thereof can be prepared by subjecting the compound (IIf) or a salt thereof to oxidation reaction.
Z5 Suitable salt of the compound (IIf) can be referred to the acid addition salt exempli~ied for the compound (I).
~uitable oxidizing agent to be used in this oxidation reaction may include conventional ones such as 2,3-dichloro-5,6-dicyano-1,4-benzoquinone ~DDQ), : ~a and the like.
The present o~idation is carried out with solvent such as benzene, toluene, chloroform, methylene chloride, carbon tetrachloride, diethyl ether, dimethylformamide or any other solvent which does not adversely affect ~5~ the reaction, and the solvent is optionally selected .
- -~.: - - . ~ -:,. : - ~ : . :
.: ~: ~. -, :,.. i. , .
: -, :
.. .. - ~, - 25 - ~ ~6~5~
according to a kind of oxidizing a~ent to be used.
The reaction temperature of the oxidation reaction oftthis process is not critical, and the reaction is carried out under coolin~, at ambient temperature, under warming or under heating. The reaction temperature is optionally selected according to a kind of oxidizing agent to be used.
Process G :
The compound (IIIe) or a salt thereof can be prepared by subjecting the compound (IIId) or a salt thereof to introduction reaction of the hydroxy protective group.
The present reaction can be carried out in a conventional manner.
In case that the protective group to be introduced is a silyl group, the present reaction is carried out by reacting the compound (IIId) or a salt thereof with the compound of the formula :
Ra - X (VI) wherein Ra is a trisubstituted silyl and X is an acid residue.
.
Suitable acid residue may include halogen (e.g., chlorine, bromine; etc.) or the like.
The present reaction is preferably carried out in the presence or imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole.
~o The reaction is usually carried out in a conventional~
solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetatP, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
. .
.
.,..: .
.: ;~
:
' ~ , .
:
. .
:. , - ~ . ~ , ~, ,,...... , .. :
- , 25 1 ~ 2 6~ ~ S ~
The reaction temperature is not critical and the reaction is usually carried out under cooling, at ambient temperature or under warminy.
Process H :
The compound (IIi) or a salt thereof can be prepared ~y subjecting the compound (IIh) or a salt thereof to elimination reaction of the hydroxy protective group.
The present elimination reaction is carried out in accordance with a conventional method such as Process 1.
The present reactlon is preferably carried out in the presence of a mild reagent such as tetra-n-butylammonium fluoride.
The reac~ion is usually carried out in a con-ventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
The reaction temperature is not critical and the reaction is usually carried out under cooling, at ambient temperature or under warming.
- (to be continued to the next page.) :
:`
3~
: :
:' .. . : .
:- , -~2~ 58 ~roceSs I
The object compound (IIk) or a salt thereof can be prepared by oxidizing the compound (IIj) or a salt - thereof.
The oxidizing agent to be used in this reaction may include an inorganic peracid or a salt thereof (e.g. periodic acid, persulfuric acid, or sodium or potassium salt thereof, etc.), an organic peracid or a salt thereof (e.g. perbenzoic acid, m chloro-perbenzoic acid, performic acid, peracetic acid, chloroperacetic acid, trifluoroperacetic acid, or sodium or potassium salt thereof, etc.), ozone, hydrogen peroxide, urea-hydrogen peroxide, N-halosuccinimide (e.g. N-bromosuccinimide, N-chloro-succinimide, etc.), hypochlorite compound (e.g.
tert-butyl hypochlorite, etc.), permanganate (e.g.
potassium permanganate, etc.), or any other conventional oxidizing agent which can oxidide a sulfinyl group to a sulfonyl group.
The present reaction can also be carried out in the presence of a compound comprising Group Vb or VIb metal in the Periodic Table of elements, for example, tungstic acid, molybdic acid, vanadic acid, etc., or an alkali or an alkaline earth metal salt thereof.
The present oxidation reaction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, acetic acid, chloroform, methylene chloride, acetone, methanol, ethanol or a mixture thereof.
The reaction temperature is not critical and the reaction is preferably carried out under cooling to at ambient temperature.
. .
.
:
, :
'; ' ; : ': . : ' :
~ , " , ;8~
Particularly, the compounds (I) possessing the most potent antimicrobial activity can be represented by the following formula:
Ri R3 R2f~N ~1 wherein Rl, R2, R3 and R7 are each as defined above, and more particularly, Rl is tetrazolylamido, R2 and R7 are each hydrogen, and R3 is aryloxy or aroyl.
(to be continued to the next page.) , ~ ~ , .:
. 30 :
,~
:
:~
~: .. : ::. .: .
. . ~ : : :: . .
' 1'.', . . . .. , - . .
lZ684~
For the purpose of showing pharmaceutical utility of the quinolizinone compound (I), pharmaceutical test data thereof are illustrated in the following.
S [1] Test compound :
N-[5-(lH-Tetrazolyl)l-4H-quinolizin-4-one-3-carboxamide (hereinafter referred to as compound ~ ) ..
N-[5-(lH-Tetrazolyl)]-l-phenyl-4H-quinolizin-4-one-3-carboxamide (here:inafter referred to as compound ~ ) [2] Test :
(A) Inhibition on stress ulcer Test Method :
Sprague-Dawley rats weighing about 200 g were used.
Each animal was immobilized in a small cage and put in - a water bath allowing to respire. The temperature of the water bath kept at 22C. The test compound ~ and X were administered orally just before the immobilization.
Seven hours la~er, the animals were sacrificed ~nd their stomachs were removed. The stomach was then ; fixed with 2% formalin. The area of ulcers was measured for each animal. The mean area (mm2) in the test animals was compared with that in the control animals. ;
~ ~a :
`: :
.
.
.
:126~5~
Test Result :
" Ulcer index .
. Treatment No. -'2 . Inh.
1 19 Mean + S.E. .
~ ~ 19.2 + ~.8 Compound ~ 2 5 L~ 6.~ + 3.0 67 .7 _ _ . ~ ~ _ .
: Ulcer index : Treatment No. 2 . . Inh. %
mm Mean~+ S.E.
Control ~ ~ 48.4 + 3~3 ~ 1 10 . ~ . _ `~: Compound ~ : 2 ll :
3 3 8.4 ~ 1.9 83.7 3s ~ ~
~ r:
' ~
~ ' ` ' ,' '~ . . ..
. . ',1 : .
` . .
,~ . , ': '.
~Z~i8458 (B) Effect on passive cutaneous anaphylaxis (PCA).
~ Test Method Recipient animals for PCA reactions were female Sprague-Dawley rats, 7 weeks old, 180g-200g (Nihon Kurea).
Each experiment included 5 observations.
Five times crystallized ovalbumin (OVA) (Sigma Lot, 31F-8061) was used as antigen.
Female BDFl mice, 7 weeks old (Nihon Kurea~, were - given a primary injection (lefl foot pad, s.c.) of 100 mcg OVA in 0.05ml saline and after 20 days a booster injection by the same route. Blood was collected 28 - days after the primary injection and the sera were stored at -80C.
The animals were shared with an electric clipper in advance and prepared for Passive Cutaneous Anaphylaxis - (PCA) by injecting 0.05ml of mouse antiserum dilutions (1/16, 1/32) in each side of the dorsal skin.
They were then challenged 48 hours later with an intravenous injection of 1 ml of 0.5% Evans Blue containing
5 mg OVA. Fifty minutes later, they were killed and the lesions (diameter) mFasured.
A minimal skin response was one with a 5 mm or greater diameter blue spot measured on the dermal side of reflected skin. Drug activity was estimated using 3~ the following formula;
inhibition = (1 ~ ) x 100 Drugs were suspended in 0.1% methyl cellulose/saline and yiven intravenously with the antigen.
. .
~: :::
: . : ~
';
.:, .: ~ .
; ~. . .~
.. ~
~:6Ei ~5~
Test Result :
. _ . .. .. ._ . Dose Inhibition (%) S rng/kg Antiserum concentration .. ._ 1/16 1/3 1 97.2 100 Compound ~ . - . .
94.5 100 1 0 . . .. .. _ The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains an active substance of this invention in admixture with an organic or inorganic carrier or excipient suitable for external, oral or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, ; suppositories/ solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, collidal ilica, potato ~ ::
starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or ::~
liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes~may be ~:; 30 used. The pharmaceutical compositions can also contain ::
- preservative or bacteriostatic agents to keep the active ingredient in the desired preparations stable ~ ~:
: in acti~ity. The active object compound is included ~: in the pharmaceutical:composition in an amount sufficient :~ 35 to produce the desired therapeutic effect upon the ' .
' . '~ ' :
. :
:
~, : : -..
. :. . ::
lZ~i84S8 process or condition of diseases.
For applying this composition to humans, it is preferably to apply it by intravenous, intramuscular S or oral administration. ~hile the dosage or thera-peutically effective amount of the object compound of this invention varies from and also depends upon the age and condition of each individual patient to be treated, a daily doses of about 0.05-5 mg of the active ingredien~kg of a human being or an animal in generally give for treating diseases, and an average, single dose of about 2.5 mg, 25 mg and 250 mg in generally administered.
The following preparations and examples are given for purpose of illustrating this invention.
Preparation 1 To a solution of 2-methylpyridine (7 ml) in tetra-~0 hydrofuran (140 ml) was added dropwise a solution of n-butyl lithium (49 ml of 1.59 mol solution in hexane) with ice-cooling. The resulting dark red solution was allowed to warm to ambient temperature and stirred for an hour. After cooling to -78C, a solution of diethyl ethoxymethylenemalonate (15.68 ml) in tetrahydrofuran (50 ml) was added over a period of 30 minutes. The reaction mixture was allowed to warm to -20C and stirred for 30 minutes at -20C. Acetic acid (4.48 ml) was added. The solvent was distilled off, the residue 3~ wa~ dissolved in ethyl acetate and washed with 10%
aqueous solution of sodium bicarbonate, water and saturated aqueous sodium chloride~ After drying over magnesium sulfate, the ethyl acetate extract was filtered and evaporated to give an oil (27 g). The residue was ~5 chromatographed on silica gel (Merck 70 - 230 mesh, 270 g) , ,~"
.
' ~
` ~
.~ :
~ 30 - ~ z eluting with chloroform to give ethyl 3-ethoxy-2-ethoxycarbonyl-4-(2 pyridyl)butyrate (19 g) as an oil.
IR (film) : 1730, 1590, 1470, 1440, 1370 cm 1 NMR (CDC13) ~ : 0.97 tt, 3H, ~=8Hz), 1.26 tt, 6H, J=8Hz), 3.12 (d, lH, J=8Hz), 3.2-3.6 (m, 2H), 3.~2 (d, lH, J=8Hz), 4.21 (q, 4H, J=8Hz), 4.47 (q, 2H, J=8Hz), 6.97-7.80 (m, 3H), 8.42-8.67 (m, 1~) Preparation 2 A mixture of ethyl 3-ethoxy-2-ethoxycarbonyl 4-(2-pyridyl)butyrate (18.9 g), diphenyl (48.85 g) and diphenyl ether (135.8 g) was heated to 250C for 40 minutes. The reaction mixture was cooled to ambient temperature and chromatographed on silica gel (Merck 70-230 mesh, 620 g) eluting with hexane and then a mixture of ethanol and chloroform (1:49~ to give a crude oil, which was crystallized from a mixture of ether and haxane (1:1) to give 3-ethoxycarbonyl-4X-quinolizin-4-one (11.48 g) as yellow crystal.
IR (Nujol) : 1670, 1625, 1490 cm 1 NMR (CDC13) ~ : 1.42 (t, 3H, J=7Hz)/ 4.42 (q, 2H, J=7Hz), 6.62 (d, lH, J=8Hz), 7.02-7.38 (m, lH), ; 7.53 7.68 (m, 2H), 8.33 (d, lH, J=8Hz~, 9.23-9.47 (m, lH) Preparation 3 The following compounds were obtained according to a similar manner to that of Pre~a a lon 1.
~1) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-[2-~5-ethylpyridyl)]butyrate.
; IR (film) : 1750, 1730 cm ,:~
.:
(2) Ethvl 3-ethoxy-2-ethoxycarbonyl-4-(2-~uinolyl)-butyrate.
;.~ :
;
- . . -, ,,.. , - , .
~684S15 IR (film) : 1750 (sh), 1730 cm 1 (3) Ethyl 4-phenyl-3-ethoxy-2-ethoxycarbonyl-4-(2-pyridyl)butyrate.
IR (film) : 1750 (sh), 1730 cm 1 (4) Ethyl 3-e~hoxy-2-ethoxycarbonyl-4-[2-(5-hydroxypyridyl)]butyrate.
IR (fi~m) : 2550, 1730, 1490, 1270, 1160, 1090, 1025 cm 1 NMR (CDC13) ~ : 0.97 (t, 3H, J=7Hz), 1.25 (t, 6H, J=7Hz), 3.07 (d, 2H, J=5Hz), 3.20-4.77 (m, 8H),
A minimal skin response was one with a 5 mm or greater diameter blue spot measured on the dermal side of reflected skin. Drug activity was estimated using 3~ the following formula;
inhibition = (1 ~ ) x 100 Drugs were suspended in 0.1% methyl cellulose/saline and yiven intravenously with the antigen.
. .
~: :::
: . : ~
';
.:, .: ~ .
; ~. . .~
.. ~
~:6Ei ~5~
Test Result :
. _ . .. .. ._ . Dose Inhibition (%) S rng/kg Antiserum concentration .. ._ 1/16 1/3 1 97.2 100 Compound ~ . - . .
94.5 100 1 0 . . .. .. _ The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains an active substance of this invention in admixture with an organic or inorganic carrier or excipient suitable for external, oral or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, ; suppositories/ solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, collidal ilica, potato ~ ::
starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or ::~
liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes~may be ~:; 30 used. The pharmaceutical compositions can also contain ::
- preservative or bacteriostatic agents to keep the active ingredient in the desired preparations stable ~ ~:
: in acti~ity. The active object compound is included ~: in the pharmaceutical:composition in an amount sufficient :~ 35 to produce the desired therapeutic effect upon the ' .
' . '~ ' :
. :
:
~, : : -..
. :. . ::
lZ~i84S8 process or condition of diseases.
For applying this composition to humans, it is preferably to apply it by intravenous, intramuscular S or oral administration. ~hile the dosage or thera-peutically effective amount of the object compound of this invention varies from and also depends upon the age and condition of each individual patient to be treated, a daily doses of about 0.05-5 mg of the active ingredien~kg of a human being or an animal in generally give for treating diseases, and an average, single dose of about 2.5 mg, 25 mg and 250 mg in generally administered.
The following preparations and examples are given for purpose of illustrating this invention.
Preparation 1 To a solution of 2-methylpyridine (7 ml) in tetra-~0 hydrofuran (140 ml) was added dropwise a solution of n-butyl lithium (49 ml of 1.59 mol solution in hexane) with ice-cooling. The resulting dark red solution was allowed to warm to ambient temperature and stirred for an hour. After cooling to -78C, a solution of diethyl ethoxymethylenemalonate (15.68 ml) in tetrahydrofuran (50 ml) was added over a period of 30 minutes. The reaction mixture was allowed to warm to -20C and stirred for 30 minutes at -20C. Acetic acid (4.48 ml) was added. The solvent was distilled off, the residue 3~ wa~ dissolved in ethyl acetate and washed with 10%
aqueous solution of sodium bicarbonate, water and saturated aqueous sodium chloride~ After drying over magnesium sulfate, the ethyl acetate extract was filtered and evaporated to give an oil (27 g). The residue was ~5 chromatographed on silica gel (Merck 70 - 230 mesh, 270 g) , ,~"
.
' ~
` ~
.~ :
~ 30 - ~ z eluting with chloroform to give ethyl 3-ethoxy-2-ethoxycarbonyl-4-(2 pyridyl)butyrate (19 g) as an oil.
IR (film) : 1730, 1590, 1470, 1440, 1370 cm 1 NMR (CDC13) ~ : 0.97 tt, 3H, ~=8Hz), 1.26 tt, 6H, J=8Hz), 3.12 (d, lH, J=8Hz), 3.2-3.6 (m, 2H), 3.~2 (d, lH, J=8Hz), 4.21 (q, 4H, J=8Hz), 4.47 (q, 2H, J=8Hz), 6.97-7.80 (m, 3H), 8.42-8.67 (m, 1~) Preparation 2 A mixture of ethyl 3-ethoxy-2-ethoxycarbonyl 4-(2-pyridyl)butyrate (18.9 g), diphenyl (48.85 g) and diphenyl ether (135.8 g) was heated to 250C for 40 minutes. The reaction mixture was cooled to ambient temperature and chromatographed on silica gel (Merck 70-230 mesh, 620 g) eluting with hexane and then a mixture of ethanol and chloroform (1:49~ to give a crude oil, which was crystallized from a mixture of ether and haxane (1:1) to give 3-ethoxycarbonyl-4X-quinolizin-4-one (11.48 g) as yellow crystal.
IR (Nujol) : 1670, 1625, 1490 cm 1 NMR (CDC13) ~ : 1.42 (t, 3H, J=7Hz)/ 4.42 (q, 2H, J=7Hz), 6.62 (d, lH, J=8Hz), 7.02-7.38 (m, lH), ; 7.53 7.68 (m, 2H), 8.33 (d, lH, J=8Hz~, 9.23-9.47 (m, lH) Preparation 3 The following compounds were obtained according to a similar manner to that of Pre~a a lon 1.
~1) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-[2-~5-ethylpyridyl)]butyrate.
; IR (film) : 1750, 1730 cm ,:~
.:
(2) Ethvl 3-ethoxy-2-ethoxycarbonyl-4-(2-~uinolyl)-butyrate.
;.~ :
;
- . . -, ,,.. , - , .
~684S15 IR (film) : 1750 (sh), 1730 cm 1 (3) Ethyl 4-phenyl-3-ethoxy-2-ethoxycarbonyl-4-(2-pyridyl)butyrate.
IR (film) : 1750 (sh), 1730 cm 1 (4) Ethyl 3-e~hoxy-2-ethoxycarbonyl-4-[2-(5-hydroxypyridyl)]butyrate.
IR (fi~m) : 2550, 1730, 1490, 1270, 1160, 1090, 1025 cm 1 NMR (CDC13) ~ : 0.97 (t, 3H, J=7Hz), 1.25 (t, 6H, J=7Hz), 3.07 (d, 2H, J=5Hz), 3.20-4.77 (m, 8H),
6.47 (m, lH), 7.07-7.37 (m, 2H), 8.17 (m, lH) (5) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-(1-isoquinolyl)-butyrate.
IR (film) : 1750, 1730 cm 1 (6) Ethyl 3-ethoxy-2-ethoxycarbonyl-3-[8-(5,6,7,8-tetrahydroquinolyl)]propionate.
IR (film) : 1750, 1730 cm 1
IR (film) : 1750, 1730 cm 1 (6) Ethyl 3-ethoxy-2-ethoxycarbonyl-3-[8-(5,6,7,8-tetrahydroquinolyl)]propionate.
IR (film) : 1750, 1730 cm 1
(7) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-~2-(3-methylpyridyl)]butyrate.
IR (Nujol~ : 1750, 1735, 1575, 1440, 860, 790 cm 1 ~ ;
N~R (CDC13) ~ : 0.92 (t, 3H, J=5Hz), 1.27 (t, 6H, J=5Hz), 2.37 (s, 3H), 3.08-3.60 (m, 4H), 3.70 (d, lH~, ~=SHz), 4.~18 (q, 2H, J=5Hz), 4.22 (q, 2H; J=SHz), 4.52 (m, lH), 7.05 (dd, ;
3~ lH,-J=6Hz and 3~z), 7.45 (d, lH, J=6Hz),
IR (Nujol~ : 1750, 1735, 1575, 1440, 860, 790 cm 1 ~ ;
N~R (CDC13) ~ : 0.92 (t, 3H, J=5Hz), 1.27 (t, 6H, J=5Hz), 2.37 (s, 3H), 3.08-3.60 (m, 4H), 3.70 (d, lH~, ~=SHz), 4.~18 (q, 2H, J=5Hz), 4.22 (q, 2H; J=SHz), 4.52 (m, lH), 7.05 (dd, ;
3~ lH,-J=6Hz and 3~z), 7.45 (d, lH, J=6Hz),
8.42 (d, lH, J=3Hz) (8) Ethyl 3-ethoxy-2-carboethoxy-4-[2-(4-methylpyridyl)]butyrate.
- 35 IR (film) : 1750, 1730, 1600, 1240, 1150, 1020 cm 1 , :
:;: :
~.:
~ ..... .
,.
- : .
' ~, .: ~ : , . : ' ' - 32 - ~ ~6~45~
.
NMR (CDC13) ~ : 0.97 (t~ 3H, J=7Hz), 1.27 (t, 6H, J-7Hz), 2.32 (s, 3H), 3.10 (d, 2H, J=5.5Hz), 3.28-3.58 (m, 2H), 4.20 (q, 3H, J=7Hz), 4.23 (q, 3H, J-7Xz), 6.87-7.13 (m, 2H), 8.40 (d, lH, J=6Hz)
- 35 IR (film) : 1750, 1730, 1600, 1240, 1150, 1020 cm 1 , :
:;: :
~.:
~ ..... .
,.
- : .
' ~, .: ~ : , . : ' ' - 32 - ~ ~6~45~
.
NMR (CDC13) ~ : 0.97 (t~ 3H, J=7Hz), 1.27 (t, 6H, J-7Hz), 2.32 (s, 3H), 3.10 (d, 2H, J=5.5Hz), 3.28-3.58 (m, 2H), 4.20 (q, 3H, J=7Hz), 4.23 (q, 3H, J-7Xz), 6.87-7.13 (m, 2H), 8.40 (d, lH, J=6Hz)
(9) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-[2-(6-methylpyridyl~]butyrate.
IR (film) o 1650, 1630, 1590, 1580, 1270, 1150, 1090 cm NMR (CDC13) ~ : 0.97 (t, 3H, J=7Hz), 1.25 (t, 6H, J=7Hz), 2.48 (s, 3H), 3.07 (d, 2H, J=5.5Hz), 3.60 (q, 2H, J=7Hz), 3.23-3.57 (m, lH), 4.18 (q, 4H, J=7Hz), 4.33-4.67 (m, lH), 6.85-7.15 (m, 2H), 7.33-7.66 (m, lH)
IR (film) o 1650, 1630, 1590, 1580, 1270, 1150, 1090 cm NMR (CDC13) ~ : 0.97 (t, 3H, J=7Hz), 1.25 (t, 6H, J=7Hz), 2.48 (s, 3H), 3.07 (d, 2H, J=5.5Hz), 3.60 (q, 2H, J=7Hz), 3.23-3.57 (m, lH), 4.18 (q, 4H, J=7Hz), 4.33-4.67 (m, lH), 6.85-7.15 (m, 2H), 7.33-7.66 (m, lH)
(10) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-(2-pyridyl)-pentanoate.
IR (film) : 1750, 1730, 1590, 1300, 1090, 1020 cm NMR (CDC13) ~ : 1.00 (t, 3~, J=7Hz), ~1.35 (t~ J=7Hz), ; 1.25 (t, J=7Hz), 1.25 (s) 9H], 3.00-3.75 (m, 4H), 3.93-4.58 (m, 5H), 6.98-7.60 (m, 2H), 7.65 (m, lH), 8.58 (m, lH)
IR (film) : 1750, 1730, 1590, 1300, 1090, 1020 cm NMR (CDC13) ~ : 1.00 (t, 3~, J=7Hz), ~1.35 (t~ J=7Hz), ; 1.25 (t, J=7Hz), 1.25 (s) 9H], 3.00-3.75 (m, 4H), 3.93-4.58 (m, 5H), 6.98-7.60 (m, 2H), 7.65 (m, lH), 8.58 (m, lH)
(11) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-~2-(5- ;
methylpyridyl)]butyrate.
;~ IR (film) : 1740, 1730, 1600, 1480, 1150, 1090, 1025 cm 1 ; NMR (CDC13) ~ : 1.00 (t, 3H, J=7Hz), 1.27 (t, 6H, 3a J=7Hz), 2.32 (s, 3H), 3.00-3.77 (m, 4H), 4.22 (q, 3H, J=7Hz), 4.25 (q, 3H, J=7Hz), 7.03-7.50 (m, 2H), 8.37 (m, lH) ,~
methylpyridyl)]butyrate.
;~ IR (film) : 1740, 1730, 1600, 1480, 1150, 1090, 1025 cm 1 ; NMR (CDC13) ~ : 1.00 (t, 3H, J=7Hz), 1.27 (t, 6H, 3a J=7Hz), 2.32 (s, 3H), 3.00-3.77 (m, 4H), 4.22 (q, 3H, J=7Hz), 4.25 (q, 3H, J=7Hz), 7.03-7.50 (m, 2H), 8.37 (m, lH) ,~
(12) Ethyl 3-ethoxy-2-ethoxycaxbonyl-3-~7-(6,7-~ 35 dihydro-5H-cyclopenta [b] pyridyl~]pxopionate.
:1 :
:
lZG84~ii8 IR (film) : 1750 (sh), 1730, 1590, 1580 cm 1 NMR (CDC13) ~ : 0.80 (t, 3H, J=7Hz), 1.30 (t, 6H, ~=7Hz), 2.00-2.40 (m, 2H), 2.80-3.70 (m, 4H), 4.0 (q, 2H, J=7Hz), 4.20 (q, 4H, J=7Hz), 4.80 (dd, lH, J=8Hz and 2Hz), 7.00-7.60 (m, 2H), - 8.3-8.50 (m, lH)
:1 :
:
lZG84~ii8 IR (film) : 1750 (sh), 1730, 1590, 1580 cm 1 NMR (CDC13) ~ : 0.80 (t, 3H, J=7Hz), 1.30 (t, 6H, ~=7Hz), 2.00-2.40 (m, 2H), 2.80-3.70 (m, 4H), 4.0 (q, 2H, J=7Hz), 4.20 (q, 4H, J=7Hz), 4.80 (dd, lH, J=8Hz and 2Hz), 7.00-7.60 (m, 2H), - 8.3-8.50 (m, lH)
(13) Ethyl 3-ethoxy-4-methoxy-4-(2-pyridyl)-2-ethoxycarbonylbutyrate.
IR (~ilm) : 1750, 1730, 1590, 1365, 1090, 1025, 760 cm 1 NMR (CDC13) ~ : 0.78 (t, 3H, J=7Hz), 1.25 (t, 3H, J=7Hz), 1.28 (t, 3H, J=7Hz), 3.33 (d, 2H, J=4Hz), 3.60-4.60 (m, ~H ), 7.07-7.90 (m, 3H), 8.62 (m, lH)
IR (~ilm) : 1750, 1730, 1590, 1365, 1090, 1025, 760 cm 1 NMR (CDC13) ~ : 0.78 (t, 3H, J=7Hz), 1.25 (t, 3H, J=7Hz), 1.28 (t, 3H, J=7Hz), 3.33 (d, 2H, J=4Hz), 3.60-4.60 (m, ~H ), 7.07-7.90 (m, 3H), 8.62 (m, lH)
(14) Ethyl 3-ethoxy-4-ethoxycarbonyl-4-(2-pyridyl)-butyrate.
.; ~ :
20 Prepa_ation 4 :
The following compounds wexe obtained according to a similar manner to that of Preparation 2.
~;~ (1) 2-Ethoxycarbonyl-lH-pyrido[1,2-a]quinolin-1-one.
mp. 104-105C. : ~ :
IR (Nujol) : 1730, 1660, 1530 cm 1 ;~ NMR (CDC13) ~ : ~ 1.43 (t, 3H, J=7Hz), 4.43 (q, 2H, J=7Hz), 6.40 (d, lH, J=8Hz)~, 7.0 and 7.45 ; (ABq, 2H, J=lOHz), 7.50-7.70 (m, 4H), 8.20 : ~30 (d, lH, J=8Hz~, 9.70-10.0 (m, IH) ~;
~ (2) 7-Ethyl-3-athoxycarbonyl-4H-~uinolizin-4-one.
- mp. 81-83C.
IR (Nujol) : 1720, 1630 cm 1 ;35 NMR (CDC13) ~ : 1.32 (t, 3H, J=7Hz), 1.44 (t, 3H, .
' ,::: - ' ~ -- 34 ~ iLZ ~ 845 8 J=7Hz), 2.76 (q, 2EI, J=7Hz), 4.40 tq, 2H, J=7Hz), 6u60 (d, lH, J=8Hz), 7.52 (s, 2H), 8.32 (d, lH, J=8Hz), 9.20 (s, lH) (3) 1-Phenyl-3-ethoxycar~onyl-4H-quinolizin-4-one.
mp. 120-123C.
IR (Nujol) : 1730, 1620 cm 1 NMR (CDC13) ~ : 1.36 (t, 3H, J=7Hz), 4.38 (q, 2H, J=7Hz), 7.04-7.76 (m, 7H), 8.32 (s, lH), 9.48 (d, lH, J=8Hz) (4) 8-Hydroxy-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp. 242C. ~dec.) IR (Nujol) : 3300, 3200, 1680, 1660, 1620, 1300, ;; 15 1140, 960, 900 cm 1 ` NMR (DMSO-d6) ~: 2~27 (t, 3H, J=7Hz), 4.23 (q, 2H, J=8Hz), 6.13 (d, lH, J=8Hz), 7.58 (dd, lH, J=2Hz, 8Hz), 7.90 (d, lH, J=8Hz), 8.07 (d, lH, J=8Hz), 8.82 (d, lH, J=2Hz) Anal. Calcd for C12HllNO4 : C, 61~80; H~ 4-75 Found : C, 62.18; H, 5.05 `l (5) 3-E~hoxycarbonyl-4H-pyrido~2,1-a~isoquinolin-4-`~' one. mp. 155C.
IR (Nujol) : 3100, 1740, 1650, 1640 cm 1 NMR (CDC13) ~ :~ 1.46 (t, 3H, J=7Hz), 4.46 (q, 2H,~
J=7Hz), 7.23 (d, lH, J=8Hz), 7.35 (d, lH, J=8Hz), 7.50-7.83 (m, 3H), 8.20-8.50 (m, lH), 8.46 (d, lH, J=8Hz), 9.10~(d, lH, J=8Hz), ` ~ 30 Anal. Cal~d for C16H13NO3 :
C; 71.90, H; 4.90, N; 5.24 Found : C; 71.40, H; 5.06, N; 5.17 ::` ` : : :
(6) 9-Nethyl-3-ethoxycarbonyl-4H-quinoLizin-4-one.
mp. 125-126C.
: ~
:~
- 35 - ~Z6~4s~
IR (Nujol) : 3090, 1725, 1645, 1590, 1125, 1100 cm 1 NMR (CDC13) ~ : 1.40 (t, 3H, J=7Hz~, 2.50 (s, 3H), 4.42 (q, 2H, J=7Hz), 6.63 (d, lH, J=9Hz), 7.07 (t, lH, J=7Hz), 7.47 (d, lH, J=7Hz), 8.35 (d, lH, J=9Hz), 9.32 (d, J=7Hz, lH) 13 13 3 C; 67.52, H; 5.67 Found : C; 67.51, H; 5.83 _ (7) 8-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one. mp. 146-148C.
IR (Nujol) : 3060, 1720, 1660, 1640, 1245, 1155, 790 cm~l NMR (CDC13) ~ : 1.40 (t, 3H, J=7Hz), 2.50 (s, 3H), 4.38 (q, 2H, J=7Hz), 6.50 (d, lE, J=9Hz), 7.00 (dd, lH, J=7Hz, 2Hz), 7.30 (d, lH, J=2Hz), 8.32 (d, lH, J=9Hz), 9.28 (d, lH, J=7Hz) r C13H13NO3 : C; 67.52, H; 5.67 Found : C; 67.38, H; 5.65 (8) 3-Ethoxycarbonyl-6-methyl-4H-quinolizin-4-one. mp. 90-93C.
IR (Nujol) : 1720, 1650, 1620, 1590, 1265, 1120, ~ 1100, 795 cm 1 NMR (CDC13) ~ : 1.35 (t, 3H, J=7Hz), 3.05 (s, 3H), 4.38 (q, 2H, J=7Hæ), 6.38 (d, lH, J=8Hz), 6.67 (m, lH), 7.25 (d, lH, J=4.5Hz), 8.18 (d, lH, J=8Hz) Anal. Calcd for C13H13NO3 :
C; 67.52, H; 5.67, N; 6.07 Found : C; 67.28, H; 5.63, N; 6.03 (9) 1-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one. mp. 142-143C.
, . ~ . .
. ~.
.
~ . :
- 36 - ~Z~5~
IR (Nujol) : 1720, 1650, 1620, 1595, 1300, 1230, 1160, 1120, 775 cm 1 NMR (CDC13) ~ : 1.42 (t, 3H, J=7Hz), 2.40 (s, 3H), 4.43 (q, 2H, J=7Hz), 7.20 (m, lH), 7.62-7.80 ; 5 (m, 2H), 8.25 (s, lH), 9.47 (m, 1~) Anal. Calcd for C13H13NO3 :
C; 67.52, H; 5.67, N; 6.06 Found : C; 67.49, H; 5.94, N; 6.06 (10) 7-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one. mp. 146-149C.
IR (Nujol) : 1720, 1620, 1145, lIlD cm 1 NMR (CDC13) ~ : 1.42 (t, 3H, J=7Hz), 2.45 (s, 3H), 4.43 (q, 2H, J=7Hz), 6.62 (d, lH, J=8Hæ), 7.47-7.57 (m, 2H), 8.33 (d, lH, J=8Hz), 9.23 (m, lH) Anal. Calcd for C13H13NO3 C; 67.52, H; 5.62, N; 6.06 Found : C; 67.44, H; 5.85j N; 6.00 (11) 2-Ethoxycarbonyl-8,9-dihydrocyclopenta[ij¦-3H-quinolizin-3-one. mp. 149C.
`l IR (Nujol) : 3100, 1720, 1640, 1620, 1600, 1550, 1210, 1150 cm 1 ; 25 NMR (CDC13) ~ : 1.43~(t, 3H, J-7Hz), 3.30 (broad s, 4H), 4.30 (q, 2H, J=7Hz),~ 7.0-7.30 ~m, 2H), 8.30 (s, lH), 8.86 (d, lH, J=6Hz) Anal. Calcd for C14H13NO3 :
C; 69.12, H; 5.39, N; 5.76 Found : C; 68.16, H; 5.47, N; 5.69 :~ :
~12) 2-Ethoxycarbonyl-9,10-dihydro-8H-benzo[ij]-3H-quinoli2in-3-one. mp. 118C.
IR (Nujol) ~: 1680, 1620, 1600, 1220 cm NMR (CDC13) ~ : 1.40 (t, 3~, J=7Hz), 1.85-2.20 (m, 2H), :: :
::
, . , ... ... ~ . .
~Z16~5~
2.80-3.20 (m, 4H), 4.40 (q, 2H, J=7Hz), 6.85-7.30 (m, 2H), 8.13 (s, lH), 9.20 (d, lE, J=7Hz) Anal. Calcd for C15H15NO3 :
C; 70.02, ~; 5.88, N; 5.44 Found : C; 69.78, ~; 5.95, N; 5.38 (13) 1-Methoxy-3-ethoxycarbonyl-4H quinolizin-4-one. mp. 132-133C.
IR (Nujol) : 1680, 1670, 1620, 1595, 1360, 1120, 1020, 770 cm NMR (CDC13) ~ : 1.43 (t, 3H, J=7Hz), 3.93 (s, 3H), 4.45 (q, 2H, J=7Hz), 7.25 (m, lH), 7.67 (m, lH), 7.97-8.20 (m, 2H), 9.47 (d, lH, J=7.5Hz) Anal. Calcd for C13H13NO4 :
C; 63.15, H; 5.30, N; 5.66 Found : C; 62.80, H; 5.33, N; 5.63 (143 1-Ethoxycarbonyl-4H-quinolizin-4-one.
mp. 114C.
IR (Nujol) : 1725, 1680, 1630 c~ 1 Anal. Calcd for C12HllNO3 :
~ C; 66.35, H; 5.10, N; 10.45 -~ 25 Found : C; 66.19, H; 4.81, N; 6.42 -~ Preparation 5 A solution of 2-ethoxycarbonyl-8,~-dihydrocyclopenta-[ij]-3H-quinolizin-3-one (2.2 g)~and~dich}orodicyano-benzoquinone (2~26 g) in benzene (110 ml) was refluxed for two hours. The reaction mixture was cooled to 0C
and the precipitates were filter~ed The filtrate was concentrated and the residue was chromatographed on silica gel column (44 g) eluting with chloroform-methanol (100:1 - 10:1). Evaporation of corresponding fractions :
: ` :
~: :
~Z~8~
gave crude crystals which was washed with a mixture of ether and hexane to afford 2-ethoxycarbonylcyclopenta-[ij]-3H-quinolizin-3-one (1.82 g), mp. 127C.
IR (Nujol) : 3100, 1680-1700 (broad), 1620, 1570, S 1230, 1210 cm 1 NMR (CDC13)~ : 1.46 (t/ 3H, J=7Hz), 4.46 (q, 2H, J=7Hz), 6.80-7.60 (m, 3X), 8.13 (d, lH, ~=8Hz), 8.70 (s, lH), 9.20 (d, lH, J=8Hz) Anal. Calcd for C14HllNO3 :
C; 69.70/ H; 4.60, N; 5.81 Found : C; 69.34, H; 4.80, N; 5.78 Preparation 6 :
To a stirred solution of 3-ethoxycarbonyl-7-hydroxy-4H-quinolizin-4-one (4.5 g) in dry N,N-dimethylformamide (90 ml) was added sodium hydride (60% in mineral oil, 0.93 g) at room temperature an~ the resulting solution was kept for 30 minutes at 50C. The rcac~tion mixture was treated with methyl iodide (4.13 g) and stirred for 30 minute at the same temperature. The reaction mixture ` was poured into dilute hydrochloric acid solution and extracted with chloroform. The organic layer was washed ` with water, dried over anhydrous magnesium sulfate and evaporated to give an oil (12.3 g) which was applied to a silica gel column. Elution with chloroform-methanol (99:1) ga~e 3-ethoxycarbonyl-7-methoxy-4H-quinolizin-4-one (3.75 g), mp, 156-158C.
IR (Nujol) : 1720, 1620, lS00, 1140, 1100 cm 1 NMR (CDC13) ~ : 1.43 (t, 3H,~J=7Hz), 3.93 (s, 3H), 4.43 (q, 2H, J=7Hz), 6.63 (d, lH, ~=8.5Hz), 7.23-7.70 (m, 2H), 7.28 (d, lH, ~=8.5Hz), 9.00 (m, lH) ; Anal. Calcd for C13H13NO4 : C; 63.15, H; 5.30 Found : C; 62.62, H; 5.52 . .
,..
.
- 3~ -45~
Preparation 7 The following compounds were obtained according to a similar manner to that of Preparatlon 6.
S (1) 3-Ethoxycarbonyl-7-n-butoxy-4H-quinolizin-4-one.
mp. 132-133C.
IR (Nujol) : 1710, 1620, 1540, 1280, 1240, 1140, 845, 780 cm 1 NMR (CDC13) ~ : 1.00 (t, 3H, J=6Hz), 1.43 (t, 3H, J=7.5Hz), 1.50-2.33 (m, 4H), 4.10 (t, 2H, J=6Hz), 4.43 (q, 2H, J=7.5Hz), 6.63 (d, lH, J=8Hz), 7.23-7.67 (m, 2H), 8.28 (d, lH, J=8Hz), 8.97 (d, lH, J=2Hz) Anal. Calcd for C16H19NO4 :
C; 66.42, H; 6.62, N; 4.84 Found : C; 66.54, H; 6.52, N; 4.82 (2) 3-Ethoxycarbonyl-7-isopropoxy-4H-quinolizin-4-one. mp. 132-134C
IR (Nujol) : 1725, 1625, 1240, 1140, 1100, 970, 840 cm~l NMR (CDC13) ~ : 1.42 (d, 6H, J=6Hz), 1.43 (t, 3H, J=7.5Hz), 4.43 (q, lH, J=7.5Hz), 4.65 (m, 2H), 6.62 (d, lH, J=8.5Hz), 7.20-7.68 (m, 2H), 8.27 (d, lH, J=8.5Hz) t 9.00 (d, lH, J=2Hz) Anal. Calcd for C15H17NO4 :
C; 65.44, H; 6.22, N; 5.09 Found : C; 65.66, H; 6.15, N; 5.10 Preparation 8 A solution of ethyl 2-pyridyl acetate (6.10 ml) in ethanol (120 ml) containing sodium ethoxide (3.25 g) was refluxed for one hour. The resulting reaction mixture was treated with ethyl ethoxyacrylate (7.06 ml) and then ; 35 refluxed for three days. Acetic acid (4.6 ml) was added .
: . :
. ~ .. - . . - .: . : - - :
.: : ~ , , :
:
; ~. :. .
- ~o -~Z6~51~
to the reaction mixture and the solvent was evaporated to dryness. The oily residue was dissolved in ethyl acetate and washed with water, aqueous sodium bicarbonate solution. The organic layer was dried over magnesium S sulfate and then evaporated to give an oily residue which was chromatographed on silica gel column.
Elution with benzene-ethyl acetate (lO:l) gave ethyl 3-ethoxy-4-ethoxycarbonyl-4-(2-pyridyl)butyrate (9.80 g) as an oil.
---(to be continued to the next page.) ::~
..
... . .. ..
~: , .
.: ,...... .
~: --,: ,,, , :
~Z~
Preparation 9 The following compounds were obtained according to a similar manner to that of Preparation l.
(1) Ethyl 4-phenyl-4-(2-quinolyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1500, 1150, 1090, 1030 cm 1 NMR (CDC13, ~) : 0.82 (3H, t, J=7Hz), 1.20 (3H, t, J=7Hz), 1.28 (3H, t, J=7Hz), 3.12 (lH, m), 3.42-4.47 (6H, m), 4.67 (lH, m), 5.25 (lH, m), 7.12-8.27 (llH, m) (2) Ethyl 4-(2-pyridyl)-4-(1-naphthyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1720, 1580, 780, 750 cm 1 NMR (CDC13, ~) : 0.60 (3H, t, J=7Hz), 1.20 (6H, t, J=7Hz), 2.20-4.53 (8H, m), 5.33 (lH, m), 6.95-8010 (lOH, m), 8.58 (lH, m) (3) Ethyl 4-(2-pyridyl)-4-(4-biphenylyl~-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1485, 1300, 1150, NMR (CDC13, ~) : 0.83 (3~, t, J=7Hz), 1.33 (6H, t, J-7Hz), 3.28 (lH, m~, 3.63 (2H, q, J=7Hz), 4.25 (4H, q, J-7Hz), 4.50-5~30 (2H, m), - 7.02-7.83 (2H, m), 8.65 (lH, m) (4) Ethyl 4-phenoxy-4-(2-pyridyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, lS90, 1490, 1220, 1060, 750 cm 1 N~ (CDC13, ~) : 0.80 (3H, t, J=7Hz), 1.03 (3H, t, J-7Hz), 1.28 (3~, t, J=7Hz), 2.73 (lH, m), - . - :: , . . ,, - . :: : ~ ,.,: . ::: .: - , ~2ti~5~
3.17-3.70 (2H, m~, 3.80-4.40 (4H, m), 4.60 (lH, m), 5.55 (lH, m), 6.80-7.03 (3H, m), 7.10-7.40 (3H, m), 7.42-7.80 (2H, m), 8.65 (lH, m) (5) Ethyl 4-(3-tolyl)-4-(2-pyridyl~-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1600, 1590, 1100, 700 cm -- NMR (CC14, ~) : 0.72 (3H, t, J=7Hz), 1.07-1.45 (6H, m), 2.33 (3H, s), 3.12-3.73 (3H, m~, 3.87-4.48 (5H, m~, 4.95 (lH, m~, 6.85-7.72 (7H, m), 8.58 (lH, m~
(6) Ethyl 4-(2-pyridyl~-4-(4-chlorophenyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1490, 1090, 750 cm 1 NMR (CDC13, ~) : 0.63-0.97 (3H, m), 1.05-1.50 (6H, m), 3.03-3.82 (3H, m), 3.93-4.58 (5H, m), 4.93 (lH, m), 6.90-7.72 (7H, m), 8.53 (lH, m) (7) Ethyl-4-(2-pyridyl)-4-(3-methoxyphenyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : I750, 1730, 1590, 1470, 1440, 1370, 1160, 1100, 1040, 760, 700 cm 1 NMR (CC14, ~) : 0.73 (3H, t, J-7Hz), 1.07-1.48 (6H, m~, 2.85-4.53 (8H, m), 3.72 (3H, s), 4.93 (lH, m), 6.50 7.70 (7H, m~, 8.60 (lH, m) (8) Ethyl 4-(2-tolyl) 4-(2-pyridyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 3060, 1740, 1720, 1590, 1440, 1090, 860, 750 cm 1 ,. , . - . . ~ - . .
~, ;- ,;...; ~ : -- , - :. .
~LZ6~
NMR (CC14, ~) : 0.70 (3H, t, J=7Hz), 1.03-1.48 (6H, m), 2.4 (3H, m), 2.80-4.93 (9H, m), 6.80-7.60 (7H, m), 8.47 (lH, m) (9) Ethyl 4-(2-pyridyl)-4-t-butyldimethylsiloxy-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1580 cm Preparation 10 The following compounds were obtained according to a similar manner to that of Preparation 2.
(1) 2-E~hoxycaxbonyl-4-phenyl-lH-pyrido~1,2-a]-quinolin-l-one.
mp : 1;8-159C
IR (Nujol) : 1690, 1670, 1625, 1580, 1230, 1130, 1000 cm NMR (CDC13, ~) : 1.40 (3H, t, J=7Hz), 4.42 (2H, q, J=7Hz), 7.10-7.70 (lOH, m), 8.23 (lH, s), 9.68 (}H, m) Anal. Calcd for C22H17N03 :
C; 76.95, H; 4.99, N; 4.08 Found : C; 76.76, H; 5.05, N; 4.00 (2) 1-(l Naphthyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 161-163C
IR (Nujol) : 1690, 1665, 1590, 1270, 1240, 780, 770 cm 1 3~ NMR (CDCl3, ~) o 1.38 (3H, t, J=7Hz), 4.43 (2H, q, J=7Hz), 7.05-7.77 (8H, m), 7.80-8.10 (2E, m), 8.43 (lH, s), 9.58 (lH, m) Anal. Calcd for C22~17N03 :
C; 76.95, H; 4.39, N; 4.08 Found : C; 77.14~ H; 5.27, N; 3.89 - . ~. . ~ :
: .: :
- . . ,: . : ~ .
-:, , ', :;''' :" :: ; : ' :
~ 44 ~ ~Z~845~
(3) 1-(4-Biphenylyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 183-184.5C
IR (Nujol) : 1690, 1680, 1625, 1590, 1260, 770, 740 cm NMR (CDC13, ~) : 1.40 (3~i, t, J=7Hz), 4.50 (2H, q, J=7Hz), 7.08-8.02 (12H, m), 8.43 (lH, s), 9.55 (lH, m), Anal. Calcd for C24HlgNO3-1/4H2O :
C; 77.09, H; 5.27, N; 3.75 Found : C; 77.04, H; 5.49, N; 3.60 ~4) 1-Phenoxy-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 108-109C
IR (Nujol) : 1680, 1670, 1620, lS90, 1225, 1200, 1000 cm NMR (CDC13, ~) : 1.40 (3H, t, J=7Hz), 4.42 (2H, q, J=7Hz), 6.78-7.48 (6H, m), 7.57-7.98 (2H, m), 8.23 (lH, s), 9O45 (lH, m) Anal. Calcd for C18H15NO4 :
C; 69.89, H; 4.89, N; 4.53 Found : C; 70.18, H; 5.03, N; 4.51 (5) 1-(3-Tolyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 109-111C
IR (Nujol) : 1725, 1645, 1620, 1595, 1240, 770 cm 1 NMR (CDC13, ~) : 1.42 (3H, t, J=7Hz), 2.45 (3H, s), ~0: 4.45 (2H, q, J=7Hz), 7.08-7.48 (5H, m), 7.53-7.95 (2H, m), 8.42 (lHi, s), 9.55 (lH, m) Anal. Calcd for ClgH17NO3 1/SH2O :
C; 73.39, H; 5.64, N; 4.50 Found : C; 73.58, H; 5.62, N; 4.49 ~5 .
~Z68458 (6) 1-(4-Chlorophenyl)-3-ethoxycarbonyl-4H-- quinolizin-4-one.
mp : 159-160C
IR (Nujol) : 1680, 1670, 1490, 1295, 1260, 1240, 1130r 1020, 765 cm NMR (CDC13, ~) : 1.40 (3H, t, J=7Hz), 4.43 (2H, q, J=7Hz),6.97-7.87 (7H, m), 8.32 (lH, s), 9.48 (lH, m) Anal. Calcd for C18H14ClNO3 :
C~ 65.96, H; 4.31, N; 4.27 Found : C; 65.81, H; 4.49, N; 4.19 (7) 1-(3-Methoxyphenyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 155-157C
IR (Nujol) : 3070, 1730, 1650, 1625, 1595, 1130, 1100, 780 cm 1 NMR (CDC13, ~) : 1.42 (3H, t, J=7Hz), 3.80 (3H, s), `-4.40 (2~, q, J=7Hz), 6.85-7.93 (7H, m), 8.35 (lH, s), 9.47 (lH, m) Anal. Calcd for ClgH17NO4-1/4H2O :
C; 69.61, H; 5.38, N; 4.27 Found : C; 69.62, H; 5.29, N; 4~19 (8) 1-(2-Tolyl)-3-e~hoxycarbonyl-4H-quinolizin-4-one.
mp : 97-98C
IR (Nujol) : 1730, 1680, 1620j 1480, 1230, 1100, 785 cm 1 a~ NMR (CDC13, ~) : 1.45 (3H, t, J=7Hz), 2.10 (3H, s), 4.48 (2H, q, J=7Hz), 7.18-7.83 (7H, m), 8.42 (lH, s)~ 9.68 (lH, m) Anal. Calcd for ClgH17NO3 :
C; 74.25, H; 5.57, N; 4.56 ~5~ Found : C; 74.50, H;~5.66, N; 4.50 :.., - ~6 -iZ6~3~5~
(9) 1-t-Butyldimethylsiloxy-3-ethoxycaxbonyl-4H-quinolizin-4-one.
mp : 80C
IR (Nujol) : 1695, 1675, 1620, 1590 cm NL~R (CDC13~ ~) o 0.2 (6H" s), l.lO (9H, s), 1.45 (3H, t, J=7Hz), 4.45 (2H, q, J=7Hz), 7.10-8.0 (3H, m), 8.10 (lH, s), 9.15 ~lH, d, J=8Hz) Anal. Calcd for Cl8H25NO4Si C; 62.22, H; 7.25, N; 4.03 Found : C; 61.97, H; 7.04, N; 4.08 Preparation ll A mixture of 2-hydroxymethylpyridine (19.3 ml), t-butyldimethylsilyl chloride (36.2 g) and imidazole t27.2 g) in dLmethylformamide (190 ml~ was stirred for two hours at room temperature. Water was added to th~ reaction mixture a~d extracted with n-hexane.
The organi~ layer was washed with water, dried over magnesium sulfate and then evaporated. The residue was distilled to give 2-t-~utyldimethylsiloxymethyl-pyridine ~42.30 g).
IR (Film) : 1595, 1585, 1260, 1160, 1140 cm 1 NMR tCDCl3, ~ : l.0 (6~, s),~1.83 (9H, s~, 4.70 (2H, s), 6.85-7.20 (}Hj m), 7.25-7.70 (2H, m), 8.20-8.30 (lH, m) : ~ :
Preparation 12 To a solution of l-t-butyldimethylsiloxy-3-3Q ethoxycarbonyl-4H-quinolizin-4-one (3.32 g) in tetrahydrofuran (lO0 ml) was added a solution of tetra- ;
n-butylammonium fluoride (lM, 11.47 m}) at 0C.
The mixture was stirred ~or one hour and the solvent was distilled off. The residue was dissolved in ~5 ethyl acetate, washed with wa~er and saturated sodium : :
. . .
. ;-~ , , , : . .. ,:
., . :: , -lZ6~SE~
chloride solution. After drying over magnesium sulfate, the solvent was filtered and evaporated. The residue was chromatographed on silica gel eluting with chloroform to give l-hydroxy-3-~ethoxycarbonyl-4H-quinolizin-4-one (1.13 g)O
mp : > 250C -IR (Nujol) : 3 100, 1690, 1650, 1620 cm NMR (D~O-d6, ~) : 1.30 ~3H, t, J=7Hz), 4.25 (2H, q, J=7Hz), 7.20-7.60 (lH, m), 7.90-8.10 (2H, m), 9.20-9.30 (lH, m), 9.60 (lH, s) Anal. Calcd for C12HllNO4 :
C; 61.80, H; 4.75~ N; 6.01 Found : C; 61.11, H; 4.58, N; 5.91 ( to be continued to the next page.) 2~
~` :
.
, . : .' ' : ,~
. ,. ~
.. : ,, .. :, ., ~.' . :. :'~,- - ..
~Z68~
Freparation 13 _ The following compounds were obtained according - to a simllar manner to that of Preparation 1.
(1) Ethyl 4-phenyl-3-ethoxy-2-ethoxycarbonyl-4-(5-hydroxy-2-pyridyl)butyrate.
(2) Ethyl 3-ethoxy-2-ethoxycar~onyl-4-(N-methylanilino)-4-(2-pyridyl)butyrate.
NMR (CDC13, ~) : 0.90 (3H, t, J=7.2Hz), 1.14 (3H, t, J=7.2Hz), 1.30 (3H, t, J=7.2Hz), 3.03 (3H, s), 3.20-4.50 (7H, m), 5.00-5.60 (2H, m), 6.50-7.80 (8H, m), 8.57 (lH, d, J=4.4Hz) (3) Ethyl 3-ethoxy-2-ethoxycarbonyl-4~benzoyl-4-(2-pyridyl)butyrate.
(4) Ethyl 3-ethoxy-2-ethoxy~arbonyl-4-(2-pyridyl)-4-~enzylbutyrate.
IR (film) : 1750, 1730, 1635, 1585, 1365, 1290, 1245, 1185, 1140, 1090, 1025, 7a5, 700 cm NMR (CDC13, ~) 0 0.98-1.50 (9H, m), 2.93-4.67 (llH, m), 6.73-7.63 (8H, m), 8.48-8.63 (lH, m) (5) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-(2-pyridyl)-4-phenylthiobutyrate.
IR (film) : 1750, 1730, 159Q, 1440, 1300, 1150, 1090, 1025, 760 cm 1 ~MR (CDC13, ~j : 0.83-1.40 (9H, m), 3.07-4.43 (7H, m), 4.53-4.92 (2H, m), 7.0-7.73 (8H, m), 8.53 (lH, m) ,.. .
.;, , ."
;, ''- ,~ - .: .
gLZ6~58 Preparation 14 The following compounds were obtained according to a similar manner to that of Preparation 2.
(1) 3-Ethoxycarbonyl-7-hydrox~ phenyl-4H-quinolizin-4-one.
IR (Nujol) : 1720, 1620, 1490, 1450 cm NMR (DMSO-d6, ~) : 1.30 (3H, t, J=7Hz), 4.26 (2H, q, J=7Hz) " .46 (5H, m), 7.60-7.70 (2H, m), 7.97 (lH, s), 8.98 (lH, d, J=2Hz) Anal. Calcd for C18H15NO4 :
C, 69.89; H, 4.89; N, 4.53 Found : C, 69.20; H, 5.30; N, 4.14 (2) 3-Ethoxycarbonyl-l-(N-methylanilino)-4H-quinolizin-4-one.
IR (Nujol) : 1690, 1680, 1600, 1510, 1380, 1235 cm NMR (DMSO-d6, ~) : 1.30 (3H, t, J=7Hz), 3.30 (3H, s), 4.28 (2H, q, Ja7Hz), 6.50-8.10 (8H, m), 8.15 (lH, s), 9.40 (lH, d, J=7Hz) Anal. Calcd for ClgH18N~O3 C, 70.79; H, 5.63; N, 8.69 Found : C, 71.~0; H, 5.40; M, 8.56 mp : 129-132C
(3) 3-Ethoxycarbonyl-l-benzoyl-4H-quinolizin-4-one.
mp : 176-178C
IR (Nujol) : 1750, 1630, 1580, 1485, 1220, 1110, 785 cm 1 NMR (CDC13, ~) : 1.37 (3H, t, J=7Hz), 4.38 (2H, q, J=7Hz), 7.20-8.07 (7H, m), 8.62 (lH, s), 8.82-9.10 (lH, m), 9.42-9.67 (lH, m) ~, .
. .
: ~ ' , . ". .
.~ .
- ~ ~
:. , : , . . ..
..~
, ,~
,~ .
~ 50 ~ 1~684~
Anal. Calcd for C19H15NO4 :
C, 71.02; H, 4.70; N, 4.36 Found : C, 70.76; H, 4.96; N, 4.33 (4) 3-Ethoxycarbon~ benzyl-4H-quinolizin-4-one.
mp : 102-105C
IR (Nujol) : 1690, 1670, :L625, 1595, 1320, 1235, 765, 725 cm 1 NMR (CDC13, ~ 43 (3H, t, J=7Hz), 4.23 (2~, s), 4.48 (2H, q, J=7H;~), 7.02-7.42 (6H, m), 7.52-7.78 (2H, m), 8.28 (lH, s), 9.45 (lH, m) Anal. Calcd for C19H17NO3 :
C, 74.25; H, 5.57; N, 4.56 Found : C, 73.97; H, 5.72; N, 4.42 (5) 3-Ethoxycarbonyl-l-phenylthio-4H-quinolizin-4-one.
mp : 171-173C
IR (Nujol) : 1740, 1660, 1625, 1575, 1280, 1220, 1140, 1120, 780, 750 cm }
NMR ~CDC13, ~ : 1.40 (3H, t, J=7Hz), 4.42 (2H, q, J=7Hz), 6.68-7.47 (5Hj m), 7.73 (lH, m), 8.33 (lH, m), 8.72 (lH, s), 9.52 (lH, m) Anal. Calcd for C18H15NO3S~
C, 66.44; H, 4.65; N, 4.30 Found : C, 66.17; H, 4.69; N, 4.28 Preparat1on 15 A mixture of 2-chloromethylpyridine (50 g), N-methylaniline (42 g), and potassium carbonate tl20 g) in N,N-dimethylformamide (200 ml) was stirred for 4 hours at 120C. The reaction mixture was cooled to room temperature, added to water (1 Q), and extracted with ether. The ether extract was washed with water and then treated with actlvated carbon. After dr~ying over magnesium sulfate, the~ether extract was filtered :
~z~ s~
and concentrated. The residue was crystallized from isopropyl alcohol to give N-methyl-N-(2-pyridylmethyl)-aniline (39 g).
mp : 60C
IR (Nujol) : 1610, 1590, 1570, 1510, 1470, 1440, 1360 cm 1 Preparat1on 16 To a solution of 2-methylpyridine (9.31 g) in tetrahydrofuran (200 ml) was added a 1.5M hexane solution of n-butyllithium (73.3 ml) at -20C. The resulting solution was stirred for 30 minutes at room temperature and added to a solution of ethyl benzoate (15.02 g) in tetrahydrofuran (100 ml) at -60C. After stirring for 2 hours at -60C, acetic acid (15 ml) was added and the resulting mixture was allowed to warm to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with water.
The aqueous layer was reextracted with ethyl acetate and the combined extracts were washed with water, 10 aqueous solution of sodium hydrogen carbonate, and saturated a~ueous sodium chloride. After drying over magnesium sulfate, thè ethyl acetate extracts were filtered and evaporated. The residue ~20.5 g) was chromatographed on silica gel (Merck 70-230 mesh, 308 g) eluting with chloroform to give 2-pyridylmethyl phenyl ketone (10.86 g~ as an oil.
IR (Nuiol) : 1680, 1630, 1600, 1545, 1270, 1200, 1145, 1060, 800, 775, 690 cm 1 NMR (CDC13, ~) : 4.43 (1.5H, s), 6.02 (0.5~, s), 6.83-8.65 (9H, m) Preparation 17 (1) To a solution of 5-hydroxy-2-methylpyridine (10.66 g) in tetrahydrofuran (426 mI) was added . .
. :: : ,. . :.
,. . : .
: . . , - : .
'' '., .~., '". ' ''' ,~ ' lZ61~5~
a solution of n-butyllithium (l.SM in hexane, 143 ml) at -30~ -10C. The reaction mixture was allowed to warm to room temperature and stirred for 1 hour at room temperature. After cooling to -78C, cyclohexane (11.14 ml) was added dropwise and allowed to warm to 0C and stirred for 30 minutes at 0C. After addition of acetic acid (24.6 ml), the solvent was distilled off and the residue was diluted with ethyl acetate, and washed successively with water, 10~ aqueous sodium hydrogen carbonate and aqueous saturated sodium chloride. After drying over magnesium sulfate, the ethyl acetate extract was filtered and evaporated.
The residue was washed with ethyl acetate to give 5-hydroxy-2-~(1-hydroxycyclohexyl)methyl]pyridine (11.96 g).
IR (Nujol) : 1615, 1575, 1500, 1460 cm NMR (CD30D, ~) : 1.20-2.00 (lOH, m), 2.90 (lH, s), 4.95 (2H, s), 7.20 (2H, m), 8.05 (lH, d, J=2.0Hz) (2) A solution of S-hydroxy-2~ hydroxycyclohex-yl)methyl~pyridine (1 g) in acetic acid (15 ml) containing sulfuric acid (5 ml) was heated to reflux for 1 hour. After cooling to room temperature, the reaction mixture was poured on an ice, basified with 10~ a~ueous sodium hydrogen carbonate, and extracted with ether. The combined ether extracts were washed with aqueous saturated sodium chloride, dried over magnesium sulfate, filtered, and concentrated. The 3Q residue was washed with isopropylalcohol to give 2-benzyl-5-hydroxypyridine (409 mg).
IR (Nujol) : 1560, 1450, 1370, 1280 cm 1 NMR (CDC13, ~) : 4.07 (2H, s), 6.85-7.43 (7H, m), 8.08 (lH, d, J=3.0Hz), 10.30 (lH, broad s) ~ , .~ , .
,'' -' :; :: - : :' . . `' .: -.. : ::: : .
~268~5~
Preparation 18 To a solution of l-phenylthio-3-ethoxycarbonyl-4H-quinolizin-4-one (1.0 g) in acetic acid (20 ml) and chloroform (7.5 ml), was added potassium permanganate (583 mg) at 0C. After stirring for two hours at the same temperature, the reaction mixture was allowed to warm to room temperature and stirred further for one hour. Potassium permanganate (194 mg) was added and stirred overnight. To the resulting reaction mixture wasadded. Saturated aqueous soclium thiosulfate solution with ice-cooling and the mixture was extracted with chloroform. After drying over magnesium sulfate, the chloroform extract was filtered and evaporated. The residue was washed with diisopropyl ether to gi~e 1-phenylsulfonyl-3-ethoxycarbo~yl-4H-quinolizin-4-one (583 mg), mp 182C.
IR (Nujol) : 1710, 1680, 1640, 1580, 1200, 1150 cm 1 NMR (CDC13, ~) : 1.45 (3H~ t~ J=7Hz), 4-45 (2H, q, J=7Hz), 7.20-8.10 (7H, m), 8.60 (lH, d, J=8Hz), 9.18 (lH, s), 9.50 (lH, d, J=8Hz) Anal. Calcd for C18H15NO5S
C, 60.50; H, 4.23; N, 3.gZ
Found : C, 60.44; H, 4.51; N, 3.88 Preparation 19 To a solution of 3-ethoxycarbonyl-7-hydroxy-1-phenyl-4H-quinolizin-4-one (5 g) in N,N-dimethyl-formamide (100 ml) was added sodium hydxide (63.6~ in mineral oil, 732 mg) at 50C. After stirring for 30 minutes at 50C, n-butyliodide (2.77 ml) was added.
After stirring for 1 hour at 50C, the mixture was cooled to room temperature and added to a mixture of aqueous hydrogen chloride and an ice.
. ...
- : . --- ~
. .: -. . , - S4 ~ ~Z6~4~
The mixture was extracted with chloroform and the chloroform extract was washed with 10% aqueous sodium hydrogen carbonate and aqueous saturated sodium chloride. After drying over magnesium sulfate, the chloroform extract was filterecl and concentrated in vacuo. The residue was chromatographed on silica gel (Merck 70-230 mesh, 100 g), eluting with chloroform and then 10% methanol in chloroform to give 3~ethoxy-carbonyl-7-(n-butoxy)-1-phenyl-4H-quinolizin-4-one (2.37 g).
mp : 94-95C
IR (Nujol) : 1730, 1690, 1655, 1630, 1480 cm NMR (CDC13, ~) : 0.95 (3H, t, J=5Hz), 1.4~
(3E, t, J=5Hz), 1.30-2.10 (4H, m), 4.13 (2H, t, J=5Hz), 4.45 (2H, q, J=5Hz), 7.30 (lH, d, J=7Hz), 7.42 (5H, m), 7.67 (lH, d, J=7Hz), 8.27 (lH, s), 9.08 (lH, d, J=2Hz) Anal. Calcd for C22H23NO4 C, 72.31; H, 6.34; N, 3.~83 Found : C, 71.74; H, 6.39; N, 3.80 Preparation 20 The following compound was obtained according to a similar manner to ~hat of Preparation 6.
1-Allyloxy-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 82-84C
IR (Nujol) : 1690, 1680, 1660, 1620, 1580, 1320, 1235, 1100, 1015, 770 cm 1 NMR (CDC13, ~) : 1.43 (3H, t, J=7Hz), 4.42 (2H, a q, J=7Hz), 4.50-4.75 (2H, m), 5.15-5.67 (2H, m), 5.78-6.47 (lH, m), 6.97-8.32 (4H, m), 9.47 (lH, d, J=7.5Hz) Anal. Calcd for C15H15NO4 :
C, 65.93i H, 5.53; N, 5.13 ~`5 Found : C, 66.11; H, 5.36; N, 4.94 - '' "
lZ61~S8 Preparation 21 The following compound was obtained according to a similar manner to that of Preparation 16.
(5-Hydroxypyridin-2-yl)methyl phenyl ketone NMR ~CDC13, ~) : 4.44 (2H~ broad s), 6.85-7.70 (5~, m), 7.70-8.30 (3H, m), 9.34 (2H, s) Preparation 22 The following compound was obtained according to a similar manner to that of Preparation l.
Ethyl 4-benzoyl-3-ethoxy-2-ethoxycarbonyl-4-(5-hydroxypyridin-2-yl)butyrate IR (Nujol) : 1730, 1720, 1675, 1595 cm l Preparation 23 The followi~g compound was obtained according to a similar manner to that of Preparation 2 l-Benzoyl-3-ethoxycarbonyl-7-hydroxy-4H-quinolizin-4-one.
IR (Nujol) : 1740, 1630, 1570, 1490 cm 1 NMR tDMSO-d6, ~) : 1.22 (3H, t, J=7Hz), 4.27 (2H, q, J=7Hz), 7.~3-7.97 (6H, m), 8.22 (lH, s), 8.87 (lH, dl J=lOHz), 8.95 (lH, d, J=2Hz) Preparation_24 The following compound was obtained according to a similar manner to that of P ~ .
l-Benzoyl-3-ethoxycarbonyl-7-n-butoxy-4H-quinolizin-4-one.
mp : 158-159C
IR (NujoL) : 1740, 1680, 1630, 1580, 1510 cm " , ~
- , "
, .. . .. .
~z68~as~
NMR (CDC13, ~) : 0.98 (3H, t, J=5Hz), 1.23 (3H, t, J=7Hz), 1.30-2.10 (4H, m), 4.02-4.48 (4H, m), 7.37-8.18 (6H, m), 8.33 (lH, s), 8.88 (lH, d, J=lOHz), 9.03 (lH, cL, J=2Hz) Preparation 25 To a solution of sodium ethoxide (sodium, 151 mg) in ethanol (20 ml) was added ethyl pyrid-2-ylacetate (1 ml) at room temperature and the mixture was stirred for 1 hour at the same temperature. To the mixture was added diethyl ethoxymethylenemalonate (1.33 ml) at room temperature and the mixture was stirred at room temperature overnight. To the mixture was added acetic acid (0.75 ml) at room temperature and the precipitate was filtered and washed with water to give 1,3-diethoxycarbonyl-4H-quinolizin-4-one (896 mg).
mp : 130-131C
IR (Nujol) : 1680, 1625, 1585 cm 1 NMR (CDC13, ~) : 1.40 (6H, t), 4.20-4.55 (4H, m), 7.20-7.46 (lH, m), 7.72-8.00 (lH, m), 9.15 (lH, s), 9.27-9.64 (2H, m).
~: , :~
., : ~
: . .
. . .
~2~5~
Example 1 To a solution of 3-ethoxycarbonyl-4H-quinolizin-4-one (~.17 g) in methanol (65.2 ml) was added dropwise 6N aqueous sodium hydroxide (6.5 ml) at room temperature.
After stirring for 20 minutes, water (10 ml) was added.
After stirring for 20 minutes, water (30 ml) was also added. After stirring for an hour, the reaction mixture was acidified to pH 3 with 4M aqueous hydrochloric acid. The precipitate was filtered and washed with water to give 4H-quinolizin-4-one-3-carboxylic acid (1.75 g) as pale yellow crystal. mp 233C.
IR (Nujol) : 1730, 1610, 1585, 1320 cm 1 ~IMR (DMSO-d6) ~ : 7.26 (d, lHI J=9Hz), 7.50-7.95 (m, lH), 8.00-8.20 (m, 2H), a.41 (d, lH, lS J=9H2), 9.20-9.40 (m, lH) Example 2 To a suspension of 4H-quinolizin-4-one-3-carboxylic acid (1.69 g) in N,N-dimethylformamide ~16.9 ml) was added 1,1'-carbonyldiimidazole (2.-17 g) at ambient temperature. The resulting suspension was heated to 100C for 30 minutes and 5-amino-lI~-tetrazole (1.06 g) was added at 100C. After stirring for 20 minutes at 100C, the reaction mixture was cooled to 0C. The precipitate was filtered and washed with ( to be continued to the next page.) ~5 .
i: :.~ ' .. , ' : .. , : . - -~:
. . : ,: : : :
:. . : . .
~ 56 ~ ~26~S~
pre-cooled N,N-dimethylformamide and then ~ther to give N-~5-(lH-tetrazolyl)]-4H-quinolizin-4-one-3-carboxamide (2.0 g) as yellow solid. mp > 260C.
IR (Nujol) : 3200, 1660, 1620, 1500, 1310 cm NMR (CF3COOH) ~ : 7.42 (d, lH, J=8Hz), 7.68-7.88 (m, lH), 7.98-8.29 (m, 2H), 8.72 (d, lH, J=8Hz), 9.48 (d, lH, J=8Hz) Analysis Calcd. or CllH8O2N6 :
C; 51.56, H; 3.15, N; 32.80 Found : C; 51.70, H; 3.22, N; 32.99 Example 3 The following compounds were obtained according to a similar manner to that of Exam~le 1.
(1) 7-Ethyl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 193-195C.
IR (Nujol) : 3100, 1725, 1700, 1605 cm 1 NMR (CF3COOH) ~ : 1.52 (t, 3H, J=8Hz), 3.12 (q, 2H, J=8Hz), 7.92 (d, lH, J=9Hz), 8.32 (s, 2H), 8~73 (d, lH, J=9Hz), 9.30 (m. lH).
Analysis Calcd. for C12HllNO3 C; 66.35, H; 5.10, N; 6.45 Found : C; 66.40, H; 5.14, N; 6.46 (2) 1-Pheryl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 198C.
IR (Nujol) : 3315, 1740, 1620 cm 1 NMR (CF3COOH) ~ : 7.32-7.82 ~m, 5H), 7.92-8.23 (m, lH), 8.25-8.52 (m, 2H), 8.70 (s, lH), 9.48-9.72 (m, lH), Analysis Calcd. for C16HllNO3 5/4H2O :
C; 66.78, H; 4.64, N; 4.87 Found : C; 66.89, H; 4.22, N; 4.59 -.
.. . , .;. . .
,. , ,, , ~, .
_ 57 _ ~2~845~
(3) lH-Pyrido~1,2-a]quinolin-1-one-2-carboxylic acid.
mp. 258-260C.
IR (Nujol~ : 2500, 1720 cm 1 NMR (CF3COOH) ~ : 7.75-8.33 (m, 5H), 8.43 (d, lH, J=9Hz), 8.92 (d, lH, J-=8.5Hz), 9.73 (m, lH) ~nal. Calcd for C14HgMO3-1/10H2O :
C; 69.76, H; 3.85, N; 5.81 Found : C; 69.87, H; 4.13, N; 5.94 (4) 7-Hydroxy-4H-quinolizin-4-one-3-carboxylic acid. mp. > 270C
IR (Nujol) : 3120, 2690, 1690, 1590 cm 1 NMR (CF3COOH) ~ : 7.87 (d, lH, J=8.5Hz), 8.07-8.42 (m, 2H), 8.58 (d, lH, J=8.5Hz), 9.07 (m, lH) Anal. Calcd for CloH7NO4 1/4H2O :
C; 57.28, H; 3.61, N; 6.68 Found : C; 57.51, H; 3.60, N; 6.75 (5) 4H-P~rido[2,1-a3isoquinolin-4-one-3-carboxylic acid. mp. > 250C.
IR (Nujol) : 3100, 1730, 1640, 1620 cm 1 NMR (CF3COOH) ~ : 8.0-8.40 (m, 4H), 8.80-9.30 (m~ 4H) Anal. Calcd for C14HgMO3 :
C; 70.29, H; 3.79, N; 5~85 Fourd : C; 70.43, H; 4.15, N; 5.89 (6) 9,10-Dihydro-8H-benzo[ij]-3H-quinolizin-3-one-2-carboxylic acid. mp. 254C.
IR ~Nujol) : 3200, 1710i 1610, 1590 cm NMR (DM~O-d6) ~ : 1.80-2.30 (m, 2H), 2.70-3.20 (m, 6H), 7.30-7.85 (m, 2H), 8.10 (s, lHj, 9.10 ~d, lH, J=7Hz), 14~30 (s, lH) -.
~684~5~
Anal. Calcd for C13HllNO3 :
C; 68.11, H; 4.84, N; 6.11 Found : C; 68.21, H; 5.12, N; 6.07 (7) 7-Methoxy-4H-quinolizin-4-one-3-carboxylic acid.
mp. 215-216C.
IR (Nujol) : 3150, 3100, 1700, 1610, 1590 cm 1 NMR (CF3COOH) ~ : 4.18 (s, 3H), 7.88 (d, lH, J=8.5Hz), 8.10-8.47 (m, 2H), 8.67 (d, lH, J=8.5Hz), 8.88 (m, lH) Anal. Calcd for CllHgNO4 :
C; 60.27, H; 4.14, N; 6.39 Found : C; 59.90, H; 4.38, N; 6.48 (8) 9-Methyl-4H -quinolizin-4-one-3-carboxylic acid.
mp. 259-260C.
IR (NU3O1) : 3100, 3020, 1740, 1610, 1590, 1120, 780 cm 1 NMR (DMSO-d6) ~ : 2.92 (Sr 3H), 7.90 (d, lH, J=7.5Hz), 8.07 (d, lH, J=9.5Hz), 8,05-8.38 (m, lH), 8.82 (d, lH, J=9.5Hz), 9.42 (d, lH, J=7.5Hz) Anal. Calcd for Cl1HgNO3 :
C; 65.02, H; 4.46, N; 6.89 Found : C; 64.92, H; 4.76~ N; 6.89 (9) 8-Methyl-4H-quinolizin-4-one-3-carboxylic acid. mp. 228-230C
IR (Nujol) : 3090, 3030, 2700, 1630, 1620, 1580, 785 cm 1 NMR (CF3COOH) ~ : 2.82 (s, 3H), 7.82 (d, lH, J--9Hz), 7.92 (dd, lH, J=7Hz, 2Hz), 8.17 (d, lH, J=2Hz), 8.68 (d, lH, J-9Hz), 9.37 (d, lH, J=7Hz) Anal. Calcd for CllHgNO3 : C; 65.02, H; 4.46, N;6.89 Found : C; 64.88, H; 4.79, N; 6.85 , :
~ 59 126~4S8 (10) 6-Methyl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 185-187C.
IR (Nujol) : 3100, 2700, 1720, 1615, 1595, 1295, 1040, 800 c~ 1 S NMR (CF3COOH) ~ : 3.45 (s, 3H), 7.82 (d, lH, J=9Hz), 7.58-7.97 (m, lH), 8.10-8.30 (m, 2H), 8.68 (d, lH, J=9Hz) Anal. Calcd for CllHgNO3 : C; 65.02, H; 4.46, N; 6.89 Found : C; 64.60, H; 4.52, N; 6.91 (11) 1-Methyl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 258-260C.
IR (Nujol) : 1740, 1610, 1450, 780 cm 1 NMR (CF3COOH) ~ : 2.87 (s, 3H), 8.15 (m, lH), ~5 8.35-8.77 (m, 3H), 9.66 (m, lH~
Anal. Calcd for CllHgNO3 : C; 65.02, H 4.46, N; 6.89 Found : C; 64.70, H; 4.56, N; 6.86 (12) Cyclopenta[ij]-3H-quinolizin-3-one-2-carboxylic 2Q acid. mp > 250C
IR (Nujol) : 1730, 1620, 1590 cm 1 Anal. Calcd for C12H7NO3: C; 67-61, H; 3-31, N; 6.57 Found : C; 67.72, H; 3.37, N; 6.59 (13) 7-Methyl-4H-quinolizin-4-one-3-carboxylic acid . mp. 222-224C
IR (Nujol) : 1720, 1600, 1590, 1320, 1125, 1110, 840 cm 1 NMR (CF3COOH) ~ : 2.77 (s, 3H), 7.93 (d, lH, J=9Hz),~
~a, 3~22-8.38 (m, 2H), 8.73 (d, lH, J=9Hz), 9.32 (s, 1~) Anal. Calcd for CllHgNO3: C; 65.02, H; 4.46, N; 6.89 Found : C; 65.04, H; 4.31, N~ 6.91 (14) 4H-Quinolizin-4-one-1-carboxylic acid.
. ,.: :. -, ::-.
, i2~ 5~
mp. > 250C
IR (Nujol) : 1695, 1650 cm NMR (DMSO-d6) ~ : 6.46 (d, lH, J=lOHz), 7.30-8.20 (m, 2H), 8.41 (d, lH, J=lOHz), 9.20-9.40 (m, 2H) Anal. Calcd for CloH7NO3: C; 63,49, H; 3.73, N; 7.40 Found : C; 63.50, H; 3.81, N; 7.53 ~15) 1-Methoxy-4H-quinolizin-4-one-3-carboxylic acid.
mp. 259-261C.
IR (Nujol) : 3100, 1630-, 1620, 1580, 1100, 1070, 780 cm 1 NMR (CF3COOH) ~ : 4.27 (s, 3H), 8.00-8.67 (m, 3H), 8.90 (m, lH), 9.52 (d, lH, J=7.5Hz) Anal. Calcd for CllHgNO4: C; 60.28, H; 4 14, N; 6.39 Found : C; 59.64, H; 4.15, N; 6:30 (16) 7-n-Butoxy-4H-quinolizin-4-one-3-carboxylic acid. mp. 120-122C.
IR (Nujol) : 1725, 1600, 1590, 1320, 1070, 1000 cm 1 NMR (CF3COOH~ ~ : 1.07 (t, 3H, J=6H ), 1.30-2.20 (m, 4H), 4.40 (t, 2H, J=6HZ), 7~90 (d, lH, J=9.5Hz), 8.13-8.43 (m, 2H), 8.67 (d, lH, J=9.5H2), 8.93 (d, lH, J=2Hz) Anal- Calcd for C14H15~O4: C; 64.36, H; 5.79, N; 5.36 Found : C; 64.46, H; 5.80, N; 5.31 :
(17) 7-Isopropoxy-4H-quinolizin-4-one-3-carboxylic acid. mp. 218-219C.
IR (Nujol) : 3140, 3090, 1720, 1620, 1120, 1060, 1000, 780 cm~l ;
NMR (CF3COOH) ~ : 1.67 (d, 6H, J=6Hz), 4.97 (lH, J=6Hz), 7.88 (d, lH, J=9Hz), 8.10-8.43 (m, 4H), 8.63 ~d, lH, J=9Hz), 8.90~(d, lH, J=2Hz) -.:
:
, . ..
- .~ . : :
Anal. Calcd for C13H13NO4: C; 63.15, H; 5.30, N; 5.66 Found : C; 63.28, H; 5.18, N; 5.65 Example 4 The following compounds were o~tained according to a similar manner to that of Example 2.
(1) N-[3-(4H-1,2,4-Triazol~1)]-4H-quinoliæin-4-one 3-carboxamide. mp. > 250C.
IR (Nujol) : 3400, 3300, 1700, 1660, 1650, 1620 cm 1 NMR (CF3COOH) ~ : 7.90-9.60 (m, 7H) Anal. Calcd for C12HgN5O2 :
C; 56.47, H; 3.55, N; 27.44 - Found : C; 56.83, H; 3.79, N; 27.50 (2) N-[5-(lH-Tetrazolyl)]-9-methyl-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 3100, 3080, 1660, 1620, 1590, 790 cm~l NMR (CF3COOH) ~ : 2.80 (s, 3H), 7.50-7.87 (m, 2H), 8.08 (d, lH, J=7Hz), 8.78 (d, lH, J=9Hz), - 9.43 (d, lH, J=7Hz) Anal. Calcd for C12HloN6O2 :
C; 53.33, H; 3 73, N; 35.10 Found : C; 55.28, H; 3.88, N; 31.35 (3) N-[5-~lH-Tetrazolyl)]-7-ethyl-4H-quinolizin-4-one~3-carboxamide. mp. > 250C. ~
IR (Nujol) : 3200, 1660, 1640, 162~0, 1590, 1490 cm~l NMR (CF3COOH) ~ : 1.50 (t, 3H, J-7Hz), 3.05 (q, 2H, J=7.5Hz), 7.45 (d, lH, J=9Hz), 8.08 (s, 2H), 8.68 (d, lH, J=9Hz), 9.33 (m, lH) Anal. Calccl for C13H12N6O2 : C; 5~.93, H; 4.25, N; 29.~56 Found : C; 55.32; H; 4.32, N; 29.72 :
:, ....
- 62 _ lZ6~458 (4) N-[5-(lH-Tetrazolyl)]-l-phenyl-4H-quinolizin-4-one-3-carboxamide. mp. ~ 270C.
IR (Nujol) : 3180, 3100, 1680, 1620, 1490 cm 1 NMR (CF3COOH) ~ : 7.27-8.02 (m, 6H), 8.05-8.35 (m, 2H), 8.70 (s, lH), 9.48-9.75 (m, lH) Anal. Calcd for C17H12N6O2 :
C; 61.44, H; 3.64, N; 25.29 Found : C; 61.21, H; 3.80, N; 24.83 t5) N-[5-(lH-Tetrazolyl)]-lH-pyrido[1,2-a]-quinolin-l-one-2-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 1670, 1610, 1580, 1530, 1480 cm 1 NMR (CF3COOH) ~ : 7.32 (d, lH, J=9Hz~, 7.48-8.33 (m, SH), 8.83 (dt lH, J=8Hz), 9.63 (m, lH) Anal. Calcd for C15HloN6O2 :
C; 58.82, H; 3.29, N, 27.44 Found : C; 59.16, H; 3.42, N; 27.29 ~6) N-~5-(lH-Tetrazolyl)]-7-hydroxy-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3120, 3090, 2530, 1670, 1640, 1540, 980 cm~l NMR (CF3COOH) ~ : 7.73-7.70 (m, 2H), 8.03 (m, lH), 8.67 (m, lH), 9.15 (m, lH) Anal. Calcd for CllH8N6O3 :
C; 49.06, H; 3.32, N; 32.11 Found : C; 48.56, H; 3.47, N; 32.66 (7) N-[5-(lH-Tetrazolyl)]-4H-pyrido[2,1-a]-isoquinolin-4-one-3-carboxamide. mp. ~ 250C
IR (Nujol) : 3200, 1660, 1640, 1620 cm 1 Anal. Calcd for C15HloN6O2 :
C; 58.82, H; 3.29, N; 27.44 Found : C; 59.12, H; 3.57, N; 27.86 `
" : . . .
.. ....
. . .
1268~
(8) N-[5-(lH-Tetrazolyl)]-9,10-dihydro-8H-benzo-[ij]-3H-quinolizin-3-one-2-carboxamide. mp. > 250C.
IR (Nujol) : 3200, 1660, 1640, 1620, 1600 cm 1 NMR tCF3CooH) ~ : 2.00-2.50 (m, 2H), 3.00-3.60 (m, 4H), 7.70-8.20 (m, 2H), 8.55 (s, lH), 9.40 (d, lH, J=7Hz) Anal. Calcd for C14H12N6O2 :
C; 56.75, H; 4.08, N; 28.36 Found : C; 56.86, H; 4.27, N; 28.58 (9) N-[5-(lH-Tetrazolyl)]-7-methoxy-4H-quinolizin-4-one-3-carboxamide. mp. >270C.
IR (Nujol) : 3200, 3100, 1680, 1650, 1610 cm 1 NMR (CF3COOH) ~ : 4.13 (s, 3H), 7.42 (d, lH, J=9Hz), 7.73-8.17 (m, 2H), 8.5a (d, lH, J=9Hz), 8.92 (m, lH) Anal. Calcd for C12HloN6O3 :
C; 50.35, H; 3.52, N; 29.36 Found : C; 50.54, H; 3.55, N; 29.63 (10) N-(2-Thiazolyl)-4H-quinoIizin-4-one-3-carboxamide. mp. 240C.
IR (Nujol) : 3100, 1665, 1620, 1490, 1320 cm 1 NMR (CF3COOH) ~ : 7.30-7.90 (m,~4H), 8.03-8.47 (m, 2H), 8.75 (d, lH, J=9Hz), 9.42 (d, lH, J=7Hz) Anal. Calcd for C13HgN3OS ~
C; 57.56, H; 3.34, N; 15.49 Found : C; 57.25, H; 3.77, N; 15.24 (11) N-(2-Hydroxyphenyl)-4H-quinolizin-4-one-3-car~oxamide. mp. 247C.
IR (Nujol) : 1650, 1630, 1600 cm NMR (CDC13) ~ : 6.ao-7.50 (m, SH), 7.70 (d, 2H, ; 35 J-7Hz)~ 8.76 (d, lH, J=8Hz), 9.40 (d, lH, ~;
J=8Hz), 10.10 (s, lH) :
,.
,, :. ~ " . ~ ~ :
" . : , .. . . .
- ~4 -~Z6~58 Anal. Calcd for C16H12N2O3 :
C; 68.57, H; 4.32, N; 9.99 Found : C; 68.04, H; 4.48, N; 10.11 (12) N-(2-Pyrimidinyl)-4H-quinolizin-4-one-3-carboxamide. mp. 218C.
IR (Nujol) : 1690, 1650, 1620 cm NMR (DMSO-d6) ~ : 7.10-8.20 (m, 5H), 8.50-8 80 (m, 3H), 9.20-9.40 (m, lH) Anal. Calcd for C14HloN4O2 :
C; 63.15, H; 3.79, N; 21.04 Found : C; 61.20, H; 4.19, N; 20.76 (13) N-[5-(lH-Tetrazolyl)]-8-methyl-4H-quinolizin-4-one-3-car~oxamide~ mp. > 270C
IR (Nujol) : 3200, 3150, 1660, 1635, 1590, 780 cm 1 N~ (CF3COOH) ~ : 2.73 (~, 3H), 7.35 (d, lH, J=9Hz), 7.65 (dd, lH, J=7Hz, 2Hz), 7.83 (d, lH, J=2Hz), 8.65 (d, lH, J=9Hz), 9.38 (d, lH, J=7Hz) Anal. Calcd for C12HloN6O2 :
C; 53.33, H; 3.73, N; 31.10 Found : C; 54.03, H; 3.84; N; 30.38 (14) N-~5-(lH-Tetrazolyl)]-6-methyl-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 1660, 1620, 1590, 1030, 820 790 cm 1 NMR (CF3COOH) ~ : 3.33 (s, 3H), 7.37 (d, lH, J=9Hz), 7.37-7.62 (m, lH), 7.87-8.07 (m, 2H), 8.60 (d, lH, J=9Hz) Anal. Calcd for Cl~HloN6O2 :
C; 53.33, H; 3.73, N; 31.10 Found : C; 53.63, H; 3.92, N; 31.42 ~ , . , . :
- - .
.. ~ :
.. .
- : : ,;' :
- 65 - 1~6~4~
.; ~ :
20 Prepa_ation 4 :
The following compounds wexe obtained according to a similar manner to that of Preparation 2.
~;~ (1) 2-Ethoxycarbonyl-lH-pyrido[1,2-a]quinolin-1-one.
mp. 104-105C. : ~ :
IR (Nujol) : 1730, 1660, 1530 cm 1 ;~ NMR (CDC13) ~ : ~ 1.43 (t, 3H, J=7Hz), 4.43 (q, 2H, J=7Hz), 6.40 (d, lH, J=8Hz)~, 7.0 and 7.45 ; (ABq, 2H, J=lOHz), 7.50-7.70 (m, 4H), 8.20 : ~30 (d, lH, J=8Hz~, 9.70-10.0 (m, IH) ~;
~ (2) 7-Ethyl-3-athoxycarbonyl-4H-~uinolizin-4-one.
- mp. 81-83C.
IR (Nujol) : 1720, 1630 cm 1 ;35 NMR (CDC13) ~ : 1.32 (t, 3H, J=7Hz), 1.44 (t, 3H, .
' ,::: - ' ~ -- 34 ~ iLZ ~ 845 8 J=7Hz), 2.76 (q, 2EI, J=7Hz), 4.40 tq, 2H, J=7Hz), 6u60 (d, lH, J=8Hz), 7.52 (s, 2H), 8.32 (d, lH, J=8Hz), 9.20 (s, lH) (3) 1-Phenyl-3-ethoxycar~onyl-4H-quinolizin-4-one.
mp. 120-123C.
IR (Nujol) : 1730, 1620 cm 1 NMR (CDC13) ~ : 1.36 (t, 3H, J=7Hz), 4.38 (q, 2H, J=7Hz), 7.04-7.76 (m, 7H), 8.32 (s, lH), 9.48 (d, lH, J=8Hz) (4) 8-Hydroxy-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp. 242C. ~dec.) IR (Nujol) : 3300, 3200, 1680, 1660, 1620, 1300, ;; 15 1140, 960, 900 cm 1 ` NMR (DMSO-d6) ~: 2~27 (t, 3H, J=7Hz), 4.23 (q, 2H, J=8Hz), 6.13 (d, lH, J=8Hz), 7.58 (dd, lH, J=2Hz, 8Hz), 7.90 (d, lH, J=8Hz), 8.07 (d, lH, J=8Hz), 8.82 (d, lH, J=2Hz) Anal. Calcd for C12HllNO4 : C, 61~80; H~ 4-75 Found : C, 62.18; H, 5.05 `l (5) 3-E~hoxycarbonyl-4H-pyrido~2,1-a~isoquinolin-4-`~' one. mp. 155C.
IR (Nujol) : 3100, 1740, 1650, 1640 cm 1 NMR (CDC13) ~ :~ 1.46 (t, 3H, J=7Hz), 4.46 (q, 2H,~
J=7Hz), 7.23 (d, lH, J=8Hz), 7.35 (d, lH, J=8Hz), 7.50-7.83 (m, 3H), 8.20-8.50 (m, lH), 8.46 (d, lH, J=8Hz), 9.10~(d, lH, J=8Hz), ` ~ 30 Anal. Cal~d for C16H13NO3 :
C; 71.90, H; 4.90, N; 5.24 Found : C; 71.40, H; 5.06, N; 5.17 ::` ` : : :
(6) 9-Nethyl-3-ethoxycarbonyl-4H-quinoLizin-4-one.
mp. 125-126C.
: ~
:~
- 35 - ~Z6~4s~
IR (Nujol) : 3090, 1725, 1645, 1590, 1125, 1100 cm 1 NMR (CDC13) ~ : 1.40 (t, 3H, J=7Hz~, 2.50 (s, 3H), 4.42 (q, 2H, J=7Hz), 6.63 (d, lH, J=9Hz), 7.07 (t, lH, J=7Hz), 7.47 (d, lH, J=7Hz), 8.35 (d, lH, J=9Hz), 9.32 (d, J=7Hz, lH) 13 13 3 C; 67.52, H; 5.67 Found : C; 67.51, H; 5.83 _ (7) 8-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one. mp. 146-148C.
IR (Nujol) : 3060, 1720, 1660, 1640, 1245, 1155, 790 cm~l NMR (CDC13) ~ : 1.40 (t, 3H, J=7Hz), 2.50 (s, 3H), 4.38 (q, 2H, J=7Hz), 6.50 (d, lE, J=9Hz), 7.00 (dd, lH, J=7Hz, 2Hz), 7.30 (d, lH, J=2Hz), 8.32 (d, lH, J=9Hz), 9.28 (d, lH, J=7Hz) r C13H13NO3 : C; 67.52, H; 5.67 Found : C; 67.38, H; 5.65 (8) 3-Ethoxycarbonyl-6-methyl-4H-quinolizin-4-one. mp. 90-93C.
IR (Nujol) : 1720, 1650, 1620, 1590, 1265, 1120, ~ 1100, 795 cm 1 NMR (CDC13) ~ : 1.35 (t, 3H, J=7Hz), 3.05 (s, 3H), 4.38 (q, 2H, J=7Hæ), 6.38 (d, lH, J=8Hz), 6.67 (m, lH), 7.25 (d, lH, J=4.5Hz), 8.18 (d, lH, J=8Hz) Anal. Calcd for C13H13NO3 :
C; 67.52, H; 5.67, N; 6.07 Found : C; 67.28, H; 5.63, N; 6.03 (9) 1-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one. mp. 142-143C.
, . ~ . .
. ~.
.
~ . :
- 36 - ~Z~5~
IR (Nujol) : 1720, 1650, 1620, 1595, 1300, 1230, 1160, 1120, 775 cm 1 NMR (CDC13) ~ : 1.42 (t, 3H, J=7Hz), 2.40 (s, 3H), 4.43 (q, 2H, J=7Hz), 7.20 (m, lH), 7.62-7.80 ; 5 (m, 2H), 8.25 (s, lH), 9.47 (m, 1~) Anal. Calcd for C13H13NO3 :
C; 67.52, H; 5.67, N; 6.06 Found : C; 67.49, H; 5.94, N; 6.06 (10) 7-Methyl-3-ethoxycarbonyl-4H-quinolizin-4-one. mp. 146-149C.
IR (Nujol) : 1720, 1620, 1145, lIlD cm 1 NMR (CDC13) ~ : 1.42 (t, 3H, J=7Hz), 2.45 (s, 3H), 4.43 (q, 2H, J=7Hz), 6.62 (d, lH, J=8Hæ), 7.47-7.57 (m, 2H), 8.33 (d, lH, J=8Hz), 9.23 (m, lH) Anal. Calcd for C13H13NO3 C; 67.52, H; 5.62, N; 6.06 Found : C; 67.44, H; 5.85j N; 6.00 (11) 2-Ethoxycarbonyl-8,9-dihydrocyclopenta[ij¦-3H-quinolizin-3-one. mp. 149C.
`l IR (Nujol) : 3100, 1720, 1640, 1620, 1600, 1550, 1210, 1150 cm 1 ; 25 NMR (CDC13) ~ : 1.43~(t, 3H, J-7Hz), 3.30 (broad s, 4H), 4.30 (q, 2H, J=7Hz),~ 7.0-7.30 ~m, 2H), 8.30 (s, lH), 8.86 (d, lH, J=6Hz) Anal. Calcd for C14H13NO3 :
C; 69.12, H; 5.39, N; 5.76 Found : C; 68.16, H; 5.47, N; 5.69 :~ :
~12) 2-Ethoxycarbonyl-9,10-dihydro-8H-benzo[ij]-3H-quinoli2in-3-one. mp. 118C.
IR (Nujol) ~: 1680, 1620, 1600, 1220 cm NMR (CDC13) ~ : 1.40 (t, 3~, J=7Hz), 1.85-2.20 (m, 2H), :: :
::
, . , ... ... ~ . .
~Z16~5~
2.80-3.20 (m, 4H), 4.40 (q, 2H, J=7Hz), 6.85-7.30 (m, 2H), 8.13 (s, lH), 9.20 (d, lE, J=7Hz) Anal. Calcd for C15H15NO3 :
C; 70.02, ~; 5.88, N; 5.44 Found : C; 69.78, ~; 5.95, N; 5.38 (13) 1-Methoxy-3-ethoxycarbonyl-4H quinolizin-4-one. mp. 132-133C.
IR (Nujol) : 1680, 1670, 1620, 1595, 1360, 1120, 1020, 770 cm NMR (CDC13) ~ : 1.43 (t, 3H, J=7Hz), 3.93 (s, 3H), 4.45 (q, 2H, J=7Hz), 7.25 (m, lH), 7.67 (m, lH), 7.97-8.20 (m, 2H), 9.47 (d, lH, J=7.5Hz) Anal. Calcd for C13H13NO4 :
C; 63.15, H; 5.30, N; 5.66 Found : C; 62.80, H; 5.33, N; 5.63 (143 1-Ethoxycarbonyl-4H-quinolizin-4-one.
mp. 114C.
IR (Nujol) : 1725, 1680, 1630 c~ 1 Anal. Calcd for C12HllNO3 :
~ C; 66.35, H; 5.10, N; 10.45 -~ 25 Found : C; 66.19, H; 4.81, N; 6.42 -~ Preparation 5 A solution of 2-ethoxycarbonyl-8,~-dihydrocyclopenta-[ij]-3H-quinolizin-3-one (2.2 g)~and~dich}orodicyano-benzoquinone (2~26 g) in benzene (110 ml) was refluxed for two hours. The reaction mixture was cooled to 0C
and the precipitates were filter~ed The filtrate was concentrated and the residue was chromatographed on silica gel column (44 g) eluting with chloroform-methanol (100:1 - 10:1). Evaporation of corresponding fractions :
: ` :
~: :
~Z~8~
gave crude crystals which was washed with a mixture of ether and hexane to afford 2-ethoxycarbonylcyclopenta-[ij]-3H-quinolizin-3-one (1.82 g), mp. 127C.
IR (Nujol) : 3100, 1680-1700 (broad), 1620, 1570, S 1230, 1210 cm 1 NMR (CDC13)~ : 1.46 (t/ 3H, J=7Hz), 4.46 (q, 2H, J=7Hz), 6.80-7.60 (m, 3X), 8.13 (d, lH, ~=8Hz), 8.70 (s, lH), 9.20 (d, lH, J=8Hz) Anal. Calcd for C14HllNO3 :
C; 69.70/ H; 4.60, N; 5.81 Found : C; 69.34, H; 4.80, N; 5.78 Preparation 6 :
To a stirred solution of 3-ethoxycarbonyl-7-hydroxy-4H-quinolizin-4-one (4.5 g) in dry N,N-dimethylformamide (90 ml) was added sodium hydride (60% in mineral oil, 0.93 g) at room temperature an~ the resulting solution was kept for 30 minutes at 50C. The rcac~tion mixture was treated with methyl iodide (4.13 g) and stirred for 30 minute at the same temperature. The reaction mixture ` was poured into dilute hydrochloric acid solution and extracted with chloroform. The organic layer was washed ` with water, dried over anhydrous magnesium sulfate and evaporated to give an oil (12.3 g) which was applied to a silica gel column. Elution with chloroform-methanol (99:1) ga~e 3-ethoxycarbonyl-7-methoxy-4H-quinolizin-4-one (3.75 g), mp, 156-158C.
IR (Nujol) : 1720, 1620, lS00, 1140, 1100 cm 1 NMR (CDC13) ~ : 1.43 (t, 3H,~J=7Hz), 3.93 (s, 3H), 4.43 (q, 2H, J=7Hz), 6.63 (d, lH, ~=8.5Hz), 7.23-7.70 (m, 2H), 7.28 (d, lH, ~=8.5Hz), 9.00 (m, lH) ; Anal. Calcd for C13H13NO4 : C; 63.15, H; 5.30 Found : C; 62.62, H; 5.52 . .
,..
.
- 3~ -45~
Preparation 7 The following compounds were obtained according to a similar manner to that of Preparatlon 6.
S (1) 3-Ethoxycarbonyl-7-n-butoxy-4H-quinolizin-4-one.
mp. 132-133C.
IR (Nujol) : 1710, 1620, 1540, 1280, 1240, 1140, 845, 780 cm 1 NMR (CDC13) ~ : 1.00 (t, 3H, J=6Hz), 1.43 (t, 3H, J=7.5Hz), 1.50-2.33 (m, 4H), 4.10 (t, 2H, J=6Hz), 4.43 (q, 2H, J=7.5Hz), 6.63 (d, lH, J=8Hz), 7.23-7.67 (m, 2H), 8.28 (d, lH, J=8Hz), 8.97 (d, lH, J=2Hz) Anal. Calcd for C16H19NO4 :
C; 66.42, H; 6.62, N; 4.84 Found : C; 66.54, H; 6.52, N; 4.82 (2) 3-Ethoxycarbonyl-7-isopropoxy-4H-quinolizin-4-one. mp. 132-134C
IR (Nujol) : 1725, 1625, 1240, 1140, 1100, 970, 840 cm~l NMR (CDC13) ~ : 1.42 (d, 6H, J=6Hz), 1.43 (t, 3H, J=7.5Hz), 4.43 (q, lH, J=7.5Hz), 4.65 (m, 2H), 6.62 (d, lH, J=8.5Hz), 7.20-7.68 (m, 2H), 8.27 (d, lH, J=8.5Hz) t 9.00 (d, lH, J=2Hz) Anal. Calcd for C15H17NO4 :
C; 65.44, H; 6.22, N; 5.09 Found : C; 65.66, H; 6.15, N; 5.10 Preparation 8 A solution of ethyl 2-pyridyl acetate (6.10 ml) in ethanol (120 ml) containing sodium ethoxide (3.25 g) was refluxed for one hour. The resulting reaction mixture was treated with ethyl ethoxyacrylate (7.06 ml) and then ; 35 refluxed for three days. Acetic acid (4.6 ml) was added .
: . :
. ~ .. - . . - .: . : - - :
.: : ~ , , :
:
; ~. :. .
- ~o -~Z6~51~
to the reaction mixture and the solvent was evaporated to dryness. The oily residue was dissolved in ethyl acetate and washed with water, aqueous sodium bicarbonate solution. The organic layer was dried over magnesium S sulfate and then evaporated to give an oily residue which was chromatographed on silica gel column.
Elution with benzene-ethyl acetate (lO:l) gave ethyl 3-ethoxy-4-ethoxycarbonyl-4-(2-pyridyl)butyrate (9.80 g) as an oil.
---(to be continued to the next page.) ::~
..
... . .. ..
~: , .
.: ,...... .
~: --,: ,,, , :
~Z~
Preparation 9 The following compounds were obtained according to a similar manner to that of Preparation l.
(1) Ethyl 4-phenyl-4-(2-quinolyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1500, 1150, 1090, 1030 cm 1 NMR (CDC13, ~) : 0.82 (3H, t, J=7Hz), 1.20 (3H, t, J=7Hz), 1.28 (3H, t, J=7Hz), 3.12 (lH, m), 3.42-4.47 (6H, m), 4.67 (lH, m), 5.25 (lH, m), 7.12-8.27 (llH, m) (2) Ethyl 4-(2-pyridyl)-4-(1-naphthyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1720, 1580, 780, 750 cm 1 NMR (CDC13, ~) : 0.60 (3H, t, J=7Hz), 1.20 (6H, t, J=7Hz), 2.20-4.53 (8H, m), 5.33 (lH, m), 6.95-8010 (lOH, m), 8.58 (lH, m) (3) Ethyl 4-(2-pyridyl)-4-(4-biphenylyl~-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1485, 1300, 1150, NMR (CDC13, ~) : 0.83 (3~, t, J=7Hz), 1.33 (6H, t, J-7Hz), 3.28 (lH, m~, 3.63 (2H, q, J=7Hz), 4.25 (4H, q, J-7Hz), 4.50-5~30 (2H, m), - 7.02-7.83 (2H, m), 8.65 (lH, m) (4) Ethyl 4-phenoxy-4-(2-pyridyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, lS90, 1490, 1220, 1060, 750 cm 1 N~ (CDC13, ~) : 0.80 (3H, t, J=7Hz), 1.03 (3H, t, J-7Hz), 1.28 (3~, t, J=7Hz), 2.73 (lH, m), - . - :: , . . ,, - . :: : ~ ,.,: . ::: .: - , ~2ti~5~
3.17-3.70 (2H, m~, 3.80-4.40 (4H, m), 4.60 (lH, m), 5.55 (lH, m), 6.80-7.03 (3H, m), 7.10-7.40 (3H, m), 7.42-7.80 (2H, m), 8.65 (lH, m) (5) Ethyl 4-(3-tolyl)-4-(2-pyridyl~-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1600, 1590, 1100, 700 cm -- NMR (CC14, ~) : 0.72 (3H, t, J=7Hz), 1.07-1.45 (6H, m), 2.33 (3H, s), 3.12-3.73 (3H, m~, 3.87-4.48 (5H, m~, 4.95 (lH, m~, 6.85-7.72 (7H, m), 8.58 (lH, m~
(6) Ethyl 4-(2-pyridyl~-4-(4-chlorophenyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1490, 1090, 750 cm 1 NMR (CDC13, ~) : 0.63-0.97 (3H, m), 1.05-1.50 (6H, m), 3.03-3.82 (3H, m), 3.93-4.58 (5H, m), 4.93 (lH, m), 6.90-7.72 (7H, m), 8.53 (lH, m) (7) Ethyl-4-(2-pyridyl)-4-(3-methoxyphenyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : I750, 1730, 1590, 1470, 1440, 1370, 1160, 1100, 1040, 760, 700 cm 1 NMR (CC14, ~) : 0.73 (3H, t, J-7Hz), 1.07-1.48 (6H, m~, 2.85-4.53 (8H, m), 3.72 (3H, s), 4.93 (lH, m), 6.50 7.70 (7H, m~, 8.60 (lH, m) (8) Ethyl 4-(2-tolyl) 4-(2-pyridyl)-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 3060, 1740, 1720, 1590, 1440, 1090, 860, 750 cm 1 ,. , . - . . ~ - . .
~, ;- ,;...; ~ : -- , - :. .
~LZ6~
NMR (CC14, ~) : 0.70 (3H, t, J=7Hz), 1.03-1.48 (6H, m), 2.4 (3H, m), 2.80-4.93 (9H, m), 6.80-7.60 (7H, m), 8.47 (lH, m) (9) Ethyl 4-(2-pyridyl)-4-t-butyldimethylsiloxy-3-ethoxy-2-ethoxycarbonylbutyrate.
IR (Film) : 1750, 1730, 1590, 1580 cm Preparation 10 The following compounds were obtained according to a similar manner to that of Preparation 2.
(1) 2-E~hoxycaxbonyl-4-phenyl-lH-pyrido~1,2-a]-quinolin-l-one.
mp : 1;8-159C
IR (Nujol) : 1690, 1670, 1625, 1580, 1230, 1130, 1000 cm NMR (CDC13, ~) : 1.40 (3H, t, J=7Hz), 4.42 (2H, q, J=7Hz), 7.10-7.70 (lOH, m), 8.23 (lH, s), 9.68 (}H, m) Anal. Calcd for C22H17N03 :
C; 76.95, H; 4.99, N; 4.08 Found : C; 76.76, H; 5.05, N; 4.00 (2) 1-(l Naphthyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 161-163C
IR (Nujol) : 1690, 1665, 1590, 1270, 1240, 780, 770 cm 1 3~ NMR (CDCl3, ~) o 1.38 (3H, t, J=7Hz), 4.43 (2H, q, J=7Hz), 7.05-7.77 (8H, m), 7.80-8.10 (2E, m), 8.43 (lH, s), 9.58 (lH, m) Anal. Calcd for C22~17N03 :
C; 76.95, H; 4.39, N; 4.08 Found : C; 77.14~ H; 5.27, N; 3.89 - . ~. . ~ :
: .: :
- . . ,: . : ~ .
-:, , ', :;''' :" :: ; : ' :
~ 44 ~ ~Z~845~
(3) 1-(4-Biphenylyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 183-184.5C
IR (Nujol) : 1690, 1680, 1625, 1590, 1260, 770, 740 cm NMR (CDC13, ~) : 1.40 (3~i, t, J=7Hz), 4.50 (2H, q, J=7Hz), 7.08-8.02 (12H, m), 8.43 (lH, s), 9.55 (lH, m), Anal. Calcd for C24HlgNO3-1/4H2O :
C; 77.09, H; 5.27, N; 3.75 Found : C; 77.04, H; 5.49, N; 3.60 ~4) 1-Phenoxy-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 108-109C
IR (Nujol) : 1680, 1670, 1620, lS90, 1225, 1200, 1000 cm NMR (CDC13, ~) : 1.40 (3H, t, J=7Hz), 4.42 (2H, q, J=7Hz), 6.78-7.48 (6H, m), 7.57-7.98 (2H, m), 8.23 (lH, s), 9O45 (lH, m) Anal. Calcd for C18H15NO4 :
C; 69.89, H; 4.89, N; 4.53 Found : C; 70.18, H; 5.03, N; 4.51 (5) 1-(3-Tolyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 109-111C
IR (Nujol) : 1725, 1645, 1620, 1595, 1240, 770 cm 1 NMR (CDC13, ~) : 1.42 (3H, t, J=7Hz), 2.45 (3H, s), ~0: 4.45 (2H, q, J=7Hz), 7.08-7.48 (5H, m), 7.53-7.95 (2H, m), 8.42 (lHi, s), 9.55 (lH, m) Anal. Calcd for ClgH17NO3 1/SH2O :
C; 73.39, H; 5.64, N; 4.50 Found : C; 73.58, H; 5.62, N; 4.49 ~5 .
~Z68458 (6) 1-(4-Chlorophenyl)-3-ethoxycarbonyl-4H-- quinolizin-4-one.
mp : 159-160C
IR (Nujol) : 1680, 1670, 1490, 1295, 1260, 1240, 1130r 1020, 765 cm NMR (CDC13, ~) : 1.40 (3H, t, J=7Hz), 4.43 (2H, q, J=7Hz),6.97-7.87 (7H, m), 8.32 (lH, s), 9.48 (lH, m) Anal. Calcd for C18H14ClNO3 :
C~ 65.96, H; 4.31, N; 4.27 Found : C; 65.81, H; 4.49, N; 4.19 (7) 1-(3-Methoxyphenyl)-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 155-157C
IR (Nujol) : 3070, 1730, 1650, 1625, 1595, 1130, 1100, 780 cm 1 NMR (CDC13, ~) : 1.42 (3H, t, J=7Hz), 3.80 (3H, s), `-4.40 (2~, q, J=7Hz), 6.85-7.93 (7H, m), 8.35 (lH, s), 9.47 (lH, m) Anal. Calcd for ClgH17NO4-1/4H2O :
C; 69.61, H; 5.38, N; 4.27 Found : C; 69.62, H; 5.29, N; 4~19 (8) 1-(2-Tolyl)-3-e~hoxycarbonyl-4H-quinolizin-4-one.
mp : 97-98C
IR (Nujol) : 1730, 1680, 1620j 1480, 1230, 1100, 785 cm 1 a~ NMR (CDC13, ~) : 1.45 (3H, t, J=7Hz), 2.10 (3H, s), 4.48 (2H, q, J=7Hz), 7.18-7.83 (7H, m), 8.42 (lH, s)~ 9.68 (lH, m) Anal. Calcd for ClgH17NO3 :
C; 74.25, H; 5.57, N; 4.56 ~5~ Found : C; 74.50, H;~5.66, N; 4.50 :.., - ~6 -iZ6~3~5~
(9) 1-t-Butyldimethylsiloxy-3-ethoxycaxbonyl-4H-quinolizin-4-one.
mp : 80C
IR (Nujol) : 1695, 1675, 1620, 1590 cm NL~R (CDC13~ ~) o 0.2 (6H" s), l.lO (9H, s), 1.45 (3H, t, J=7Hz), 4.45 (2H, q, J=7Hz), 7.10-8.0 (3H, m), 8.10 (lH, s), 9.15 ~lH, d, J=8Hz) Anal. Calcd for Cl8H25NO4Si C; 62.22, H; 7.25, N; 4.03 Found : C; 61.97, H; 7.04, N; 4.08 Preparation ll A mixture of 2-hydroxymethylpyridine (19.3 ml), t-butyldimethylsilyl chloride (36.2 g) and imidazole t27.2 g) in dLmethylformamide (190 ml~ was stirred for two hours at room temperature. Water was added to th~ reaction mixture a~d extracted with n-hexane.
The organi~ layer was washed with water, dried over magnesium sulfate and then evaporated. The residue was distilled to give 2-t-~utyldimethylsiloxymethyl-pyridine ~42.30 g).
IR (Film) : 1595, 1585, 1260, 1160, 1140 cm 1 NMR tCDCl3, ~ : l.0 (6~, s),~1.83 (9H, s~, 4.70 (2H, s), 6.85-7.20 (}Hj m), 7.25-7.70 (2H, m), 8.20-8.30 (lH, m) : ~ :
Preparation 12 To a solution of l-t-butyldimethylsiloxy-3-3Q ethoxycarbonyl-4H-quinolizin-4-one (3.32 g) in tetrahydrofuran (lO0 ml) was added a solution of tetra- ;
n-butylammonium fluoride (lM, 11.47 m}) at 0C.
The mixture was stirred ~or one hour and the solvent was distilled off. The residue was dissolved in ~5 ethyl acetate, washed with wa~er and saturated sodium : :
. . .
. ;-~ , , , : . .. ,:
., . :: , -lZ6~SE~
chloride solution. After drying over magnesium sulfate, the solvent was filtered and evaporated. The residue was chromatographed on silica gel eluting with chloroform to give l-hydroxy-3-~ethoxycarbonyl-4H-quinolizin-4-one (1.13 g)O
mp : > 250C -IR (Nujol) : 3 100, 1690, 1650, 1620 cm NMR (D~O-d6, ~) : 1.30 ~3H, t, J=7Hz), 4.25 (2H, q, J=7Hz), 7.20-7.60 (lH, m), 7.90-8.10 (2H, m), 9.20-9.30 (lH, m), 9.60 (lH, s) Anal. Calcd for C12HllNO4 :
C; 61.80, H; 4.75~ N; 6.01 Found : C; 61.11, H; 4.58, N; 5.91 ( to be continued to the next page.) 2~
~` :
.
, . : .' ' : ,~
. ,. ~
.. : ,, .. :, ., ~.' . :. :'~,- - ..
~Z68~
Freparation 13 _ The following compounds were obtained according - to a simllar manner to that of Preparation 1.
(1) Ethyl 4-phenyl-3-ethoxy-2-ethoxycarbonyl-4-(5-hydroxy-2-pyridyl)butyrate.
(2) Ethyl 3-ethoxy-2-ethoxycar~onyl-4-(N-methylanilino)-4-(2-pyridyl)butyrate.
NMR (CDC13, ~) : 0.90 (3H, t, J=7.2Hz), 1.14 (3H, t, J=7.2Hz), 1.30 (3H, t, J=7.2Hz), 3.03 (3H, s), 3.20-4.50 (7H, m), 5.00-5.60 (2H, m), 6.50-7.80 (8H, m), 8.57 (lH, d, J=4.4Hz) (3) Ethyl 3-ethoxy-2-ethoxycarbonyl-4~benzoyl-4-(2-pyridyl)butyrate.
(4) Ethyl 3-ethoxy-2-ethoxy~arbonyl-4-(2-pyridyl)-4-~enzylbutyrate.
IR (film) : 1750, 1730, 1635, 1585, 1365, 1290, 1245, 1185, 1140, 1090, 1025, 7a5, 700 cm NMR (CDC13, ~) 0 0.98-1.50 (9H, m), 2.93-4.67 (llH, m), 6.73-7.63 (8H, m), 8.48-8.63 (lH, m) (5) Ethyl 3-ethoxy-2-ethoxycarbonyl-4-(2-pyridyl)-4-phenylthiobutyrate.
IR (film) : 1750, 1730, 159Q, 1440, 1300, 1150, 1090, 1025, 760 cm 1 ~MR (CDC13, ~j : 0.83-1.40 (9H, m), 3.07-4.43 (7H, m), 4.53-4.92 (2H, m), 7.0-7.73 (8H, m), 8.53 (lH, m) ,.. .
.;, , ."
;, ''- ,~ - .: .
gLZ6~58 Preparation 14 The following compounds were obtained according to a similar manner to that of Preparation 2.
(1) 3-Ethoxycarbonyl-7-hydrox~ phenyl-4H-quinolizin-4-one.
IR (Nujol) : 1720, 1620, 1490, 1450 cm NMR (DMSO-d6, ~) : 1.30 (3H, t, J=7Hz), 4.26 (2H, q, J=7Hz) " .46 (5H, m), 7.60-7.70 (2H, m), 7.97 (lH, s), 8.98 (lH, d, J=2Hz) Anal. Calcd for C18H15NO4 :
C, 69.89; H, 4.89; N, 4.53 Found : C, 69.20; H, 5.30; N, 4.14 (2) 3-Ethoxycarbonyl-l-(N-methylanilino)-4H-quinolizin-4-one.
IR (Nujol) : 1690, 1680, 1600, 1510, 1380, 1235 cm NMR (DMSO-d6, ~) : 1.30 (3H, t, J=7Hz), 3.30 (3H, s), 4.28 (2H, q, Ja7Hz), 6.50-8.10 (8H, m), 8.15 (lH, s), 9.40 (lH, d, J=7Hz) Anal. Calcd for ClgH18N~O3 C, 70.79; H, 5.63; N, 8.69 Found : C, 71.~0; H, 5.40; M, 8.56 mp : 129-132C
(3) 3-Ethoxycarbonyl-l-benzoyl-4H-quinolizin-4-one.
mp : 176-178C
IR (Nujol) : 1750, 1630, 1580, 1485, 1220, 1110, 785 cm 1 NMR (CDC13, ~) : 1.37 (3H, t, J=7Hz), 4.38 (2H, q, J=7Hz), 7.20-8.07 (7H, m), 8.62 (lH, s), 8.82-9.10 (lH, m), 9.42-9.67 (lH, m) ~, .
. .
: ~ ' , . ". .
.~ .
- ~ ~
:. , : , . . ..
..~
, ,~
,~ .
~ 50 ~ 1~684~
Anal. Calcd for C19H15NO4 :
C, 71.02; H, 4.70; N, 4.36 Found : C, 70.76; H, 4.96; N, 4.33 (4) 3-Ethoxycarbon~ benzyl-4H-quinolizin-4-one.
mp : 102-105C
IR (Nujol) : 1690, 1670, :L625, 1595, 1320, 1235, 765, 725 cm 1 NMR (CDC13, ~ 43 (3H, t, J=7Hz), 4.23 (2~, s), 4.48 (2H, q, J=7H;~), 7.02-7.42 (6H, m), 7.52-7.78 (2H, m), 8.28 (lH, s), 9.45 (lH, m) Anal. Calcd for C19H17NO3 :
C, 74.25; H, 5.57; N, 4.56 Found : C, 73.97; H, 5.72; N, 4.42 (5) 3-Ethoxycarbonyl-l-phenylthio-4H-quinolizin-4-one.
mp : 171-173C
IR (Nujol) : 1740, 1660, 1625, 1575, 1280, 1220, 1140, 1120, 780, 750 cm }
NMR ~CDC13, ~ : 1.40 (3H, t, J=7Hz), 4.42 (2H, q, J=7Hz), 6.68-7.47 (5Hj m), 7.73 (lH, m), 8.33 (lH, m), 8.72 (lH, s), 9.52 (lH, m) Anal. Calcd for C18H15NO3S~
C, 66.44; H, 4.65; N, 4.30 Found : C, 66.17; H, 4.69; N, 4.28 Preparat1on 15 A mixture of 2-chloromethylpyridine (50 g), N-methylaniline (42 g), and potassium carbonate tl20 g) in N,N-dimethylformamide (200 ml) was stirred for 4 hours at 120C. The reaction mixture was cooled to room temperature, added to water (1 Q), and extracted with ether. The ether extract was washed with water and then treated with actlvated carbon. After dr~ying over magnesium sulfate, the~ether extract was filtered :
~z~ s~
and concentrated. The residue was crystallized from isopropyl alcohol to give N-methyl-N-(2-pyridylmethyl)-aniline (39 g).
mp : 60C
IR (Nujol) : 1610, 1590, 1570, 1510, 1470, 1440, 1360 cm 1 Preparat1on 16 To a solution of 2-methylpyridine (9.31 g) in tetrahydrofuran (200 ml) was added a 1.5M hexane solution of n-butyllithium (73.3 ml) at -20C. The resulting solution was stirred for 30 minutes at room temperature and added to a solution of ethyl benzoate (15.02 g) in tetrahydrofuran (100 ml) at -60C. After stirring for 2 hours at -60C, acetic acid (15 ml) was added and the resulting mixture was allowed to warm to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with water.
The aqueous layer was reextracted with ethyl acetate and the combined extracts were washed with water, 10 aqueous solution of sodium hydrogen carbonate, and saturated a~ueous sodium chloride. After drying over magnesium sulfate, thè ethyl acetate extracts were filtered and evaporated. The residue ~20.5 g) was chromatographed on silica gel (Merck 70-230 mesh, 308 g) eluting with chloroform to give 2-pyridylmethyl phenyl ketone (10.86 g~ as an oil.
IR (Nuiol) : 1680, 1630, 1600, 1545, 1270, 1200, 1145, 1060, 800, 775, 690 cm 1 NMR (CDC13, ~) : 4.43 (1.5H, s), 6.02 (0.5~, s), 6.83-8.65 (9H, m) Preparation 17 (1) To a solution of 5-hydroxy-2-methylpyridine (10.66 g) in tetrahydrofuran (426 mI) was added . .
. :: : ,. . :.
,. . : .
: . . , - : .
'' '., .~., '". ' ''' ,~ ' lZ61~5~
a solution of n-butyllithium (l.SM in hexane, 143 ml) at -30~ -10C. The reaction mixture was allowed to warm to room temperature and stirred for 1 hour at room temperature. After cooling to -78C, cyclohexane (11.14 ml) was added dropwise and allowed to warm to 0C and stirred for 30 minutes at 0C. After addition of acetic acid (24.6 ml), the solvent was distilled off and the residue was diluted with ethyl acetate, and washed successively with water, 10~ aqueous sodium hydrogen carbonate and aqueous saturated sodium chloride. After drying over magnesium sulfate, the ethyl acetate extract was filtered and evaporated.
The residue was washed with ethyl acetate to give 5-hydroxy-2-~(1-hydroxycyclohexyl)methyl]pyridine (11.96 g).
IR (Nujol) : 1615, 1575, 1500, 1460 cm NMR (CD30D, ~) : 1.20-2.00 (lOH, m), 2.90 (lH, s), 4.95 (2H, s), 7.20 (2H, m), 8.05 (lH, d, J=2.0Hz) (2) A solution of S-hydroxy-2~ hydroxycyclohex-yl)methyl~pyridine (1 g) in acetic acid (15 ml) containing sulfuric acid (5 ml) was heated to reflux for 1 hour. After cooling to room temperature, the reaction mixture was poured on an ice, basified with 10~ a~ueous sodium hydrogen carbonate, and extracted with ether. The combined ether extracts were washed with aqueous saturated sodium chloride, dried over magnesium sulfate, filtered, and concentrated. The 3Q residue was washed with isopropylalcohol to give 2-benzyl-5-hydroxypyridine (409 mg).
IR (Nujol) : 1560, 1450, 1370, 1280 cm 1 NMR (CDC13, ~) : 4.07 (2H, s), 6.85-7.43 (7H, m), 8.08 (lH, d, J=3.0Hz), 10.30 (lH, broad s) ~ , .~ , .
,'' -' :; :: - : :' . . `' .: -.. : ::: : .
~268~5~
Preparation 18 To a solution of l-phenylthio-3-ethoxycarbonyl-4H-quinolizin-4-one (1.0 g) in acetic acid (20 ml) and chloroform (7.5 ml), was added potassium permanganate (583 mg) at 0C. After stirring for two hours at the same temperature, the reaction mixture was allowed to warm to room temperature and stirred further for one hour. Potassium permanganate (194 mg) was added and stirred overnight. To the resulting reaction mixture wasadded. Saturated aqueous soclium thiosulfate solution with ice-cooling and the mixture was extracted with chloroform. After drying over magnesium sulfate, the chloroform extract was filtered and evaporated. The residue was washed with diisopropyl ether to gi~e 1-phenylsulfonyl-3-ethoxycarbo~yl-4H-quinolizin-4-one (583 mg), mp 182C.
IR (Nujol) : 1710, 1680, 1640, 1580, 1200, 1150 cm 1 NMR (CDC13, ~) : 1.45 (3H~ t~ J=7Hz), 4-45 (2H, q, J=7Hz), 7.20-8.10 (7H, m), 8.60 (lH, d, J=8Hz), 9.18 (lH, s), 9.50 (lH, d, J=8Hz) Anal. Calcd for C18H15NO5S
C, 60.50; H, 4.23; N, 3.gZ
Found : C, 60.44; H, 4.51; N, 3.88 Preparation 19 To a solution of 3-ethoxycarbonyl-7-hydroxy-1-phenyl-4H-quinolizin-4-one (5 g) in N,N-dimethyl-formamide (100 ml) was added sodium hydxide (63.6~ in mineral oil, 732 mg) at 50C. After stirring for 30 minutes at 50C, n-butyliodide (2.77 ml) was added.
After stirring for 1 hour at 50C, the mixture was cooled to room temperature and added to a mixture of aqueous hydrogen chloride and an ice.
. ...
- : . --- ~
. .: -. . , - S4 ~ ~Z6~4~
The mixture was extracted with chloroform and the chloroform extract was washed with 10% aqueous sodium hydrogen carbonate and aqueous saturated sodium chloride. After drying over magnesium sulfate, the chloroform extract was filterecl and concentrated in vacuo. The residue was chromatographed on silica gel (Merck 70-230 mesh, 100 g), eluting with chloroform and then 10% methanol in chloroform to give 3~ethoxy-carbonyl-7-(n-butoxy)-1-phenyl-4H-quinolizin-4-one (2.37 g).
mp : 94-95C
IR (Nujol) : 1730, 1690, 1655, 1630, 1480 cm NMR (CDC13, ~) : 0.95 (3H, t, J=5Hz), 1.4~
(3E, t, J=5Hz), 1.30-2.10 (4H, m), 4.13 (2H, t, J=5Hz), 4.45 (2H, q, J=5Hz), 7.30 (lH, d, J=7Hz), 7.42 (5H, m), 7.67 (lH, d, J=7Hz), 8.27 (lH, s), 9.08 (lH, d, J=2Hz) Anal. Calcd for C22H23NO4 C, 72.31; H, 6.34; N, 3.~83 Found : C, 71.74; H, 6.39; N, 3.80 Preparation 20 The following compound was obtained according to a similar manner to ~hat of Preparation 6.
1-Allyloxy-3-ethoxycarbonyl-4H-quinolizin-4-one.
mp : 82-84C
IR (Nujol) : 1690, 1680, 1660, 1620, 1580, 1320, 1235, 1100, 1015, 770 cm 1 NMR (CDC13, ~) : 1.43 (3H, t, J=7Hz), 4.42 (2H, a q, J=7Hz), 4.50-4.75 (2H, m), 5.15-5.67 (2H, m), 5.78-6.47 (lH, m), 6.97-8.32 (4H, m), 9.47 (lH, d, J=7.5Hz) Anal. Calcd for C15H15NO4 :
C, 65.93i H, 5.53; N, 5.13 ~`5 Found : C, 66.11; H, 5.36; N, 4.94 - '' "
lZ61~S8 Preparation 21 The following compound was obtained according to a similar manner to that of Preparation 16.
(5-Hydroxypyridin-2-yl)methyl phenyl ketone NMR ~CDC13, ~) : 4.44 (2H~ broad s), 6.85-7.70 (5~, m), 7.70-8.30 (3H, m), 9.34 (2H, s) Preparation 22 The following compound was obtained according to a similar manner to that of Preparation l.
Ethyl 4-benzoyl-3-ethoxy-2-ethoxycarbonyl-4-(5-hydroxypyridin-2-yl)butyrate IR (Nujol) : 1730, 1720, 1675, 1595 cm l Preparation 23 The followi~g compound was obtained according to a similar manner to that of Preparation 2 l-Benzoyl-3-ethoxycarbonyl-7-hydroxy-4H-quinolizin-4-one.
IR (Nujol) : 1740, 1630, 1570, 1490 cm 1 NMR tDMSO-d6, ~) : 1.22 (3H, t, J=7Hz), 4.27 (2H, q, J=7Hz), 7.~3-7.97 (6H, m), 8.22 (lH, s), 8.87 (lH, dl J=lOHz), 8.95 (lH, d, J=2Hz) Preparation_24 The following compound was obtained according to a similar manner to that of P ~ .
l-Benzoyl-3-ethoxycarbonyl-7-n-butoxy-4H-quinolizin-4-one.
mp : 158-159C
IR (NujoL) : 1740, 1680, 1630, 1580, 1510 cm " , ~
- , "
, .. . .. .
~z68~as~
NMR (CDC13, ~) : 0.98 (3H, t, J=5Hz), 1.23 (3H, t, J=7Hz), 1.30-2.10 (4H, m), 4.02-4.48 (4H, m), 7.37-8.18 (6H, m), 8.33 (lH, s), 8.88 (lH, d, J=lOHz), 9.03 (lH, cL, J=2Hz) Preparation 25 To a solution of sodium ethoxide (sodium, 151 mg) in ethanol (20 ml) was added ethyl pyrid-2-ylacetate (1 ml) at room temperature and the mixture was stirred for 1 hour at the same temperature. To the mixture was added diethyl ethoxymethylenemalonate (1.33 ml) at room temperature and the mixture was stirred at room temperature overnight. To the mixture was added acetic acid (0.75 ml) at room temperature and the precipitate was filtered and washed with water to give 1,3-diethoxycarbonyl-4H-quinolizin-4-one (896 mg).
mp : 130-131C
IR (Nujol) : 1680, 1625, 1585 cm 1 NMR (CDC13, ~) : 1.40 (6H, t), 4.20-4.55 (4H, m), 7.20-7.46 (lH, m), 7.72-8.00 (lH, m), 9.15 (lH, s), 9.27-9.64 (2H, m).
~: , :~
., : ~
: . .
. . .
~2~5~
Example 1 To a solution of 3-ethoxycarbonyl-4H-quinolizin-4-one (~.17 g) in methanol (65.2 ml) was added dropwise 6N aqueous sodium hydroxide (6.5 ml) at room temperature.
After stirring for 20 minutes, water (10 ml) was added.
After stirring for 20 minutes, water (30 ml) was also added. After stirring for an hour, the reaction mixture was acidified to pH 3 with 4M aqueous hydrochloric acid. The precipitate was filtered and washed with water to give 4H-quinolizin-4-one-3-carboxylic acid (1.75 g) as pale yellow crystal. mp 233C.
IR (Nujol) : 1730, 1610, 1585, 1320 cm 1 ~IMR (DMSO-d6) ~ : 7.26 (d, lHI J=9Hz), 7.50-7.95 (m, lH), 8.00-8.20 (m, 2H), a.41 (d, lH, lS J=9H2), 9.20-9.40 (m, lH) Example 2 To a suspension of 4H-quinolizin-4-one-3-carboxylic acid (1.69 g) in N,N-dimethylformamide ~16.9 ml) was added 1,1'-carbonyldiimidazole (2.-17 g) at ambient temperature. The resulting suspension was heated to 100C for 30 minutes and 5-amino-lI~-tetrazole (1.06 g) was added at 100C. After stirring for 20 minutes at 100C, the reaction mixture was cooled to 0C. The precipitate was filtered and washed with ( to be continued to the next page.) ~5 .
i: :.~ ' .. , ' : .. , : . - -~:
. . : ,: : : :
:. . : . .
~ 56 ~ ~26~S~
pre-cooled N,N-dimethylformamide and then ~ther to give N-~5-(lH-tetrazolyl)]-4H-quinolizin-4-one-3-carboxamide (2.0 g) as yellow solid. mp > 260C.
IR (Nujol) : 3200, 1660, 1620, 1500, 1310 cm NMR (CF3COOH) ~ : 7.42 (d, lH, J=8Hz), 7.68-7.88 (m, lH), 7.98-8.29 (m, 2H), 8.72 (d, lH, J=8Hz), 9.48 (d, lH, J=8Hz) Analysis Calcd. or CllH8O2N6 :
C; 51.56, H; 3.15, N; 32.80 Found : C; 51.70, H; 3.22, N; 32.99 Example 3 The following compounds were obtained according to a similar manner to that of Exam~le 1.
(1) 7-Ethyl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 193-195C.
IR (Nujol) : 3100, 1725, 1700, 1605 cm 1 NMR (CF3COOH) ~ : 1.52 (t, 3H, J=8Hz), 3.12 (q, 2H, J=8Hz), 7.92 (d, lH, J=9Hz), 8.32 (s, 2H), 8~73 (d, lH, J=9Hz), 9.30 (m. lH).
Analysis Calcd. for C12HllNO3 C; 66.35, H; 5.10, N; 6.45 Found : C; 66.40, H; 5.14, N; 6.46 (2) 1-Pheryl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 198C.
IR (Nujol) : 3315, 1740, 1620 cm 1 NMR (CF3COOH) ~ : 7.32-7.82 ~m, 5H), 7.92-8.23 (m, lH), 8.25-8.52 (m, 2H), 8.70 (s, lH), 9.48-9.72 (m, lH), Analysis Calcd. for C16HllNO3 5/4H2O :
C; 66.78, H; 4.64, N; 4.87 Found : C; 66.89, H; 4.22, N; 4.59 -.
.. . , .;. . .
,. , ,, , ~, .
_ 57 _ ~2~845~
(3) lH-Pyrido~1,2-a]quinolin-1-one-2-carboxylic acid.
mp. 258-260C.
IR (Nujol~ : 2500, 1720 cm 1 NMR (CF3COOH) ~ : 7.75-8.33 (m, 5H), 8.43 (d, lH, J=9Hz), 8.92 (d, lH, J-=8.5Hz), 9.73 (m, lH) ~nal. Calcd for C14HgMO3-1/10H2O :
C; 69.76, H; 3.85, N; 5.81 Found : C; 69.87, H; 4.13, N; 5.94 (4) 7-Hydroxy-4H-quinolizin-4-one-3-carboxylic acid. mp. > 270C
IR (Nujol) : 3120, 2690, 1690, 1590 cm 1 NMR (CF3COOH) ~ : 7.87 (d, lH, J=8.5Hz), 8.07-8.42 (m, 2H), 8.58 (d, lH, J=8.5Hz), 9.07 (m, lH) Anal. Calcd for CloH7NO4 1/4H2O :
C; 57.28, H; 3.61, N; 6.68 Found : C; 57.51, H; 3.60, N; 6.75 (5) 4H-P~rido[2,1-a3isoquinolin-4-one-3-carboxylic acid. mp. > 250C.
IR (Nujol) : 3100, 1730, 1640, 1620 cm 1 NMR (CF3COOH) ~ : 8.0-8.40 (m, 4H), 8.80-9.30 (m~ 4H) Anal. Calcd for C14HgMO3 :
C; 70.29, H; 3.79, N; 5~85 Fourd : C; 70.43, H; 4.15, N; 5.89 (6) 9,10-Dihydro-8H-benzo[ij]-3H-quinolizin-3-one-2-carboxylic acid. mp. 254C.
IR ~Nujol) : 3200, 1710i 1610, 1590 cm NMR (DM~O-d6) ~ : 1.80-2.30 (m, 2H), 2.70-3.20 (m, 6H), 7.30-7.85 (m, 2H), 8.10 (s, lHj, 9.10 ~d, lH, J=7Hz), 14~30 (s, lH) -.
~684~5~
Anal. Calcd for C13HllNO3 :
C; 68.11, H; 4.84, N; 6.11 Found : C; 68.21, H; 5.12, N; 6.07 (7) 7-Methoxy-4H-quinolizin-4-one-3-carboxylic acid.
mp. 215-216C.
IR (Nujol) : 3150, 3100, 1700, 1610, 1590 cm 1 NMR (CF3COOH) ~ : 4.18 (s, 3H), 7.88 (d, lH, J=8.5Hz), 8.10-8.47 (m, 2H), 8.67 (d, lH, J=8.5Hz), 8.88 (m, lH) Anal. Calcd for CllHgNO4 :
C; 60.27, H; 4.14, N; 6.39 Found : C; 59.90, H; 4.38, N; 6.48 (8) 9-Methyl-4H -quinolizin-4-one-3-carboxylic acid.
mp. 259-260C.
IR (NU3O1) : 3100, 3020, 1740, 1610, 1590, 1120, 780 cm 1 NMR (DMSO-d6) ~ : 2.92 (Sr 3H), 7.90 (d, lH, J=7.5Hz), 8.07 (d, lH, J=9.5Hz), 8,05-8.38 (m, lH), 8.82 (d, lH, J=9.5Hz), 9.42 (d, lH, J=7.5Hz) Anal. Calcd for Cl1HgNO3 :
C; 65.02, H; 4.46, N; 6.89 Found : C; 64.92, H; 4.76~ N; 6.89 (9) 8-Methyl-4H-quinolizin-4-one-3-carboxylic acid. mp. 228-230C
IR (Nujol) : 3090, 3030, 2700, 1630, 1620, 1580, 785 cm 1 NMR (CF3COOH) ~ : 2.82 (s, 3H), 7.82 (d, lH, J--9Hz), 7.92 (dd, lH, J=7Hz, 2Hz), 8.17 (d, lH, J=2Hz), 8.68 (d, lH, J-9Hz), 9.37 (d, lH, J=7Hz) Anal. Calcd for CllHgNO3 : C; 65.02, H; 4.46, N;6.89 Found : C; 64.88, H; 4.79, N; 6.85 , :
~ 59 126~4S8 (10) 6-Methyl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 185-187C.
IR (Nujol) : 3100, 2700, 1720, 1615, 1595, 1295, 1040, 800 c~ 1 S NMR (CF3COOH) ~ : 3.45 (s, 3H), 7.82 (d, lH, J=9Hz), 7.58-7.97 (m, lH), 8.10-8.30 (m, 2H), 8.68 (d, lH, J=9Hz) Anal. Calcd for CllHgNO3 : C; 65.02, H; 4.46, N; 6.89 Found : C; 64.60, H; 4.52, N; 6.91 (11) 1-Methyl-4H-quinolizin-4-one-3-carboxylic acid.
mp. 258-260C.
IR (Nujol) : 1740, 1610, 1450, 780 cm 1 NMR (CF3COOH) ~ : 2.87 (s, 3H), 8.15 (m, lH), ~5 8.35-8.77 (m, 3H), 9.66 (m, lH~
Anal. Calcd for CllHgNO3 : C; 65.02, H 4.46, N; 6.89 Found : C; 64.70, H; 4.56, N; 6.86 (12) Cyclopenta[ij]-3H-quinolizin-3-one-2-carboxylic 2Q acid. mp > 250C
IR (Nujol) : 1730, 1620, 1590 cm 1 Anal. Calcd for C12H7NO3: C; 67-61, H; 3-31, N; 6.57 Found : C; 67.72, H; 3.37, N; 6.59 (13) 7-Methyl-4H-quinolizin-4-one-3-carboxylic acid . mp. 222-224C
IR (Nujol) : 1720, 1600, 1590, 1320, 1125, 1110, 840 cm 1 NMR (CF3COOH) ~ : 2.77 (s, 3H), 7.93 (d, lH, J=9Hz),~
~a, 3~22-8.38 (m, 2H), 8.73 (d, lH, J=9Hz), 9.32 (s, 1~) Anal. Calcd for CllHgNO3: C; 65.02, H; 4.46, N; 6.89 Found : C; 65.04, H; 4.31, N~ 6.91 (14) 4H-Quinolizin-4-one-1-carboxylic acid.
. ,.: :. -, ::-.
, i2~ 5~
mp. > 250C
IR (Nujol) : 1695, 1650 cm NMR (DMSO-d6) ~ : 6.46 (d, lH, J=lOHz), 7.30-8.20 (m, 2H), 8.41 (d, lH, J=lOHz), 9.20-9.40 (m, 2H) Anal. Calcd for CloH7NO3: C; 63,49, H; 3.73, N; 7.40 Found : C; 63.50, H; 3.81, N; 7.53 ~15) 1-Methoxy-4H-quinolizin-4-one-3-carboxylic acid.
mp. 259-261C.
IR (Nujol) : 3100, 1630-, 1620, 1580, 1100, 1070, 780 cm 1 NMR (CF3COOH) ~ : 4.27 (s, 3H), 8.00-8.67 (m, 3H), 8.90 (m, lH), 9.52 (d, lH, J=7.5Hz) Anal. Calcd for CllHgNO4: C; 60.28, H; 4 14, N; 6.39 Found : C; 59.64, H; 4.15, N; 6:30 (16) 7-n-Butoxy-4H-quinolizin-4-one-3-carboxylic acid. mp. 120-122C.
IR (Nujol) : 1725, 1600, 1590, 1320, 1070, 1000 cm 1 NMR (CF3COOH~ ~ : 1.07 (t, 3H, J=6H ), 1.30-2.20 (m, 4H), 4.40 (t, 2H, J=6HZ), 7~90 (d, lH, J=9.5Hz), 8.13-8.43 (m, 2H), 8.67 (d, lH, J=9.5H2), 8.93 (d, lH, J=2Hz) Anal- Calcd for C14H15~O4: C; 64.36, H; 5.79, N; 5.36 Found : C; 64.46, H; 5.80, N; 5.31 :
(17) 7-Isopropoxy-4H-quinolizin-4-one-3-carboxylic acid. mp. 218-219C.
IR (Nujol) : 3140, 3090, 1720, 1620, 1120, 1060, 1000, 780 cm~l ;
NMR (CF3COOH) ~ : 1.67 (d, 6H, J=6Hz), 4.97 (lH, J=6Hz), 7.88 (d, lH, J=9Hz), 8.10-8.43 (m, 4H), 8.63 ~d, lH, J=9Hz), 8.90~(d, lH, J=2Hz) -.:
:
, . ..
- .~ . : :
Anal. Calcd for C13H13NO4: C; 63.15, H; 5.30, N; 5.66 Found : C; 63.28, H; 5.18, N; 5.65 Example 4 The following compounds were o~tained according to a similar manner to that of Example 2.
(1) N-[3-(4H-1,2,4-Triazol~1)]-4H-quinoliæin-4-one 3-carboxamide. mp. > 250C.
IR (Nujol) : 3400, 3300, 1700, 1660, 1650, 1620 cm 1 NMR (CF3COOH) ~ : 7.90-9.60 (m, 7H) Anal. Calcd for C12HgN5O2 :
C; 56.47, H; 3.55, N; 27.44 - Found : C; 56.83, H; 3.79, N; 27.50 (2) N-[5-(lH-Tetrazolyl)]-9-methyl-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 3100, 3080, 1660, 1620, 1590, 790 cm~l NMR (CF3COOH) ~ : 2.80 (s, 3H), 7.50-7.87 (m, 2H), 8.08 (d, lH, J=7Hz), 8.78 (d, lH, J=9Hz), - 9.43 (d, lH, J=7Hz) Anal. Calcd for C12HloN6O2 :
C; 53.33, H; 3 73, N; 35.10 Found : C; 55.28, H; 3.88, N; 31.35 (3) N-[5-~lH-Tetrazolyl)]-7-ethyl-4H-quinolizin-4-one~3-carboxamide. mp. > 250C. ~
IR (Nujol) : 3200, 1660, 1640, 162~0, 1590, 1490 cm~l NMR (CF3COOH) ~ : 1.50 (t, 3H, J-7Hz), 3.05 (q, 2H, J=7.5Hz), 7.45 (d, lH, J=9Hz), 8.08 (s, 2H), 8.68 (d, lH, J=9Hz), 9.33 (m, lH) Anal. Calccl for C13H12N6O2 : C; 5~.93, H; 4.25, N; 29.~56 Found : C; 55.32; H; 4.32, N; 29.72 :
:, ....
- 62 _ lZ6~458 (4) N-[5-(lH-Tetrazolyl)]-l-phenyl-4H-quinolizin-4-one-3-carboxamide. mp. ~ 270C.
IR (Nujol) : 3180, 3100, 1680, 1620, 1490 cm 1 NMR (CF3COOH) ~ : 7.27-8.02 (m, 6H), 8.05-8.35 (m, 2H), 8.70 (s, lH), 9.48-9.75 (m, lH) Anal. Calcd for C17H12N6O2 :
C; 61.44, H; 3.64, N; 25.29 Found : C; 61.21, H; 3.80, N; 24.83 t5) N-[5-(lH-Tetrazolyl)]-lH-pyrido[1,2-a]-quinolin-l-one-2-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 1670, 1610, 1580, 1530, 1480 cm 1 NMR (CF3COOH) ~ : 7.32 (d, lH, J=9Hz~, 7.48-8.33 (m, SH), 8.83 (dt lH, J=8Hz), 9.63 (m, lH) Anal. Calcd for C15HloN6O2 :
C; 58.82, H; 3.29, N, 27.44 Found : C; 59.16, H; 3.42, N; 27.29 ~6) N-~5-(lH-Tetrazolyl)]-7-hydroxy-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3120, 3090, 2530, 1670, 1640, 1540, 980 cm~l NMR (CF3COOH) ~ : 7.73-7.70 (m, 2H), 8.03 (m, lH), 8.67 (m, lH), 9.15 (m, lH) Anal. Calcd for CllH8N6O3 :
C; 49.06, H; 3.32, N; 32.11 Found : C; 48.56, H; 3.47, N; 32.66 (7) N-[5-(lH-Tetrazolyl)]-4H-pyrido[2,1-a]-isoquinolin-4-one-3-carboxamide. mp. ~ 250C
IR (Nujol) : 3200, 1660, 1640, 1620 cm 1 Anal. Calcd for C15HloN6O2 :
C; 58.82, H; 3.29, N; 27.44 Found : C; 59.12, H; 3.57, N; 27.86 `
" : . . .
.. ....
. . .
1268~
(8) N-[5-(lH-Tetrazolyl)]-9,10-dihydro-8H-benzo-[ij]-3H-quinolizin-3-one-2-carboxamide. mp. > 250C.
IR (Nujol) : 3200, 1660, 1640, 1620, 1600 cm 1 NMR tCF3CooH) ~ : 2.00-2.50 (m, 2H), 3.00-3.60 (m, 4H), 7.70-8.20 (m, 2H), 8.55 (s, lH), 9.40 (d, lH, J=7Hz) Anal. Calcd for C14H12N6O2 :
C; 56.75, H; 4.08, N; 28.36 Found : C; 56.86, H; 4.27, N; 28.58 (9) N-[5-(lH-Tetrazolyl)]-7-methoxy-4H-quinolizin-4-one-3-carboxamide. mp. >270C.
IR (Nujol) : 3200, 3100, 1680, 1650, 1610 cm 1 NMR (CF3COOH) ~ : 4.13 (s, 3H), 7.42 (d, lH, J=9Hz), 7.73-8.17 (m, 2H), 8.5a (d, lH, J=9Hz), 8.92 (m, lH) Anal. Calcd for C12HloN6O3 :
C; 50.35, H; 3.52, N; 29.36 Found : C; 50.54, H; 3.55, N; 29.63 (10) N-(2-Thiazolyl)-4H-quinoIizin-4-one-3-carboxamide. mp. 240C.
IR (Nujol) : 3100, 1665, 1620, 1490, 1320 cm 1 NMR (CF3COOH) ~ : 7.30-7.90 (m,~4H), 8.03-8.47 (m, 2H), 8.75 (d, lH, J=9Hz), 9.42 (d, lH, J=7Hz) Anal. Calcd for C13HgN3OS ~
C; 57.56, H; 3.34, N; 15.49 Found : C; 57.25, H; 3.77, N; 15.24 (11) N-(2-Hydroxyphenyl)-4H-quinolizin-4-one-3-car~oxamide. mp. 247C.
IR (Nujol) : 1650, 1630, 1600 cm NMR (CDC13) ~ : 6.ao-7.50 (m, SH), 7.70 (d, 2H, ; 35 J-7Hz)~ 8.76 (d, lH, J=8Hz), 9.40 (d, lH, ~;
J=8Hz), 10.10 (s, lH) :
,.
,, :. ~ " . ~ ~ :
" . : , .. . . .
- ~4 -~Z6~58 Anal. Calcd for C16H12N2O3 :
C; 68.57, H; 4.32, N; 9.99 Found : C; 68.04, H; 4.48, N; 10.11 (12) N-(2-Pyrimidinyl)-4H-quinolizin-4-one-3-carboxamide. mp. 218C.
IR (Nujol) : 1690, 1650, 1620 cm NMR (DMSO-d6) ~ : 7.10-8.20 (m, 5H), 8.50-8 80 (m, 3H), 9.20-9.40 (m, lH) Anal. Calcd for C14HloN4O2 :
C; 63.15, H; 3.79, N; 21.04 Found : C; 61.20, H; 4.19, N; 20.76 (13) N-[5-(lH-Tetrazolyl)]-8-methyl-4H-quinolizin-4-one-3-car~oxamide~ mp. > 270C
IR (Nujol) : 3200, 3150, 1660, 1635, 1590, 780 cm 1 N~ (CF3COOH) ~ : 2.73 (~, 3H), 7.35 (d, lH, J=9Hz), 7.65 (dd, lH, J=7Hz, 2Hz), 7.83 (d, lH, J=2Hz), 8.65 (d, lH, J=9Hz), 9.38 (d, lH, J=7Hz) Anal. Calcd for C12HloN6O2 :
C; 53.33, H; 3.73, N; 31.10 Found : C; 54.03, H; 3.84; N; 30.38 (14) N-~5-(lH-Tetrazolyl)]-6-methyl-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 1660, 1620, 1590, 1030, 820 790 cm 1 NMR (CF3COOH) ~ : 3.33 (s, 3H), 7.37 (d, lH, J=9Hz), 7.37-7.62 (m, lH), 7.87-8.07 (m, 2H), 8.60 (d, lH, J=9Hz) Anal. Calcd for Cl~HloN6O2 :
C; 53.33, H; 3.73, N; 31.10 Found : C; 53.63, H; 3.92, N; 31.42 ~ , . , . :
- - .
.. ~ :
.. .
- : : ,;' :
- 65 - 1~6~4~
(15) N-[5-(lH-Tetrazolyl)]-l-methyl-4H-quinolizin-4-one-3-carboxamide mp. > 270C.
IR (Nujol) : 3180, 1665, 1640, 1620, 1595, 1500, 1040, 1020, 770 cm 1 NMR (CF3COOH) ~ : 2.77 (s, 3H), 7.83-8.10 (m, lH), 8.38 (d, 2H, J=3Hz), 8.72 (s, lH), 9.65 (d, lH, J=6Hz) Anal. Calcd for C12HloN6O2 :
C; 53.55, H; 3.73, N; 31.10 Found : C; 53.71, H; 4.04, N; 31.03
IR (Nujol) : 3180, 1665, 1640, 1620, 1595, 1500, 1040, 1020, 770 cm 1 NMR (CF3COOH) ~ : 2.77 (s, 3H), 7.83-8.10 (m, lH), 8.38 (d, 2H, J=3Hz), 8.72 (s, lH), 9.65 (d, lH, J=6Hz) Anal. Calcd for C12HloN6O2 :
C; 53.55, H; 3.73, N; 31.10 Found : C; 53.71, H; 4.04, N; 31.03
(16) N-[5-(lH-Tetrazolyl)]-7-methyl-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 1670, 1610, 1580, 1500, 1310, 1060, 1040, 849 cm 1 NMR (CF3COOH) ~ : 2.73 (s, 3H), 7.47 (d, lH, J=9Hz), 8.03-8.50 (m, 2H), 8.70 (d, lH, J=9Hz), 9.33 (s, lH) Anal. Calcd for C12HloN6O2 C; 53.33, H; 3.73, N; 31.10 Found : C; 53.61, H; 3.69, N; 31.34
IR (Nujol) : 3200, 1670, 1610, 1580, 1500, 1310, 1060, 1040, 849 cm 1 NMR (CF3COOH) ~ : 2.73 (s, 3H), 7.47 (d, lH, J=9Hz), 8.03-8.50 (m, 2H), 8.70 (d, lH, J=9Hz), 9.33 (s, lH) Anal. Calcd for C12HloN6O2 C; 53.33, H; 3.73, N; 31.10 Found : C; 53.61, H; 3.69, N; 31.34
(17) N-~6-(1,2,4-Triazinyl)]-4H-quinolizin-4-one-3-car~oxamide. mp. 263C (dec.) IR (Nujol) : 3100, 1690, 1620, 1580, 1520, 1500, 1040 cm NMR (CF3COOH) ~ : 7.33 (d, lH~ J=9Hz), 7.60-8.23 (m, 3H), 8.72 (d, lH, J=9Hz), 9.10-9.17 (m! lH), 9.27-9.68 (m, 2H) Anal. Calcd for C13HgN5O2-1/4H2O :
C; 57.51, H; 3.59, N; 25.97 Found : C; 57.51, H; 3.52, N; 25.77
C; 57.51, H; 3.59, N; 25.97 Found : C; 57.51, H; 3.52, N; 25.77
(18) N-pyrazinyl-4H-quinolizin-4-one-3-carboxamide.
mp~ > 250C.
~ `
, . . . .
.. ~ :
... . . .
~ 66 - ~268~S~
IR (Nujol) : 3400, 1675, 1620, 1580, 1520, 1500, 1400, 1320, 780 cm 1 NMR (CF3COOH) ~ : 7.43 (d, lH, J=9.5Hz), 7.78 (m, lH), 8.00-8.23 (m, 2H), 8.77 (d, 9.5Hz), 8.83 (d, J=7.5Hz), 8.78-8.98 (m, 3H), 9.55 (d, lH, J=7.5Hz), 9.82 (s, lH) Anal- Calcd for C14H10N42 H2 C; 59.15, H; 4.25, N; 19.71 Found : C; 59.58, H; 4.03, N; 19.99
mp~ > 250C.
~ `
, . . . .
.. ~ :
... . . .
~ 66 - ~268~S~
IR (Nujol) : 3400, 1675, 1620, 1580, 1520, 1500, 1400, 1320, 780 cm 1 NMR (CF3COOH) ~ : 7.43 (d, lH, J=9.5Hz), 7.78 (m, lH), 8.00-8.23 (m, 2H), 8.77 (d, 9.5Hz), 8.83 (d, J=7.5Hz), 8.78-8.98 (m, 3H), 9.55 (d, lH, J=7.5Hz), 9.82 (s, lH) Anal- Calcd for C14H10N42 H2 C; 59.15, H; 4.25, N; 19.71 Found : C; 59.58, H; 4.03, N; 19.99
(19) N-~5-(lH-Tetrazolyl)]-cyclopenta[ij]-3H-quinolizin-3-one-2-carboxamide. mp. > 250C
IR (Nujol) : 3200, 3100, 1660, 1620, 1600 cm NMR (CF3COOH) ~ : 7.10-9.50 (m, 6H) lS Anal. Calcd for C13H8N6O2 :
C; 55072, H; 2.88, N; 29.99 Found : C; 55.95, H; 3.01, N; 29.64 . .
IR (Nujol) : 3200, 3100, 1660, 1620, 1600 cm NMR (CF3COOH) ~ : 7.10-9.50 (m, 6H) lS Anal. Calcd for C13H8N6O2 :
C; 55072, H; 2.88, N; 29.99 Found : C; 55.95, H; 3.01, N; 29.64 . .
(20) N-(2-Pyridyl)-4H-quinolizin-4-one-3-2~ carboxamide. mp. 228-230C.
(21) N-~5-(lH-Tetrazolyl)]-4H-quinolizin-4-one-1-carboxamide. mp. > 250c.
IR (Nujol) : 1690 (sh), 1660, 1620 cm NMR (CF3COOH) ~ : 7.40-9.80 (m, 6H) Anal. Calcd for CllH8N6O2 :
C; 51.56, H; 3.15, N; 32.80 Found : C; 51.71, H; 3.43, N; 32.41 3Qi (22) N-~6-(3-Chloropyridazinyl)]-4H-quinolizin-4-one-3-carboxamide. mp. > 250C.
IR (Nujol) : 3100, 1680, 1620j 1580, 1510, 1070, 780 cm~l NMR (CF3COO~) ~ : 7.38 (d, lH,~=9Hz) r 7.63-8.50 -~l5~ (m, 5H), 8.77 (d, lH, J=9Hz), 9.48 (m, lH).
.. :
, ..
~7 ~ Z ~ ~ 4 5 Anal. Calcd for C14H9ClN4O2 :
C; 55.92, H; 3.02, N; 18.63 Found : C; 55.65, H; 3.15, N; 19.14 (23) N-[5-(lH-Tetrazolyl)]-l-methoxy-4H-quinolizin-54-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 1660, 1650, 1620, 1290, 1015, 775 cm~l NMR (CF3COOH) ~ : 4.33 (s, 3H), 8.13 (m, lH), 8.33 (s, lH), 8.43-9.02 (m, 2H), 9.62 (d, 10lH, J=7.5Hz) Anal. Calcd for C12HloN6O3 :
C; 50.35, H; 3.52, N; 29.36 Found : C; 50.46, H; 3.45, N; 29.39 15(24) N-~2-(4,6-Dimethylpyrimidinyl)]-4H-quinolizin-4-one-3-carboxamide. mpO 217-218C.
IR (Nujol) : 3460, 3120, 1690, 1650, 1620, 1060, 790 cm 1 NMR (CF3COOH)~ : 2.87 (s, 6H), 7.38 (d, lH, 20J=9Hz), 7.47-8.32 (m, 4H), 8.75 (d, }H, ~=9Hz), 9.63 (d, lH, J=7O5Hz) Anal- Calcd for C16H14N42 1/3H2 C; 63.99, H; 4.92, N; 19.04 Found : C; 63.99, H; 4.92, N; 18.6 (25) N-[5-(lH-Tetrazolyl)~-7-n-butoxy-4E-q~inolizin-4-one~3-carboxamide. mp. > 210C.
IR (Nujol) : 3200, 1665, 1640, 1625, 1590, 1000, 850, 780 cm-lU~NMR (CF3COOH) ~ : 1.10 (t, 3H, J=5.5Hz), }.37-2.3 (m, 4H), 4.38 ~t, 2H, J=6~5Hz), 7.53 (d, lH, J=8.5Hz), 7.97-8.28 (m, 2H), 8.67 (d, lH, J=8.5Hz), 9.03 (sj lH) Anal- Calcd for C15H16N63 C; 54-88~ H; 4-91~ N; 26-00 35~Found : C 55.14, H; 4.89, N; 25.83 .~
:
- 68 - ~Z~8~5~
(~6) N-[5-(lH-Tetrazolyl)]-7-isopropoxy-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nu~ol) : 3200, 1680, 1650, 1620, 1500, 1310, 780 cm 1 S NMR (CF3COOH) ~ : 1.77 (d, 6H, J=6Hz), 5.12 (sept, lH, J=6Hz), 7.67 (d, lH, J=8.5Hz), 8.02-8.37 (m, 2H), 8.80 (d, lH, J=8.5Hz), 9.20 (s, lH) Anal. Calcd for C14H14N6O3 :
C; 53.50, H; 4.49, N; 26.74 Found : C; 53.73, H; 4.41, N; 27.04 _ Example 5 (1) To a suspension of 4H-quinolizin-4-one-3-carboxylic acid (2.27 g) in dry N,N-dimethylformamide (22.7 ml) was added l,l'-carbonyldiimidazole (2~92 g).
The resulting suspension was heated to 100C and kept for 30 minutes. After cooling to room temperature the resulting solution was treated with dry ammonia and stirred for 20 minutes. The crystals separated was collected by filtration and washed with water to give 4H-quinolizin-4-one-3-carboxamide (1.94 g).
mp. 230-232C.
IR (Nujol) : 3350, 3120, 1660, 1630 cm 1 NMR (CF3COOH) ~ : 7.58 (d, lH, J=9Hz), 7.75-8.07 (m, lH), 8.12 (m, 2H), 8.60 (d, lH, J=9Hz) and 9.52 (d, lH, J=7Hz).
Anal. Calcd for CloH8N2O2 :
C; 63.83, H; 4.28, N; 14.89 Found : C; 63.96, H, 4.43, N; 14.90 ~0 (2) A mixture of 4H-quinolizin-4-one-3-carboxamide (1.0 g) and phosphorus oxychloride (50 ml) was refluxed for one hour. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in aqueous sodium bicarbonate soLution and chloroform.
.
.
- , : :. , ~9 1;2684SE~
The chloroform extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated. The residue was chromatographed on silica gel (30 g) eluting with chloroform-methanol (50:1) to give 3-cyano-4H-quinolizin-4-one, which on recrystallization from ether gave crystals (800 mg), mp. 198-200C.
IR (Nujol) : 2420, 1680, 1620 cm NMR (DMSO-d6) ~ : 6.93 (d, lH, J=8Hz), 7.30-7.60 (m,lH), 7.85-8.20 (m, 3H), 9.13 (d, lH, J=8Hz) (3) To a solution of 3-cyano-4H-quinolizin-4-one (1.20 g) in a mixture of pyridine (50 ml) and triethylamine (30 ml) was bubbled hydrogen sulfide gas ovex a period of 30 minutes at room temperature. The resulting mixture was allowed to stand at ambient temperature for 3 days.
The solvent was distilled off and the residue was washed with a hot mixture of chloroform and methanol (1: 1) and filtered. The filtrate was concentrated and the residue was washed again wi~h a hot mixture of chloroform and methanol (9 1) and filtered. The filtered cake was washed well with a mixture of chloroform and methanol (9:1) to give 4H-quinolizin-4-one-3-thiocarboxamide (0.76 g).
mp. 220-230C.
IR (Nujol) : 3300, 3100, 1650, 1620, 1500 cm 1 NMR (DMSO-d6) ~ : 7.07 (d, lH, J=8Hz), 7.36-7.67 (m, lH), 7.80-8.10 (m, 2H), 9.13 (d, lH, J=8Hz), 9.26 (d, lH, J=8Hz), 9.80 (broad s, lH) (4) 3-Cyano-4H-quinolizin-4-one (4.21 g), sodium azide (1.77 g), and ammonium chloride (1.45 g) was dissolved in N,N-dimethyl-formamide (42 ml) and the resulting mixture was heated at 1~0C for two days. The reaction mixture was evaporated and the residue was dissolved in - - . . : .
: - : - , .,: :
:..... ., . :.. - ~
~`7Q ~ ~2~4~5~
aqueous sodium bicarbonate solution and filtered.
The filtrate was acidified with dilute hydrochloric acid to pH 1-2. The precipitates were filtered, washed with water and then cold N,N-dimethylformamide. The filtered solid was dissolved in hot N,N-dimethylformamide and filtered. The filtrate was treated with ether and kept at 0C. The crystals separated were filtered and recrystallized from a mixture of ether and N,N-dimethyl formamide to give 3-[5-(lH-tetrazolyl)]-4H-quinolizin-4-one (1.1 g).mp. > 250C.
IR (Nujol) : 3200, 3100, 3050, 1660, 1620, 1590 cm 1 NMR (CF3COOH) ~ : 7.40 (d, lH, J=8Hz), 7.60-8.30 (m, 3H), 8.60 (d, lH, J=8Hz), 8.90 ts, lH), 9.40-9.60 (m, lH) Anal. Calcd for CloH7ON5 :
C; 56.34~ H; 3.31, N; 32.85 Found : C; 56.55, H, 3.87, N; 33.0 Z0 Example 6 (1) A suspension of 4H-quinolizin-4-one-3-carboxylic acid ~196.7 mg) in 0.lN-aqueous sodium hydroxide solution (9.9 ml) was stirred for one hour at room temperature.
The resulting reaction mixtuxe was filtered and then the filtrate was lyophilized to give sodium 4H-quinolizin-4-one-3-carboxylate (201 mg).
IR (Nujol) : 1660 cm 1 NMR (D2O) ~ : 6.80 (d, lH, J=8Hz), 7.00-7.3C (m, lH), 7.40-7.60 (m, 2H), 8.05 (d, lH, J=8Hz), 3a 8.96 (d, lH, J=8Hz) (2) The following compound was obtained according to a similar manner to that of Example 6 - (1).
N-~5-(lH-Tetrazolyl)]-4H-quinolizin-4-one-3-`:
,:. ., - ~ ., . , :
~ -': -' -.. ,: , ' ~ . :
~ 71 ~ 1 2l6~ 45 carboxamide sodium salt.
IR (Nujol) : 1670 cm NMR (D2O-DMSO-d6) ~ : 6.80 (d, lH, J=8Hz), 7.20-7.40 (m, lH), 7.40-7.60 (m, 2H), 8.10 (d, lH, J=8Hz), 8.88 (d, lH, J=8Hz) (to be continued to the next page~) ~, 30`
~5 ~ 72 ~ ~ ~ ~8~S~
Example 7 The following compounds were obtained according to a similar manner to that of Example 1.
(1) 4-Phenyl-lH-pyrido[1,2-a]quinolin-1-one-2-carboxylic acid.-mp : 194-195C
IR (Nujol) : 3150, 2650, 1740, 1725, 1590, 1440, 1115, 825 cm 1 NMR (CF3COOH, ~) : 7.48-7.82 (5H, m), 7.93-8.48 (5H, m), 8.95 (lH, s), 9.70 (lH, m) Anal. Calcd for C20H13NO3 :
C; 76.18, H; 4.16, N; 4.44 Found : C; 76.32, H; 4.56, N; 4.32 (2) 1-(1-Naphthyl)-4H-quinolizin-4-one~3-carboxylic acid.
mp : >270C
IR (Nujol) : 1730, 1720, 1610, 770 cm 1 NMR (CF3COOH, ~ : 7.10-8.37 (lOH, m), 8.82 (lH, s), 9.62 (lH, m) Anal- Calcd ~or C20H13N3-1/2H~
C; 74.07, H; 4.35, N; 4.32 Found : C; 74.12, ~; 4.13, N; 4.22 `
~5 (3) 1-(4-Bipheny}yl)-4H-quinolizin-4-one-3-carboxylic acid.
mp : 261-263C
IR (Nujol) : 3100, 1720, 1660, 1610, 1580, 1290, 890, 775 cm 1 3`~ NMR (CF3COOH, ~) : 7.20-8.47 (12H, m), 8.70 (lH, s), 9.53 (lH, m) --Anal. Calcd for C22~15NO3-1/4H2O :
C; 76.40, H; 4.52, N; 4.05 Found : C; 76.41, H; 4.57, N; 3.93 ., :.;... .. ...
.~ ., .: ,, :: , , .
~ 73 ~ ~Z6~45~
(4) 1-Phenoxy-4H-quinolizin-4-one-3-carboxylic acid.
mp : 224-226C
IR (Nujol) : 3100, 2650, 1725, 1640, 1620, 1580, 1210, 910 cm 1 N~ (CF3COOH, ~ : 7.20-7.37 ~2H, m), 7,43-7.73 ~3H, m), 8r78 (lH, s), 8.27 (lH, d, J=7.5Hz), 8.60 (lH, t, J=7.5Hz), 9.05 (lH, d, J=8.5Hz), 9.63 (lH, d, J=7.5Hz) Anal. Calcd for C16HllNO4 :
C; 68.33, H 3.94, N; 4.98 Found : C; 68.45, H; 3.96, N; 4.96 (5) 1-(3-Tolyl)-4H-quinolizin-4-one-3-carboxylic 15acid.
mp : 176-178C
IR (Nujol) : 3130, 1740, 1620, 1590, 1220, 770, 705 cm~l NMR (CF3COOH, ~) : 2.52 (3H, s), 7.17-7.67 (4H, m), 7.90-8.50 (3H, m), 8.70 (lH, s), 9.58 (lH, m) Anal. Calcd for C17H13NO3 :
C; 73.11, H; 4.69, N; 5.02 Found : C; 73.11, H; 4~85, N; 5.13 (6) 1-(4-Chlorophenyl)-4H-quinolizin-4-one-3-carboxylic acid.
mp : 269-271C
IR (Nujol) : 3140, 1740, 1620, 1490, 1320, 1290, 1~ 1090, 890, 825, 775 cm 1 NMR (CF3COO~ 7.35-7.78 (4~, m), 7.92-8.47 (3H, m), 8.73 (lH, s), 9.62 (lH, m) Anal. Calcd for C16HloClNO3 ;
C; 64.12, H; 3.36, N; 4.67 3~5 Found : C; 63.95, 3 3.33, N; 4.5 ~, . ,, :; .- ,. .: . ~
.. . .::..,: ,,,, . :.: " .
:: . . :,. ~ :
~26~345~
(7) 1-(2-Tolyl~-4H-quinolizin-4-one-3-carboxylic acid.
mp : 168-170C
IR (Nujol) : 3400, 1720, 1610, 1290, 1070, 780 cm 1 NMR (CF3COOH, ~) : 2.17 (3H, s), 7.25-7.75 (4H, m), 7.98-8.63 (3H, m), 8.80 (lH, s), 9.72 (lH, m) Anal. Calcd for C17H13NO3 :
C; 73.11, H; 4.69, N; 5~02 Found : C; 72.95, H; 4.91, N; 5.01 (8) 1-(3-Methoxyphenyl~-4H-quinolizin-4 one-3-carboxylic acid.
mp : 222-224C
IR (Nujol) : 3100, 1725, 1600, 1490, 1220, 1030, 780 cm~l NMR (CF3COOHj ~) ; 4.10 (3H, s), 7.15-8.62 (7H, m), 8.77 (lH, s), 9.62 (lH, m) Anal. Calcd for C17H13NO4 ~; 69.15, H; 4.44, N; 4 74 Found : C) 69.67, H; 4.70, N; 4.67 (9) 1-Hydroxy-4H-quinolizin-4-one-3-carboxylic acid. ~ ~
IR (Nujol) : 3200, 3100, 1690, 1620 cm 1 N~ (CF3COOH, ~) : 8.00-9.50 (SH, m), ; - Anal. Calcd for C~loH7NO4 C; 58.54, ~; 3.44, N; 6.83 Found : C; 57.93, H; 3.56, N; 6.77 :: :
Example 3 The ~ollowing compounds were obtained according to a similar manner to that of E ample 2.
:
:: : :
. .
_ 75 _ 1 Z ~ ~ ~ 5 8 (1) N-[5-(lH-Tetrazolyl)]-4-phenyl-lH-pyrido[1,2-a]-quinolin-l-one-2-carboxamide.
mp : ~270C
IR (Nujol) : 3250, 3150, 1675, 1640, 1610, 1580, 1115 cm 1 Anal. Calcd for C21H14N5O2 :
C; 65.96, H; 3.69, N; 21.98 Found : C; 66.43, H; 3.99, N; 22.15 (2) N-~5-(lH-Tetrazolyl)]-(l-naphthyl) 4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nu]ol) : 3280, 1665, 1640, 1620, 1290, 780, 770 cm NMR (CF3COO~, ~) : 7.27-8.25 (lOH, m), 8.77 (lH, s), 9.68 (lH, m) Anal. Calcd for C21H14N6O2 :
C; 65.96, H; 3.69, N; 21.98 Found : C; 60.51, H; 3.75, N; 21.91 (3) N-[5-(lH-Tetrazolyl)]-1-(4-biphenylyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3180, 1670, 1625, 1590, 1100, 1035 780, 730 cm 1 Anal. Calcd for C23H16N6O2 :
C; 67.64, H; 3.95, N; 20.58 - Found : C; 68.04, H; 4.31, N; 20.39 (4) N-[5-(lH-~etrazolyl)]-l-phenoxy-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3200, 3150, 1660, 1620, 1590, 1010, 780, 750 cm 1 NMR (CF3COOH, ~) : 7.08 7.67 (5H, m), 7.97 (lH, m), : : .. : :
. - : :
~Z6~S~
8.22-8.47 (2H, m~, 8.70 (lH, m), 9.67 (lH, m) Anal. Calcd for C17H12N6O3 :
C; 58.6~, H; 3.47, N; 24.13 Found : C; 59.39, H; 3.54, N; 24.06 (5) N-[5-(lH-Tetrazolyl)]-1-(3-tolyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3160, 1670, 1640, 1620, 1600, N~R (CF3COOH, ~) : 2.-52 (2H, s), 7.17-7.62 (m, 4H), 7.70-8.40 (3H, m), 8.73 ~lH, s), 9.63 (lH, m) Anal. Calcd for C18H14N6O2 :
C; 62.42, H; 4.07, N; 24 26 Found : C; 63.03, H; 4.16r N; 24.56 tS) N-[5-(lH-Tetrazolyl)]-1-(4-chlorophenyl) -4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nu~ol) : 3220, 1675, 1640 ~ 1600, 1480, 1290, 1040, 770 cm 1 Anal. Calcd for C17HllClN6O2 :
C; 55.67, H; 3.02, N; 22.91 Found : C; 57.45, H; 3.26, N; 21.47 ~
(7) N-(2-Pyridyl)-l-phenyl-4H-quinolizin-4-one-3-carboxamide.
mp : 227-229C
IR (Nujol) : 1680, 1620, 1550, 1480, 1300, 780, 770 cm NMR (CF3COOH, ~) : 7.35-8.18 (lOH, m), 8.35-8.77 ~
(2H, m), 9.60 (lH, m~ ;
Anal. Calcd for C21H15N32 C; 73.89, H; 4.43, N; 12.31 Found : C; 74.17, H; 4.61, N~ 12.Z6 :
- - . . .: .
, .'; ~ " ~ ' .,, :' ~ 77 ~ ~ 2l~8 4 5 8 (8) N-[5-(lH-Tetrazolyl)¦-l-hydroxy-gH-quinolizin-4-one-3-carboxamide.
mp : ~ 250C
IR (Nujol) : 3200 (sh), 1660, 1620, 1580 cm 1 Anal. Calcd for CllH$N6O3-1/2H2O :
C; 46.97, H; 3.22, N; 29.85 Found : C; 46.48, H; 3.31, N; 29.57 (9) N-~5-(lH-Tetrazolyl)]-1-(3-methoxyphenyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C ~-IR (Nujol) : 3150, 1630, 1640, 1620, 1590, 1490, 1300, 1210, 1030, 790, 780 cm 1 NMR (CF3COOH, ~) : 4.13 (3H, s), 7.17-7.52 (3H, m), 7.55-8.15 (2H, m), 8.18-8.43 (2H, m~, 8.80 (lH, s), 9.67 (lH, m) Anal. Calcd for C18H14N6O3 :
C; 59.67, H; 3.89, N; 23.19 Found : C; 59.81, H; 4.19, N; 23.35 (10) N-~5-(lH-Tetrazolyl)]-1-(2-tolyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3200, 3120, 1680, 1620, 1490, 1290, 1030, 780 cm NMR (CF3COOH, ~) : 2.15 (3H, s), 7.25-7.70 (4H, m), 7.77-8.43 (3H, m), 8.77 ~(lH, s), 9.77 (lH, s) - :~
Anal. Calcd for ~18H14N6O2 :
C; 62.42, H; 4.07, N; 24.26 Found : C; 62.75, H; 4.06, N; 24.35 :
- : :
~ ~w : `
. ~, . :
--. , :
- 78 - 1~6~5~
Example 9 The following compounds were obtained according to a similar manner to that of Exam ~e 1.
(1) 7-(n-Butoxy)-l-phenyl-4H-quinolizin-4-one-3-carboxylic acid.
mp : 155-157C
IR (Nujol) : 1720, 1610, 1495, 1425 cm NMR (DMSO-d6, ~) : 0.95 (3H, t, J=5Hz), 1.3-2.0 (4H, m), 4.20 (2H, t, J=SHz), 7.3-7.7 (5H, m), 7.80 (2H, s), 8.10 (lH, s), 8.80 (lH, s), 14.1 (lH, broad s) (Z) l-Allyloxy-4H-quinolizin-4-one-3-carboxylic acid.
mp : 140-143C
IR (Nujol) : 3100, 1730, 1720, 1610, 1580, 1420, 1095, 1065, 770 cm 1 N~R (CF3CO2H, ~) : 4.90-5.13 (2H, m), 5.35-5.78 (2H, m), 5.90-6.57 (1~, m), 7.97-8.67 (3H, m), 8.77-9.03 (lH, m), 9.39-9.67 (lX, m) (3) 1-(N-Methylanilino)-4H-quinolizin-4-one-3-carboxylic acid.
mp : 185C (dec.) IR (Nujol) : 1720, 1700 (sh), 1620 cm NMR (CF3COOH/ ~) : 3.53 (3H, s), 6.60-7.50 (5H, m), 7.80-8.60 ~3X, m), 8.64 (lH, s), 9.50 (lH, d, J=7Hz) Anal. Calcd for C17H14N2O3 :
C, 69.38; H, 4.79; N, 9.52 Found : C, 69.03; H, 4.76; N, 9.31 (4) 1-Benzyl-4H-quinolizin-4-one-3-carboxylic acid.
mp : 221-223C
IR (Nujol) : 3380, 1720, 1620, 1410, 1320, 1070, 1020, 780 cm 1 "" ~ ,", ,,: : , _ 79 _ ~Z6~4s~
Anal. Calcd for C17H13NO3 :
C, 73.11; H, 4.69; N, 5 02 Found : C, 73.72; H, 4.92; N, 5.04 (5) 1-Phenylthio-4~-quinolizin-4-one-3-carboxylic acid.
mp : 195-197C
IR (Nujol) : 3350, 1720, 1620, 1400, 1285, 1065, 885, 780, 740 cm 1 Anal. Calcd for C16HllNO3S' :
~ C, 64.63; H, 3.73; N, 4.71 Found : C, 65.04; H, 3.90; N, 4.73 (6) 1-Phenylsulfonyl-4H-quinolizin-4-one-3-carboxylic acid.
mp : >250C
IR (Nujol) : 1730, 1640, 1620, 1580, 1160, 1140 cm 1 NMR (DMSO-d6, ~) : 7O30-8.50 (7H, m), 8.60 (lH, d, J=8Hz), 9.00 (lH, s), 9.50 (lH, d, J=8Hz) Anal. Calcd for C16HllNO5S' :
C, 58.35; H, 3.37 Found : C, 58.62; H, 3.31 .
Example 10 To a solution of 3-ethoxycarbonyl-1-benzoyl-4H-quinolizin-4-one (2.14 g) in chloroform (65 ml) was added dropwise trimethylsilyliodide (1.04 ml) at 0C.
After stirring for 30 minutes at 0C, trimethyl-silyliodide (1.04 ml) was added. After stirring for 1 hour at room temperature, trimethylsilyliodide (1.04 ml) was added. After stirring for 2 hours at room temperature, the reaction mixture was diluted with chloroform and washed with water. After drying over magnesium sulfate, the chloroform extract was filtered ~5 and concentrated. The precipitate was washed wi~h a t ~
~ , ,. ' ..... ' :, .~
..
, ~ ~...... .
. ~ ..
:lZ~34~
cold chloroform to give l-ben2Oyl-4H-quinolizin-4-one-3-carboxylic acid (1.252 g) as yellow crystals.
IR (Nujol) : 1735, 1630, 1610, 1455, 1440, 1370 cm 1 N~ (CDC13, ~) : 6.70-8.30 (9H, m), 8.42-8.68 (lH, d, J=3Hz) Anal. Calcd for C17HllNO4 :
C, 69.62; H, 3.78; N, 4.78 Found : C, 62.89; H, 3.54; N, 3.70 Mass : m/e 293 (M ) Example_ll The following compounds were obtained according to a similar manner to that of Example 2.
(1) 7-(n-Butoxy)-l-phenyl-N-~5-(lH-tetrazolyl)]-4H-quinolizin-4-one-3-carboxamide.
mp : >205C (dec.~
IR (Nujol) : 1670, 1635, 1580, 1370 cm NMR (DMSO-d6, ~) : 1.00 (3H, t, J=5.6Hz), 1.02-2.10 (4H, m), 4.18-(2H, t, J=6Hz), 6.80-7.25 (2H, m), 7.30-7.65 (3H, m), 7.68-8.00 (2H, m), 8.20 (lH, s), 8.87 (lH, broad s) (2) N-~5-(lH-Tetrazolyl)]-l-phenylthio-4H-quinolizin-4-one-3-carboxamlde.
mp : >270C
IR (Nujol) : 3180, 1660, 1640, 1620, 1285, 1035, 3a 780, 730 cm Anal. Calcd for C17H12N6O2S :
Cj 56.04; ~, 3.32; N, 23.06 Found ~ C, 56.61; H, 3.53; N, 23.48 ~-5 (3) 1-(N-MethylanIllno)-N-~5-(lH-tetrazolyl)]-4H-, .
~, : :
: - :. , ,. . :
. :. ~. . . -: . .-. ,.. . . :, : ,. , -- . ~ -:: .
- 81 - ~Z6~45~
quinolizin-4-one-3-carboxamide.
mp : >230C
IR (Nujol) : 3200, 1660, 1640, 1620, 1290, 1030 cm 1 NMR (CF3COOH, ~) : 3.74 (3H, s), 6.80-7.60 (5H, m), 7.62-8.08 (lH, m), 8.15-8.40 (2H, m), 8.85 (lH, s), 9 65 (lH, d, J=7Hz) (4) N-[5-(lH-Tetrazolyl)]-l-allyloxy-4H-quinolizin-4 one-3-carboxamide.
mp : >270C (dec.) IR (Nujol) : 3200, 1660, 1620, 1580, 1500, 1220, 1100, 1040, 1020, 955, 770 cm 1 NMR (CF3COOH, ~) : 4.90-5.17 (2H, m), 5.37-5.80 (2H, m), 5.90-6.55 (lH, m), 8.93-9.02 (4H, m), 9.50-9.73 (lH, m) Anal. Calcd ~or C14H12N6O3 :
C, 53.85; H, 3.87; N, 26.91 Found : C, 54.20; H, 3.81; N, 26.93 (5) N-[5-(lH-Tetrazolyl)]-l-benzyl-4H-quinolizin-4-one-3-carboxamide.
mp : >270C.
IR (Nujol) : 3140, 1660, 1620, 1595, 1490, 1295, 1040, 1005, 775, 720, 690 cm 1 Anal. Calcd for ClgH14N62 C, 62.42; H, 4.07; N, 24.26 Found : C, 62.88; H, 4.54; ~, 24.52 (6) N-[5-(lH-Tetrazolyl)]-l-phe~ylsulfonyl-4H-quinolizin-4-one-3-carboxamide.
mp : >250C
IR (Nujol) : 1680, 1640, 1620, 1590 cm 1 Anal. Calcd for Cl7H12N6O4S :
C, 51.51; H, 3.05; N, 21.20 Found : C, 51.71; H, 2.93; N, 21.83 , :
- . . . .
~26!345~
(7) 1-Benzoyl-N-~5-(lH-tetrazolyl)]-4H-quinolizin-4-one-3-carboxamide.
mp : >250C
IR (Nujol) : 1690, 1630, 1380, 1240, 1120 cm 1 NMR (CF3COOH, ~ : 7.40-8.25 (5H, m), 8.22-8.51 (lH, m), 8.70 (lH, broad s), 8.93 (lH, s), 9.12 (lH, d, J=9Hz), 9.73 (lH, d, J=7Hz) Anal Calcd for C18H12N6O3 :
C, 60.00; H/ 3.36; N, 23.32 Found : C, 56.90; H, 3.80; N, 24,97 Example 12 The following compounds were obtained according to a similar manner to that of Example 6-(1).
(1) 1-8enzoyl-N-~5-(lH-tetrazolyl~]-4H-quinolizin-4-one-3-carboxamide sodium salt.
mp : 248-250C (dec.) IR (Nujol~ : 1670, 1610, 1550, 1480, 1450 cm 1 (2) N-~5-(lH-Tetrazolyl)]-l-phenyl-4H-quinolizin-4-one-3-carboxamide sodium salt.
mp : >250C
IR (Nujol) : 3150 (broad), 1660 (sh), 1650, 1640, 1620 cm 1 NMR (DMSO-d6, ~ .40-8.00 (9H, m), 8.50 (lH, - s~, 9.30-9.60 (lH, m) :
(3) N-[5-(lH-Tetrazolyl~]-l-phenoxy-4H-quinoliz1n-4-one-3-carboxamide sodium salt.
mp : >250C
IR (Nujol~ : 166Q cm I
NMR (DMSO-d6, ~) : 6.9-7~8 (6H, m), 8.01 (2~, d, ~5 J=4Hz~, 8.32 (lH, s), 9.42 (lH, d, J=7Hz~, 12.30 (lH,; s) ... . . ..
,,: :. - : ~ - ;:
,, . : ~ - . ..
: ~ ... ...
.
-: . . .
- 83 - ~26 Anal. Calcd for C17Hl1N6NaO3 :
C, 55.14; EI, 2.99; N, 22.70 Found : C, 54.78; H, 3.63; N, 20.44 (to be continued to the next page.) :
;
~30 , :
~.~
~26~4~
Example 13 The following compound was obtained according to a similar manner to that of Example 1.
1-Benzoyl-7-n-butoxy-4H-quinolizin-4-one-3-carboxylic acid mp : 155-156C
IR (Nujol) : 1720, 1620, 1580, 1495 cm NMR (CDC13, ~) : 1.03 (3H, t, J=6Hz), 1.30-2.17 (4H, m), 4.23 (2H, t, J=6Hz), 7.17-7.93 -r~
(6H, m), 8.70 (lH, s), 8 88 (lH, d, J=lOHz), 9.02 (lH, d, J=2Hz), 13.60 (lH, broad s) Exa~le 14 The following compounds were obtained according to a similar manner to that of Example 2.
(1) 1-Benzoyl-7-n-butoxy-N-(lH-tetrazol-5-yl)-4H-quinolizin-4-one-3-carboxamide mp : 227C
IR (Nujol) 1680, 1660, 1625, 1585, 1550, 1495 cm 1 NMR (DMSO-d6, ~) : 1.2-2.0 (4Hj m), 4~23 (2H, t, J=6Hz), 7.08 (2H, broad s), 7.37-8.17 (6H, m), 8.43 (lH, s), 8.75 (lH, d, J=lOHz), 8.93 (lH, d, J=2Hz) (2) N-(4H-5-Amino-1,2,4-triazol-3-yl)-7-n-butoxy-1-phenyl-4H-quinolizin-4-one-3-carboxamide mp : 220C
IR (Nujol) : 1690, 1650, 1490, 1465, 1450 cm 1 NMR (DMSO-~6, ~) : 0.80-1.10 (3H, t), 1.30-2.10 (4H, m), 4.18 (2H, t), 7.03 (lH, s), 7.40-7.65 (5H, m), 7.70 (lH, d, J=7Hz), 7.83 (lH, d, J=7Hæ), 8.26 (lH, s), 8.87 (lH, s) Mass : m/e 387 (M+) .. ..
:, : . . , . ,:
:,,: . : .
: .. :: - :.:. :
, :" ~' ~,. ' ., '- ' :.
- 85 - ~Z6~4S~
(3) 1-Ethoxycarbonyl-N-(lH-tetrazol-S-yl)-4H-quinolizin-4-one-3-carboxamide mp : >250C
IR (Nujol) : 1665, 1640, 1610, 1595~ 1580 cm S Mass : m/e 328 (M ) Example 15 The following compounds wPre obtained according to a similar manner to that of Example 6-(1).
(1) 1-Benzoyl-7-n-butoxy-N-(lH-tetrazol-5-yl)-4H-quinoli2in-4-one-3-carboxamide sodium salt mp : 200-203C
NMR (DMSO-d6, ~) : 0.98 (3H, t, J=6Hz), 1.20-2.0 (4H, m), 4.25 (2H, t, J=6Hz), 7.32-8.17 (6H, m), 8e57 (lH, s), ~.75 (lH, d, J=lOHz), 9.02 (lH, d, J=2Hz), 11.87 (lH, broad s) (2) 7-n-Butoxy-l-phenyl-N-(lH-tetrazol-S-yl)-4H-quinolizin-4~one-3-carboxamide sodium salt IR (Nujol) : 1680, 1640, 1620, 1585 cm 1 NMR (DMSO-d6, ~) : 0.80-1.20 (3H, m), I.30-2.10 (4H~ m), 4.00-4.48 (2H, m), 7.43-7.68 (5H, m), 7.70-7.90 (2H, m), 8~40 (1~, s), 9.00 (lH, d, J=2Hz) Example 16 To a solution of 1,3-diethoxycarbonyl-4H-quinolizin-4-one (l g) in chloroform (20 ml) was added trimethylsilyl iodide (0.49 ml) at room temperature and the mixture was stirred for 4 hours and heated with re~lux for 4 hours. After cooling to room temperature, the mixture was washed with water, aqueous sodium thiosulfate, and brine. Drying over magnesium sulfate and evaporation gave a crystalline residue, which was ~268~
washed with isopropyl alcohol to give l-ethoxycarbony -4H-quinolizin-4-one 3-carboxylic acid (794 mg).
mp : 189C
IR (Nujol) : 1735, 1710, 1635, 1620 cm NMR (DMSO-d6, ~) : 1.34 (3H, t, J=7Hz), 4.33 (2H, q, ~=7Hz), 7.45-7.95 (lH, m), 8.00-8.45 (lH, m), 8.90 (lH, ~;), 9.05-9.60 (2H, m), Mass : m/e 261 (M ) Anal. Calcd. for Cl3HllN05 :
C, 59.77; H, 4.24; N, 5.36 Found : C, 59.12; H, 4.59; N, 5.33 Example 17 To a solution of 1,3-diethoxycarbonyl-4H-quinolizin-4 one (896 mg) in methanol (9 ml) was added 6N aqueous sodium hydroxide (2.58 ml) at room temperature and the mixture was heated with reflux for an hour. After cooling to 0C, the reaction mixture was acidified to pH 2 with 6N hydrochloric acid and the precipitate was filtered and washed with water to give 4H-quinolizin-4-one~1,3-dicarboxylic acid (202 mg).
mp : >250C
IR (Nujol) : 1675, 1655, 1635 cm NMR (D2O, NaOD, 3) : 7.30-8.10 8.65 (lH, s), 8.70-9.00 (lH, m), 9.30 (lH, d, J=7Hz) Example 18 To a solution of l-ethoxycarbonyl-N-(lH-tetrazol- ~`
5-yl)-4H-quinolizin-4-one-3-carboxamide (500 mg) in N,N-dimethylformamide (5 ml) was added lN aqueous sodium hydroxide (6 ml) at room temperature and the mixture was heated at 100C for an hour. After cooling to 0C, the mixture was acidified to pH 2 with 6N hydrochloric acid and the precipitate was filtered and washed with ~, -. "-..:. ~ : .. .... - , . . .
- .: : ; . ,: ~ : , : .:;: . " ~
- 87 - ~26~4~
~ater to give l-carboxy-N-(lH-tetrazol-5-yl)-4H-quinolizin-4-one-3-carboxamide (280 mg).
mp : >250C
IR (Nujol) : 1670, 1640, 1615, 1590 cm 1 NMR (D2O-NaOD, ~) : 7.24-7.60 (lH, m), 7.60-8.07 (lH, m), 8.68-9.05 (lH, m), 8.84 (lH, s), 9.30 (lH, d, J=8Hz) Mass : m/e 272 (M+) Anal. Calcd. for C12H8N6O4.H2O :
C, 45.29; H, 3.16; Nt 26.41 Found : C, 45.29; H, 3.62; N, 26.56 Example 19 To a solution of pyridin-2-ylacetic acid hydrochloride (1 g) in N,N-dimethylformamide (10 ml) was added N,N'-carbonyldiimidazole (934 mg) at room temperature and the mixture was heated at 60C for 20 minutes. To the mixture was added 2,2-dimethyl-1,3-dioxane-4,6-dione(830 mg) at 60C and the mixture was stirred for 1 hour at the same temperature. The solvent was distilled off and the residue was diluted with chloroform and washed with water. The chloroform layer was extracted with aqueous sodium hydrogen carbonate and the aqueous layer was washed with chloroform and acidified to pH 2 with 6N hydrochloric acid at 0C
and extracted with chloroform. The chloroform layer was washed with brine, dried over magnesium sulfate, and evaporated to give 2-hydroxy-4H-quinolizin-4-one-3-carboxylic acid (220 mg).
3~ mp : 194-195C
IR (Nujol) : 1690, 1605, 1370, 1300 cm 1 NMR (DMSO-d6, ~) : 6.75 (lH, s), 7.15-7.45 (lH, m), 7.76 (2H, d), 8.90 ~lH, d, J=6Hz) Mass : m/e 205 (M ) 35~ Anal.Calcd. for CloH7NO4 : C, 58,S4; H, 3.44; N, 6.83 Found : C; 58.49; H, 3.17; N, 6.86 :, :: : ~
:' . : ' : .
~Z61~LS~
In this specification, the expression "such as" means "for example" and is not intended to be construed as limiting the values hich it qualifies.
IR (Nujol) : 1690 (sh), 1660, 1620 cm NMR (CF3COOH) ~ : 7.40-9.80 (m, 6H) Anal. Calcd for CllH8N6O2 :
C; 51.56, H; 3.15, N; 32.80 Found : C; 51.71, H; 3.43, N; 32.41 3Qi (22) N-~6-(3-Chloropyridazinyl)]-4H-quinolizin-4-one-3-carboxamide. mp. > 250C.
IR (Nujol) : 3100, 1680, 1620j 1580, 1510, 1070, 780 cm~l NMR (CF3COO~) ~ : 7.38 (d, lH,~=9Hz) r 7.63-8.50 -~l5~ (m, 5H), 8.77 (d, lH, J=9Hz), 9.48 (m, lH).
.. :
, ..
~7 ~ Z ~ ~ 4 5 Anal. Calcd for C14H9ClN4O2 :
C; 55.92, H; 3.02, N; 18.63 Found : C; 55.65, H; 3.15, N; 19.14 (23) N-[5-(lH-Tetrazolyl)]-l-methoxy-4H-quinolizin-54-one-3-carboxamide. mp. > 270C.
IR (Nujol) : 3200, 1660, 1650, 1620, 1290, 1015, 775 cm~l NMR (CF3COOH) ~ : 4.33 (s, 3H), 8.13 (m, lH), 8.33 (s, lH), 8.43-9.02 (m, 2H), 9.62 (d, 10lH, J=7.5Hz) Anal. Calcd for C12HloN6O3 :
C; 50.35, H; 3.52, N; 29.36 Found : C; 50.46, H; 3.45, N; 29.39 15(24) N-~2-(4,6-Dimethylpyrimidinyl)]-4H-quinolizin-4-one-3-carboxamide. mpO 217-218C.
IR (Nujol) : 3460, 3120, 1690, 1650, 1620, 1060, 790 cm 1 NMR (CF3COOH)~ : 2.87 (s, 6H), 7.38 (d, lH, 20J=9Hz), 7.47-8.32 (m, 4H), 8.75 (d, }H, ~=9Hz), 9.63 (d, lH, J=7O5Hz) Anal- Calcd for C16H14N42 1/3H2 C; 63.99, H; 4.92, N; 19.04 Found : C; 63.99, H; 4.92, N; 18.6 (25) N-[5-(lH-Tetrazolyl)~-7-n-butoxy-4E-q~inolizin-4-one~3-carboxamide. mp. > 210C.
IR (Nujol) : 3200, 1665, 1640, 1625, 1590, 1000, 850, 780 cm-lU~NMR (CF3COOH) ~ : 1.10 (t, 3H, J=5.5Hz), }.37-2.3 (m, 4H), 4.38 ~t, 2H, J=6~5Hz), 7.53 (d, lH, J=8.5Hz), 7.97-8.28 (m, 2H), 8.67 (d, lH, J=8.5Hz), 9.03 (sj lH) Anal- Calcd for C15H16N63 C; 54-88~ H; 4-91~ N; 26-00 35~Found : C 55.14, H; 4.89, N; 25.83 .~
:
- 68 - ~Z~8~5~
(~6) N-[5-(lH-Tetrazolyl)]-7-isopropoxy-4H-quinolizin-4-one-3-carboxamide. mp. > 270C.
IR (Nu~ol) : 3200, 1680, 1650, 1620, 1500, 1310, 780 cm 1 S NMR (CF3COOH) ~ : 1.77 (d, 6H, J=6Hz), 5.12 (sept, lH, J=6Hz), 7.67 (d, lH, J=8.5Hz), 8.02-8.37 (m, 2H), 8.80 (d, lH, J=8.5Hz), 9.20 (s, lH) Anal. Calcd for C14H14N6O3 :
C; 53.50, H; 4.49, N; 26.74 Found : C; 53.73, H; 4.41, N; 27.04 _ Example 5 (1) To a suspension of 4H-quinolizin-4-one-3-carboxylic acid (2.27 g) in dry N,N-dimethylformamide (22.7 ml) was added l,l'-carbonyldiimidazole (2~92 g).
The resulting suspension was heated to 100C and kept for 30 minutes. After cooling to room temperature the resulting solution was treated with dry ammonia and stirred for 20 minutes. The crystals separated was collected by filtration and washed with water to give 4H-quinolizin-4-one-3-carboxamide (1.94 g).
mp. 230-232C.
IR (Nujol) : 3350, 3120, 1660, 1630 cm 1 NMR (CF3COOH) ~ : 7.58 (d, lH, J=9Hz), 7.75-8.07 (m, lH), 8.12 (m, 2H), 8.60 (d, lH, J=9Hz) and 9.52 (d, lH, J=7Hz).
Anal. Calcd for CloH8N2O2 :
C; 63.83, H; 4.28, N; 14.89 Found : C; 63.96, H, 4.43, N; 14.90 ~0 (2) A mixture of 4H-quinolizin-4-one-3-carboxamide (1.0 g) and phosphorus oxychloride (50 ml) was refluxed for one hour. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in aqueous sodium bicarbonate soLution and chloroform.
.
.
- , : :. , ~9 1;2684SE~
The chloroform extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated. The residue was chromatographed on silica gel (30 g) eluting with chloroform-methanol (50:1) to give 3-cyano-4H-quinolizin-4-one, which on recrystallization from ether gave crystals (800 mg), mp. 198-200C.
IR (Nujol) : 2420, 1680, 1620 cm NMR (DMSO-d6) ~ : 6.93 (d, lH, J=8Hz), 7.30-7.60 (m,lH), 7.85-8.20 (m, 3H), 9.13 (d, lH, J=8Hz) (3) To a solution of 3-cyano-4H-quinolizin-4-one (1.20 g) in a mixture of pyridine (50 ml) and triethylamine (30 ml) was bubbled hydrogen sulfide gas ovex a period of 30 minutes at room temperature. The resulting mixture was allowed to stand at ambient temperature for 3 days.
The solvent was distilled off and the residue was washed with a hot mixture of chloroform and methanol (1: 1) and filtered. The filtrate was concentrated and the residue was washed again wi~h a hot mixture of chloroform and methanol (9 1) and filtered. The filtered cake was washed well with a mixture of chloroform and methanol (9:1) to give 4H-quinolizin-4-one-3-thiocarboxamide (0.76 g).
mp. 220-230C.
IR (Nujol) : 3300, 3100, 1650, 1620, 1500 cm 1 NMR (DMSO-d6) ~ : 7.07 (d, lH, J=8Hz), 7.36-7.67 (m, lH), 7.80-8.10 (m, 2H), 9.13 (d, lH, J=8Hz), 9.26 (d, lH, J=8Hz), 9.80 (broad s, lH) (4) 3-Cyano-4H-quinolizin-4-one (4.21 g), sodium azide (1.77 g), and ammonium chloride (1.45 g) was dissolved in N,N-dimethyl-formamide (42 ml) and the resulting mixture was heated at 1~0C for two days. The reaction mixture was evaporated and the residue was dissolved in - - . . : .
: - : - , .,: :
:..... ., . :.. - ~
~`7Q ~ ~2~4~5~
aqueous sodium bicarbonate solution and filtered.
The filtrate was acidified with dilute hydrochloric acid to pH 1-2. The precipitates were filtered, washed with water and then cold N,N-dimethylformamide. The filtered solid was dissolved in hot N,N-dimethylformamide and filtered. The filtrate was treated with ether and kept at 0C. The crystals separated were filtered and recrystallized from a mixture of ether and N,N-dimethyl formamide to give 3-[5-(lH-tetrazolyl)]-4H-quinolizin-4-one (1.1 g).mp. > 250C.
IR (Nujol) : 3200, 3100, 3050, 1660, 1620, 1590 cm 1 NMR (CF3COOH) ~ : 7.40 (d, lH, J=8Hz), 7.60-8.30 (m, 3H), 8.60 (d, lH, J=8Hz), 8.90 ts, lH), 9.40-9.60 (m, lH) Anal. Calcd for CloH7ON5 :
C; 56.34~ H; 3.31, N; 32.85 Found : C; 56.55, H, 3.87, N; 33.0 Z0 Example 6 (1) A suspension of 4H-quinolizin-4-one-3-carboxylic acid ~196.7 mg) in 0.lN-aqueous sodium hydroxide solution (9.9 ml) was stirred for one hour at room temperature.
The resulting reaction mixtuxe was filtered and then the filtrate was lyophilized to give sodium 4H-quinolizin-4-one-3-carboxylate (201 mg).
IR (Nujol) : 1660 cm 1 NMR (D2O) ~ : 6.80 (d, lH, J=8Hz), 7.00-7.3C (m, lH), 7.40-7.60 (m, 2H), 8.05 (d, lH, J=8Hz), 3a 8.96 (d, lH, J=8Hz) (2) The following compound was obtained according to a similar manner to that of Example 6 - (1).
N-~5-(lH-Tetrazolyl)]-4H-quinolizin-4-one-3-`:
,:. ., - ~ ., . , :
~ -': -' -.. ,: , ' ~ . :
~ 71 ~ 1 2l6~ 45 carboxamide sodium salt.
IR (Nujol) : 1670 cm NMR (D2O-DMSO-d6) ~ : 6.80 (d, lH, J=8Hz), 7.20-7.40 (m, lH), 7.40-7.60 (m, 2H), 8.10 (d, lH, J=8Hz), 8.88 (d, lH, J=8Hz) (to be continued to the next page~) ~, 30`
~5 ~ 72 ~ ~ ~ ~8~S~
Example 7 The following compounds were obtained according to a similar manner to that of Example 1.
(1) 4-Phenyl-lH-pyrido[1,2-a]quinolin-1-one-2-carboxylic acid.-mp : 194-195C
IR (Nujol) : 3150, 2650, 1740, 1725, 1590, 1440, 1115, 825 cm 1 NMR (CF3COOH, ~) : 7.48-7.82 (5H, m), 7.93-8.48 (5H, m), 8.95 (lH, s), 9.70 (lH, m) Anal. Calcd for C20H13NO3 :
C; 76.18, H; 4.16, N; 4.44 Found : C; 76.32, H; 4.56, N; 4.32 (2) 1-(1-Naphthyl)-4H-quinolizin-4-one~3-carboxylic acid.
mp : >270C
IR (Nujol) : 1730, 1720, 1610, 770 cm 1 NMR (CF3COOH, ~ : 7.10-8.37 (lOH, m), 8.82 (lH, s), 9.62 (lH, m) Anal- Calcd ~or C20H13N3-1/2H~
C; 74.07, H; 4.35, N; 4.32 Found : C; 74.12, ~; 4.13, N; 4.22 `
~5 (3) 1-(4-Bipheny}yl)-4H-quinolizin-4-one-3-carboxylic acid.
mp : 261-263C
IR (Nujol) : 3100, 1720, 1660, 1610, 1580, 1290, 890, 775 cm 1 3`~ NMR (CF3COOH, ~) : 7.20-8.47 (12H, m), 8.70 (lH, s), 9.53 (lH, m) --Anal. Calcd for C22~15NO3-1/4H2O :
C; 76.40, H; 4.52, N; 4.05 Found : C; 76.41, H; 4.57, N; 3.93 ., :.;... .. ...
.~ ., .: ,, :: , , .
~ 73 ~ ~Z6~45~
(4) 1-Phenoxy-4H-quinolizin-4-one-3-carboxylic acid.
mp : 224-226C
IR (Nujol) : 3100, 2650, 1725, 1640, 1620, 1580, 1210, 910 cm 1 N~ (CF3COOH, ~ : 7.20-7.37 ~2H, m), 7,43-7.73 ~3H, m), 8r78 (lH, s), 8.27 (lH, d, J=7.5Hz), 8.60 (lH, t, J=7.5Hz), 9.05 (lH, d, J=8.5Hz), 9.63 (lH, d, J=7.5Hz) Anal. Calcd for C16HllNO4 :
C; 68.33, H 3.94, N; 4.98 Found : C; 68.45, H; 3.96, N; 4.96 (5) 1-(3-Tolyl)-4H-quinolizin-4-one-3-carboxylic 15acid.
mp : 176-178C
IR (Nujol) : 3130, 1740, 1620, 1590, 1220, 770, 705 cm~l NMR (CF3COOH, ~) : 2.52 (3H, s), 7.17-7.67 (4H, m), 7.90-8.50 (3H, m), 8.70 (lH, s), 9.58 (lH, m) Anal. Calcd for C17H13NO3 :
C; 73.11, H; 4.69, N; 5.02 Found : C; 73.11, H; 4~85, N; 5.13 (6) 1-(4-Chlorophenyl)-4H-quinolizin-4-one-3-carboxylic acid.
mp : 269-271C
IR (Nujol) : 3140, 1740, 1620, 1490, 1320, 1290, 1~ 1090, 890, 825, 775 cm 1 NMR (CF3COO~ 7.35-7.78 (4~, m), 7.92-8.47 (3H, m), 8.73 (lH, s), 9.62 (lH, m) Anal. Calcd for C16HloClNO3 ;
C; 64.12, H; 3.36, N; 4.67 3~5 Found : C; 63.95, 3 3.33, N; 4.5 ~, . ,, :; .- ,. .: . ~
.. . .::..,: ,,,, . :.: " .
:: . . :,. ~ :
~26~345~
(7) 1-(2-Tolyl~-4H-quinolizin-4-one-3-carboxylic acid.
mp : 168-170C
IR (Nujol) : 3400, 1720, 1610, 1290, 1070, 780 cm 1 NMR (CF3COOH, ~) : 2.17 (3H, s), 7.25-7.75 (4H, m), 7.98-8.63 (3H, m), 8.80 (lH, s), 9.72 (lH, m) Anal. Calcd for C17H13NO3 :
C; 73.11, H; 4.69, N; 5~02 Found : C; 72.95, H; 4.91, N; 5.01 (8) 1-(3-Methoxyphenyl~-4H-quinolizin-4 one-3-carboxylic acid.
mp : 222-224C
IR (Nujol) : 3100, 1725, 1600, 1490, 1220, 1030, 780 cm~l NMR (CF3COOHj ~) ; 4.10 (3H, s), 7.15-8.62 (7H, m), 8.77 (lH, s), 9.62 (lH, m) Anal. Calcd for C17H13NO4 ~; 69.15, H; 4.44, N; 4 74 Found : C) 69.67, H; 4.70, N; 4.67 (9) 1-Hydroxy-4H-quinolizin-4-one-3-carboxylic acid. ~ ~
IR (Nujol) : 3200, 3100, 1690, 1620 cm 1 N~ (CF3COOH, ~) : 8.00-9.50 (SH, m), ; - Anal. Calcd for C~loH7NO4 C; 58.54, ~; 3.44, N; 6.83 Found : C; 57.93, H; 3.56, N; 6.77 :: :
Example 3 The ~ollowing compounds were obtained according to a similar manner to that of E ample 2.
:
:: : :
. .
_ 75 _ 1 Z ~ ~ ~ 5 8 (1) N-[5-(lH-Tetrazolyl)]-4-phenyl-lH-pyrido[1,2-a]-quinolin-l-one-2-carboxamide.
mp : ~270C
IR (Nujol) : 3250, 3150, 1675, 1640, 1610, 1580, 1115 cm 1 Anal. Calcd for C21H14N5O2 :
C; 65.96, H; 3.69, N; 21.98 Found : C; 66.43, H; 3.99, N; 22.15 (2) N-~5-(lH-Tetrazolyl)]-(l-naphthyl) 4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nu]ol) : 3280, 1665, 1640, 1620, 1290, 780, 770 cm NMR (CF3COO~, ~) : 7.27-8.25 (lOH, m), 8.77 (lH, s), 9.68 (lH, m) Anal. Calcd for C21H14N6O2 :
C; 65.96, H; 3.69, N; 21.98 Found : C; 60.51, H; 3.75, N; 21.91 (3) N-[5-(lH-Tetrazolyl)]-1-(4-biphenylyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3180, 1670, 1625, 1590, 1100, 1035 780, 730 cm 1 Anal. Calcd for C23H16N6O2 :
C; 67.64, H; 3.95, N; 20.58 - Found : C; 68.04, H; 4.31, N; 20.39 (4) N-[5-(lH-~etrazolyl)]-l-phenoxy-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3200, 3150, 1660, 1620, 1590, 1010, 780, 750 cm 1 NMR (CF3COOH, ~) : 7.08 7.67 (5H, m), 7.97 (lH, m), : : .. : :
. - : :
~Z6~S~
8.22-8.47 (2H, m~, 8.70 (lH, m), 9.67 (lH, m) Anal. Calcd for C17H12N6O3 :
C; 58.6~, H; 3.47, N; 24.13 Found : C; 59.39, H; 3.54, N; 24.06 (5) N-[5-(lH-Tetrazolyl)]-1-(3-tolyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3160, 1670, 1640, 1620, 1600, N~R (CF3COOH, ~) : 2.-52 (2H, s), 7.17-7.62 (m, 4H), 7.70-8.40 (3H, m), 8.73 ~lH, s), 9.63 (lH, m) Anal. Calcd for C18H14N6O2 :
C; 62.42, H; 4.07, N; 24 26 Found : C; 63.03, H; 4.16r N; 24.56 tS) N-[5-(lH-Tetrazolyl)]-1-(4-chlorophenyl) -4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nu~ol) : 3220, 1675, 1640 ~ 1600, 1480, 1290, 1040, 770 cm 1 Anal. Calcd for C17HllClN6O2 :
C; 55.67, H; 3.02, N; 22.91 Found : C; 57.45, H; 3.26, N; 21.47 ~
(7) N-(2-Pyridyl)-l-phenyl-4H-quinolizin-4-one-3-carboxamide.
mp : 227-229C
IR (Nujol) : 1680, 1620, 1550, 1480, 1300, 780, 770 cm NMR (CF3COOH, ~) : 7.35-8.18 (lOH, m), 8.35-8.77 ~
(2H, m), 9.60 (lH, m~ ;
Anal. Calcd for C21H15N32 C; 73.89, H; 4.43, N; 12.31 Found : C; 74.17, H; 4.61, N~ 12.Z6 :
- - . . .: .
, .'; ~ " ~ ' .,, :' ~ 77 ~ ~ 2l~8 4 5 8 (8) N-[5-(lH-Tetrazolyl)¦-l-hydroxy-gH-quinolizin-4-one-3-carboxamide.
mp : ~ 250C
IR (Nujol) : 3200 (sh), 1660, 1620, 1580 cm 1 Anal. Calcd for CllH$N6O3-1/2H2O :
C; 46.97, H; 3.22, N; 29.85 Found : C; 46.48, H; 3.31, N; 29.57 (9) N-~5-(lH-Tetrazolyl)]-1-(3-methoxyphenyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C ~-IR (Nujol) : 3150, 1630, 1640, 1620, 1590, 1490, 1300, 1210, 1030, 790, 780 cm 1 NMR (CF3COOH, ~) : 4.13 (3H, s), 7.17-7.52 (3H, m), 7.55-8.15 (2H, m), 8.18-8.43 (2H, m~, 8.80 (lH, s), 9.67 (lH, m) Anal. Calcd for C18H14N6O3 :
C; 59.67, H; 3.89, N; 23.19 Found : C; 59.81, H; 4.19, N; 23.35 (10) N-~5-(lH-Tetrazolyl)]-1-(2-tolyl)-4H-quinolizin-4-one-3-carboxamide.
mp : ~ 270C
IR (Nujol) : 3200, 3120, 1680, 1620, 1490, 1290, 1030, 780 cm NMR (CF3COOH, ~) : 2.15 (3H, s), 7.25-7.70 (4H, m), 7.77-8.43 (3H, m), 8.77 ~(lH, s), 9.77 (lH, s) - :~
Anal. Calcd for ~18H14N6O2 :
C; 62.42, H; 4.07, N; 24.26 Found : C; 62.75, H; 4.06, N; 24.35 :
- : :
~ ~w : `
. ~, . :
--. , :
- 78 - 1~6~5~
Example 9 The following compounds were obtained according to a similar manner to that of Exam ~e 1.
(1) 7-(n-Butoxy)-l-phenyl-4H-quinolizin-4-one-3-carboxylic acid.
mp : 155-157C
IR (Nujol) : 1720, 1610, 1495, 1425 cm NMR (DMSO-d6, ~) : 0.95 (3H, t, J=5Hz), 1.3-2.0 (4H, m), 4.20 (2H, t, J=SHz), 7.3-7.7 (5H, m), 7.80 (2H, s), 8.10 (lH, s), 8.80 (lH, s), 14.1 (lH, broad s) (Z) l-Allyloxy-4H-quinolizin-4-one-3-carboxylic acid.
mp : 140-143C
IR (Nujol) : 3100, 1730, 1720, 1610, 1580, 1420, 1095, 1065, 770 cm 1 N~R (CF3CO2H, ~) : 4.90-5.13 (2H, m), 5.35-5.78 (2H, m), 5.90-6.57 (1~, m), 7.97-8.67 (3H, m), 8.77-9.03 (lH, m), 9.39-9.67 (lX, m) (3) 1-(N-Methylanilino)-4H-quinolizin-4-one-3-carboxylic acid.
mp : 185C (dec.) IR (Nujol) : 1720, 1700 (sh), 1620 cm NMR (CF3COOH/ ~) : 3.53 (3H, s), 6.60-7.50 (5H, m), 7.80-8.60 ~3X, m), 8.64 (lH, s), 9.50 (lH, d, J=7Hz) Anal. Calcd for C17H14N2O3 :
C, 69.38; H, 4.79; N, 9.52 Found : C, 69.03; H, 4.76; N, 9.31 (4) 1-Benzyl-4H-quinolizin-4-one-3-carboxylic acid.
mp : 221-223C
IR (Nujol) : 3380, 1720, 1620, 1410, 1320, 1070, 1020, 780 cm 1 "" ~ ,", ,,: : , _ 79 _ ~Z6~4s~
Anal. Calcd for C17H13NO3 :
C, 73.11; H, 4.69; N, 5 02 Found : C, 73.72; H, 4.92; N, 5.04 (5) 1-Phenylthio-4~-quinolizin-4-one-3-carboxylic acid.
mp : 195-197C
IR (Nujol) : 3350, 1720, 1620, 1400, 1285, 1065, 885, 780, 740 cm 1 Anal. Calcd for C16HllNO3S' :
~ C, 64.63; H, 3.73; N, 4.71 Found : C, 65.04; H, 3.90; N, 4.73 (6) 1-Phenylsulfonyl-4H-quinolizin-4-one-3-carboxylic acid.
mp : >250C
IR (Nujol) : 1730, 1640, 1620, 1580, 1160, 1140 cm 1 NMR (DMSO-d6, ~) : 7O30-8.50 (7H, m), 8.60 (lH, d, J=8Hz), 9.00 (lH, s), 9.50 (lH, d, J=8Hz) Anal. Calcd for C16HllNO5S' :
C, 58.35; H, 3.37 Found : C, 58.62; H, 3.31 .
Example 10 To a solution of 3-ethoxycarbonyl-1-benzoyl-4H-quinolizin-4-one (2.14 g) in chloroform (65 ml) was added dropwise trimethylsilyliodide (1.04 ml) at 0C.
After stirring for 30 minutes at 0C, trimethyl-silyliodide (1.04 ml) was added. After stirring for 1 hour at room temperature, trimethylsilyliodide (1.04 ml) was added. After stirring for 2 hours at room temperature, the reaction mixture was diluted with chloroform and washed with water. After drying over magnesium sulfate, the chloroform extract was filtered ~5 and concentrated. The precipitate was washed wi~h a t ~
~ , ,. ' ..... ' :, .~
..
, ~ ~...... .
. ~ ..
:lZ~34~
cold chloroform to give l-ben2Oyl-4H-quinolizin-4-one-3-carboxylic acid (1.252 g) as yellow crystals.
IR (Nujol) : 1735, 1630, 1610, 1455, 1440, 1370 cm 1 N~ (CDC13, ~) : 6.70-8.30 (9H, m), 8.42-8.68 (lH, d, J=3Hz) Anal. Calcd for C17HllNO4 :
C, 69.62; H, 3.78; N, 4.78 Found : C, 62.89; H, 3.54; N, 3.70 Mass : m/e 293 (M ) Example_ll The following compounds were obtained according to a similar manner to that of Example 2.
(1) 7-(n-Butoxy)-l-phenyl-N-~5-(lH-tetrazolyl)]-4H-quinolizin-4-one-3-carboxamide.
mp : >205C (dec.~
IR (Nujol) : 1670, 1635, 1580, 1370 cm NMR (DMSO-d6, ~) : 1.00 (3H, t, J=5.6Hz), 1.02-2.10 (4H, m), 4.18-(2H, t, J=6Hz), 6.80-7.25 (2H, m), 7.30-7.65 (3H, m), 7.68-8.00 (2H, m), 8.20 (lH, s), 8.87 (lH, broad s) (2) N-~5-(lH-Tetrazolyl)]-l-phenylthio-4H-quinolizin-4-one-3-carboxamlde.
mp : >270C
IR (Nujol) : 3180, 1660, 1640, 1620, 1285, 1035, 3a 780, 730 cm Anal. Calcd for C17H12N6O2S :
Cj 56.04; ~, 3.32; N, 23.06 Found ~ C, 56.61; H, 3.53; N, 23.48 ~-5 (3) 1-(N-MethylanIllno)-N-~5-(lH-tetrazolyl)]-4H-, .
~, : :
: - :. , ,. . :
. :. ~. . . -: . .-. ,.. . . :, : ,. , -- . ~ -:: .
- 81 - ~Z6~45~
quinolizin-4-one-3-carboxamide.
mp : >230C
IR (Nujol) : 3200, 1660, 1640, 1620, 1290, 1030 cm 1 NMR (CF3COOH, ~) : 3.74 (3H, s), 6.80-7.60 (5H, m), 7.62-8.08 (lH, m), 8.15-8.40 (2H, m), 8.85 (lH, s), 9 65 (lH, d, J=7Hz) (4) N-[5-(lH-Tetrazolyl)]-l-allyloxy-4H-quinolizin-4 one-3-carboxamide.
mp : >270C (dec.) IR (Nujol) : 3200, 1660, 1620, 1580, 1500, 1220, 1100, 1040, 1020, 955, 770 cm 1 NMR (CF3COOH, ~) : 4.90-5.17 (2H, m), 5.37-5.80 (2H, m), 5.90-6.55 (lH, m), 8.93-9.02 (4H, m), 9.50-9.73 (lH, m) Anal. Calcd ~or C14H12N6O3 :
C, 53.85; H, 3.87; N, 26.91 Found : C, 54.20; H, 3.81; N, 26.93 (5) N-[5-(lH-Tetrazolyl)]-l-benzyl-4H-quinolizin-4-one-3-carboxamide.
mp : >270C.
IR (Nujol) : 3140, 1660, 1620, 1595, 1490, 1295, 1040, 1005, 775, 720, 690 cm 1 Anal. Calcd for ClgH14N62 C, 62.42; H, 4.07; N, 24.26 Found : C, 62.88; H, 4.54; ~, 24.52 (6) N-[5-(lH-Tetrazolyl)]-l-phe~ylsulfonyl-4H-quinolizin-4-one-3-carboxamide.
mp : >250C
IR (Nujol) : 1680, 1640, 1620, 1590 cm 1 Anal. Calcd for Cl7H12N6O4S :
C, 51.51; H, 3.05; N, 21.20 Found : C, 51.71; H, 2.93; N, 21.83 , :
- . . . .
~26!345~
(7) 1-Benzoyl-N-~5-(lH-tetrazolyl)]-4H-quinolizin-4-one-3-carboxamide.
mp : >250C
IR (Nujol) : 1690, 1630, 1380, 1240, 1120 cm 1 NMR (CF3COOH, ~ : 7.40-8.25 (5H, m), 8.22-8.51 (lH, m), 8.70 (lH, broad s), 8.93 (lH, s), 9.12 (lH, d, J=9Hz), 9.73 (lH, d, J=7Hz) Anal Calcd for C18H12N6O3 :
C, 60.00; H/ 3.36; N, 23.32 Found : C, 56.90; H, 3.80; N, 24,97 Example 12 The following compounds were obtained according to a similar manner to that of Example 6-(1).
(1) 1-8enzoyl-N-~5-(lH-tetrazolyl~]-4H-quinolizin-4-one-3-carboxamide sodium salt.
mp : 248-250C (dec.) IR (Nujol~ : 1670, 1610, 1550, 1480, 1450 cm 1 (2) N-~5-(lH-Tetrazolyl)]-l-phenyl-4H-quinolizin-4-one-3-carboxamide sodium salt.
mp : >250C
IR (Nujol) : 3150 (broad), 1660 (sh), 1650, 1640, 1620 cm 1 NMR (DMSO-d6, ~ .40-8.00 (9H, m), 8.50 (lH, - s~, 9.30-9.60 (lH, m) :
(3) N-[5-(lH-Tetrazolyl~]-l-phenoxy-4H-quinoliz1n-4-one-3-carboxamide sodium salt.
mp : >250C
IR (Nujol~ : 166Q cm I
NMR (DMSO-d6, ~) : 6.9-7~8 (6H, m), 8.01 (2~, d, ~5 J=4Hz~, 8.32 (lH, s), 9.42 (lH, d, J=7Hz~, 12.30 (lH,; s) ... . . ..
,,: :. - : ~ - ;:
,, . : ~ - . ..
: ~ ... ...
.
-: . . .
- 83 - ~26 Anal. Calcd for C17Hl1N6NaO3 :
C, 55.14; EI, 2.99; N, 22.70 Found : C, 54.78; H, 3.63; N, 20.44 (to be continued to the next page.) :
;
~30 , :
~.~
~26~4~
Example 13 The following compound was obtained according to a similar manner to that of Example 1.
1-Benzoyl-7-n-butoxy-4H-quinolizin-4-one-3-carboxylic acid mp : 155-156C
IR (Nujol) : 1720, 1620, 1580, 1495 cm NMR (CDC13, ~) : 1.03 (3H, t, J=6Hz), 1.30-2.17 (4H, m), 4.23 (2H, t, J=6Hz), 7.17-7.93 -r~
(6H, m), 8.70 (lH, s), 8 88 (lH, d, J=lOHz), 9.02 (lH, d, J=2Hz), 13.60 (lH, broad s) Exa~le 14 The following compounds were obtained according to a similar manner to that of Example 2.
(1) 1-Benzoyl-7-n-butoxy-N-(lH-tetrazol-5-yl)-4H-quinolizin-4-one-3-carboxamide mp : 227C
IR (Nujol) 1680, 1660, 1625, 1585, 1550, 1495 cm 1 NMR (DMSO-d6, ~) : 1.2-2.0 (4Hj m), 4~23 (2H, t, J=6Hz), 7.08 (2H, broad s), 7.37-8.17 (6H, m), 8.43 (lH, s), 8.75 (lH, d, J=lOHz), 8.93 (lH, d, J=2Hz) (2) N-(4H-5-Amino-1,2,4-triazol-3-yl)-7-n-butoxy-1-phenyl-4H-quinolizin-4-one-3-carboxamide mp : 220C
IR (Nujol) : 1690, 1650, 1490, 1465, 1450 cm 1 NMR (DMSO-~6, ~) : 0.80-1.10 (3H, t), 1.30-2.10 (4H, m), 4.18 (2H, t), 7.03 (lH, s), 7.40-7.65 (5H, m), 7.70 (lH, d, J=7Hz), 7.83 (lH, d, J=7Hæ), 8.26 (lH, s), 8.87 (lH, s) Mass : m/e 387 (M+) .. ..
:, : . . , . ,:
:,,: . : .
: .. :: - :.:. :
, :" ~' ~,. ' ., '- ' :.
- 85 - ~Z6~4S~
(3) 1-Ethoxycarbonyl-N-(lH-tetrazol-S-yl)-4H-quinolizin-4-one-3-carboxamide mp : >250C
IR (Nujol) : 1665, 1640, 1610, 1595~ 1580 cm S Mass : m/e 328 (M ) Example 15 The following compounds wPre obtained according to a similar manner to that of Example 6-(1).
(1) 1-Benzoyl-7-n-butoxy-N-(lH-tetrazol-5-yl)-4H-quinoli2in-4-one-3-carboxamide sodium salt mp : 200-203C
NMR (DMSO-d6, ~) : 0.98 (3H, t, J=6Hz), 1.20-2.0 (4H, m), 4.25 (2H, t, J=6Hz), 7.32-8.17 (6H, m), 8e57 (lH, s), ~.75 (lH, d, J=lOHz), 9.02 (lH, d, J=2Hz), 11.87 (lH, broad s) (2) 7-n-Butoxy-l-phenyl-N-(lH-tetrazol-S-yl)-4H-quinolizin-4~one-3-carboxamide sodium salt IR (Nujol) : 1680, 1640, 1620, 1585 cm 1 NMR (DMSO-d6, ~) : 0.80-1.20 (3H, m), I.30-2.10 (4H~ m), 4.00-4.48 (2H, m), 7.43-7.68 (5H, m), 7.70-7.90 (2H, m), 8~40 (1~, s), 9.00 (lH, d, J=2Hz) Example 16 To a solution of 1,3-diethoxycarbonyl-4H-quinolizin-4-one (l g) in chloroform (20 ml) was added trimethylsilyl iodide (0.49 ml) at room temperature and the mixture was stirred for 4 hours and heated with re~lux for 4 hours. After cooling to room temperature, the mixture was washed with water, aqueous sodium thiosulfate, and brine. Drying over magnesium sulfate and evaporation gave a crystalline residue, which was ~268~
washed with isopropyl alcohol to give l-ethoxycarbony -4H-quinolizin-4-one 3-carboxylic acid (794 mg).
mp : 189C
IR (Nujol) : 1735, 1710, 1635, 1620 cm NMR (DMSO-d6, ~) : 1.34 (3H, t, J=7Hz), 4.33 (2H, q, ~=7Hz), 7.45-7.95 (lH, m), 8.00-8.45 (lH, m), 8.90 (lH, ~;), 9.05-9.60 (2H, m), Mass : m/e 261 (M ) Anal. Calcd. for Cl3HllN05 :
C, 59.77; H, 4.24; N, 5.36 Found : C, 59.12; H, 4.59; N, 5.33 Example 17 To a solution of 1,3-diethoxycarbonyl-4H-quinolizin-4 one (896 mg) in methanol (9 ml) was added 6N aqueous sodium hydroxide (2.58 ml) at room temperature and the mixture was heated with reflux for an hour. After cooling to 0C, the reaction mixture was acidified to pH 2 with 6N hydrochloric acid and the precipitate was filtered and washed with water to give 4H-quinolizin-4-one~1,3-dicarboxylic acid (202 mg).
mp : >250C
IR (Nujol) : 1675, 1655, 1635 cm NMR (D2O, NaOD, 3) : 7.30-8.10 8.65 (lH, s), 8.70-9.00 (lH, m), 9.30 (lH, d, J=7Hz) Example 18 To a solution of l-ethoxycarbonyl-N-(lH-tetrazol- ~`
5-yl)-4H-quinolizin-4-one-3-carboxamide (500 mg) in N,N-dimethylformamide (5 ml) was added lN aqueous sodium hydroxide (6 ml) at room temperature and the mixture was heated at 100C for an hour. After cooling to 0C, the mixture was acidified to pH 2 with 6N hydrochloric acid and the precipitate was filtered and washed with ~, -. "-..:. ~ : .. .... - , . . .
- .: : ; . ,: ~ : , : .:;: . " ~
- 87 - ~26~4~
~ater to give l-carboxy-N-(lH-tetrazol-5-yl)-4H-quinolizin-4-one-3-carboxamide (280 mg).
mp : >250C
IR (Nujol) : 1670, 1640, 1615, 1590 cm 1 NMR (D2O-NaOD, ~) : 7.24-7.60 (lH, m), 7.60-8.07 (lH, m), 8.68-9.05 (lH, m), 8.84 (lH, s), 9.30 (lH, d, J=8Hz) Mass : m/e 272 (M+) Anal. Calcd. for C12H8N6O4.H2O :
C, 45.29; H, 3.16; Nt 26.41 Found : C, 45.29; H, 3.62; N, 26.56 Example 19 To a solution of pyridin-2-ylacetic acid hydrochloride (1 g) in N,N-dimethylformamide (10 ml) was added N,N'-carbonyldiimidazole (934 mg) at room temperature and the mixture was heated at 60C for 20 minutes. To the mixture was added 2,2-dimethyl-1,3-dioxane-4,6-dione(830 mg) at 60C and the mixture was stirred for 1 hour at the same temperature. The solvent was distilled off and the residue was diluted with chloroform and washed with water. The chloroform layer was extracted with aqueous sodium hydrogen carbonate and the aqueous layer was washed with chloroform and acidified to pH 2 with 6N hydrochloric acid at 0C
and extracted with chloroform. The chloroform layer was washed with brine, dried over magnesium sulfate, and evaporated to give 2-hydroxy-4H-quinolizin-4-one-3-carboxylic acid (220 mg).
3~ mp : 194-195C
IR (Nujol) : 1690, 1605, 1370, 1300 cm 1 NMR (DMSO-d6, ~) : 6.75 (lH, s), 7.15-7.45 (lH, m), 7.76 (2H, d), 8.90 ~lH, d, J=6Hz) Mass : m/e 205 (M ) 35~ Anal.Calcd. for CloH7NO4 : C, 58,S4; H, 3.44; N, 6.83 Found : C; 58.49; H, 3.17; N, 6.86 :, :: : ~
:' . : ' : .
~Z61~LS~
In this specification, the expression "such as" means "for example" and is not intended to be construed as limiting the values hich it qualifies.
Claims (9)
1. A compound of the formula :
wherein R1 is carbamoyl, pyridylcarbamoyl, pyrimidinylcarbamoyl, pyrimidinylcarbamoyl having lower alkyl, pyrazinylcarbamoyl, phenylcarbamoyl, phenylcarbamoyl having hydroxy, thiazolylcarbamoyl, triazinylcarbamoyl, triazolylcarbamoyl, triazolylcarbamoyl having amino, pyridazinylcarbamoyl, pyridazinylcarbamoyl having halogen, tetrazolylcarbamoyl, thiocarbamoyl or tetrazolyl group, R7 is hydrogen or aryl selected from phenyl, tolyl, xylyl, cumenyl, naphthyl and biphenylyl, R2 is hydrogen, hydroxy, lower alkyl or lower alkoxy; and R3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, lower alkenyloxy, phenyl, naphthyl, biphenylyl, phenyl having one or more substituent(s) selected from halogen, lower alkyl and lower alkoxy, arylthio selected from phenylthio, tolylthio, xylythio, cumenylthio, naphthylthio and biphenylylthio, aroyl selected from benzoyl, toluoyl and naphthoyl, ar(lower)alkyl selected from phenyl(lower)-alkyl, tolyl(lower)alkyl, xylyl(lower)alkyl, cumenyl(lower)alkyl, naphthyl(lower)alkyl and biphenylyl(lower)alkyl, arenesulfonyl selected from benzenesulfonyl and p-toluenesulfonyl, arylamino selected from phenylamino, naphthylamino, biphenylylamino, phenylamino having lower alkyl on the nitrogen atom or aryloxy selected from phenoxy and tolyloxy, or R2 and R3 can be located at any place on the quinolizinone ring and can be linked together to form -CH2CH2CH2-, -CH=CH-or -CH=CH-CH=CH-, and pharmaceutically acceptable salts thereof.
wherein R1 is carbamoyl, pyridylcarbamoyl, pyrimidinylcarbamoyl, pyrimidinylcarbamoyl having lower alkyl, pyrazinylcarbamoyl, phenylcarbamoyl, phenylcarbamoyl having hydroxy, thiazolylcarbamoyl, triazinylcarbamoyl, triazolylcarbamoyl, triazolylcarbamoyl having amino, pyridazinylcarbamoyl, pyridazinylcarbamoyl having halogen, tetrazolylcarbamoyl, thiocarbamoyl or tetrazolyl group, R7 is hydrogen or aryl selected from phenyl, tolyl, xylyl, cumenyl, naphthyl and biphenylyl, R2 is hydrogen, hydroxy, lower alkyl or lower alkoxy; and R3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, lower alkenyloxy, phenyl, naphthyl, biphenylyl, phenyl having one or more substituent(s) selected from halogen, lower alkyl and lower alkoxy, arylthio selected from phenylthio, tolylthio, xylythio, cumenylthio, naphthylthio and biphenylylthio, aroyl selected from benzoyl, toluoyl and naphthoyl, ar(lower)alkyl selected from phenyl(lower)-alkyl, tolyl(lower)alkyl, xylyl(lower)alkyl, cumenyl(lower)alkyl, naphthyl(lower)alkyl and biphenylyl(lower)alkyl, arenesulfonyl selected from benzenesulfonyl and p-toluenesulfonyl, arylamino selected from phenylamino, naphthylamino, biphenylylamino, phenylamino having lower alkyl on the nitrogen atom or aryloxy selected from phenoxy and tolyloxy, or R2 and R3 can be located at any place on the quinolizinone ring and can be linked together to form -CH2CH2CH2-, -CH=CH-or -CH=CH-CH=CH-, and pharmaceutically acceptable salts thereof.
2. A compound of claim 1, wherein R7 is hydrogen or phenyl, R3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkoxycarbonyl, carboxy, lower alkenyloxy, phenyl, naphthyl, biphenyl, phenyl having a lower alkyl, phenyl having a halogen, phenyl having a lower alkoxy, phenylthio, benzoyl, phenyl(lower)alkyl, benzenesulfonyl, phenylamino having a lower-alkyl on the nitrogen atom, or phenoxy, and R2 and R3 can be located at any place on the quinolizinone ring and can be linked together to form -CH2CH2CH2-, -CH=CH- or -CH=CH-CH=CH-.
3. A compound of clalm 2, wherein R1 is carbamoyl, pyrid-2-ylcarbamoyl, 4,6-dimethylpyrimidin-2-ylcarbamoyl, pyrazinyl-carbamoyl, phenylcarbamoyl, pyrimidin-2-ylcarbamoyl, 2-hydroxyphenylcarbamoyl, 4H-1,2,4-triazol-3-ylcarbamoyl, 4H-5-amino-1,2,4-triazol-3-ylcarbamoyl, 1H-tetrazol-5-yl-carbamoyl, thiazol-2-ylcarbamoyl, 1,2,4-triazin-6-ylcarbamoyl, pyrazinylcarbamoyl, 3-chloropyridazin-6-ylcarbamoyl, thiocarbamoyl or tetrazolyl group, R2 is hydrogen, hydroxy, methyl, ethyl or methoxy, R3 is hydrogen, hydroxy, methyl, methoxy, isopropoxy, n-butoxy, ethoxycarbonyl, carboxy, allyloxy, phenyl, naphthyl, biphenyl, 3-methylphenyl, phenoxy, 4-chlorophenyl, 2-methylphenyl, 3-methoxyphenyl, benzyl, phenylthio, benzoyl, benzenesulfonyl or N-methylanilino.
4. A compound of claim 3, which is N-[5-(1H-tetrazolyl)]-4H-quinolizin-4-one-3-carboxamide or its sodium sait.
5. A compound of claim 3, which is N-[5-(1H-tetrazolyl)]-1-phenyl-4-H-quinolizin-4-one-3-carboxamide or its sodium salt.
6. A compound of claim 3, which is N-[5-(1H-tetrazolyl)]-1-phenoxy-4H-quinolizin-4-one-3-carboxamide or its sodium salt.
7. A compound of claim 3, which is N-[5-(1H-tetrazolyl)]-1-benzoyl-4H-quinolizin-4-one-3-carboxamide or its sodium salt.
8. A process for preparing a compound of the formula wherein R1 is carbamoyl, pyridylcarbamoyl, pyrimidinyl-carbamoyl, pyrimidinylcarbamoyl having lower alkyl, pyrazinylcarbamoyl, phenylcarbamoyl, phenylcarbamoyl having hydroxy, thiazolylcarbamoyl.
triazinylcarbamoyl, triazolylcarbamoyl, triazolylcarbamoyl having amino pyridazinyl-carbamoyl, pyridazinylcarbamoyl having halogen, tetrazolylcarbamoyl, thiocarbamoyl or tetrazolyl group, R7 is hydrogen or aryl selected from phenyl, tolyl, xylyl, cumenyl, naphthyl and biphenylyl, R2 is hydrogen, hydroxy, lower alkyl or lower alkoxy; and R3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, lower alkenyloxy, phenyl, naphthyl, biphenylyl, phenyl having one or more substituent(s) selected from halogen, lower alkyl and lower alkoxy, arylthio selected from phenylthio, tolylthio, xylylthio, cumenylthio, naphthylthio and biphenylylthio, aroyl selected from benzoyl, toluoyl and naphthoyl, ar(lower)alkyl selected from phenyl(lower)-alkyl, tolyl(lower)alkyl, xylyl(lower)alkyl, cumenyl(lower)alkyl, naphthyl(lower)alkyl and biphenylyl(lower)alkyl, arenesulfonyl selected from benzenesulfonyl and p-toluenesulfonyl, arylamino selected from phenylamino, naphthylamino, biphenylylamino, phenylamino having lower alkyl on the nitrogen atom or aryloxy selected from phenoxy and tolyloxy, or R2 and R3 can be located at any place on the quinolizinone ring and can be linked together to form -CH2CH2CH2-, -CH=CH-or -CH-CH-CH=CH-, or a salt thereof which comprises (1) subjecting a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or its reactive derivative at the carboxy group or a salt thereof, to amidation reaction, to give a compound of the formula :
wherein R7, R2 and R3 are each as defined above, and R? is carbamoyl, pyridylcarbamoyl, pyrimidinylcarbamoyl, pyrimidinylcarbamoyl having lower alkyl, pyrazinylcarbamoyl, phenylcarbamoyl, phenylcarbamoyl having hydroxy, thiazolylcarbamoyl, triazinyl-carbamoyl, triazolylcarbamoyl, triazolylcarbamoyl having amino, pyridazinylcarbamoyl, pyridazinylcarbamoyl having halogen, tetrazolylcarbamoyl, or a salt thereof; or (2) reacting a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or a salt thereof, with hydrogen sulfide, to give a compound of the formula:
wherein R7, R2 and R3 are each as defined above, or a salt thereof; or (3) subjecting a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or a salt thereof, to the formation reaction of a tetrazole group, to give a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or a salt thereof, or (4) subjecting a compound of the formula :
wherein R1, R2 and R7 are each as defined above, and Ra is lower alkoxycarbonyl, or a salt thereof, to elimination reaction of the carboxy protective group, to give a compound of the formula :
wherein R1, R2 and R7 are each as defined above, or a salt thereof.
triazinylcarbamoyl, triazolylcarbamoyl, triazolylcarbamoyl having amino pyridazinyl-carbamoyl, pyridazinylcarbamoyl having halogen, tetrazolylcarbamoyl, thiocarbamoyl or tetrazolyl group, R7 is hydrogen or aryl selected from phenyl, tolyl, xylyl, cumenyl, naphthyl and biphenylyl, R2 is hydrogen, hydroxy, lower alkyl or lower alkoxy; and R3 is hydrogen, hydroxy, lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, lower alkenyloxy, phenyl, naphthyl, biphenylyl, phenyl having one or more substituent(s) selected from halogen, lower alkyl and lower alkoxy, arylthio selected from phenylthio, tolylthio, xylylthio, cumenylthio, naphthylthio and biphenylylthio, aroyl selected from benzoyl, toluoyl and naphthoyl, ar(lower)alkyl selected from phenyl(lower)-alkyl, tolyl(lower)alkyl, xylyl(lower)alkyl, cumenyl(lower)alkyl, naphthyl(lower)alkyl and biphenylyl(lower)alkyl, arenesulfonyl selected from benzenesulfonyl and p-toluenesulfonyl, arylamino selected from phenylamino, naphthylamino, biphenylylamino, phenylamino having lower alkyl on the nitrogen atom or aryloxy selected from phenoxy and tolyloxy, or R2 and R3 can be located at any place on the quinolizinone ring and can be linked together to form -CH2CH2CH2-, -CH=CH-or -CH-CH-CH=CH-, or a salt thereof which comprises (1) subjecting a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or its reactive derivative at the carboxy group or a salt thereof, to amidation reaction, to give a compound of the formula :
wherein R7, R2 and R3 are each as defined above, and R? is carbamoyl, pyridylcarbamoyl, pyrimidinylcarbamoyl, pyrimidinylcarbamoyl having lower alkyl, pyrazinylcarbamoyl, phenylcarbamoyl, phenylcarbamoyl having hydroxy, thiazolylcarbamoyl, triazinyl-carbamoyl, triazolylcarbamoyl, triazolylcarbamoyl having amino, pyridazinylcarbamoyl, pyridazinylcarbamoyl having halogen, tetrazolylcarbamoyl, or a salt thereof; or (2) reacting a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or a salt thereof, with hydrogen sulfide, to give a compound of the formula:
wherein R7, R2 and R3 are each as defined above, or a salt thereof; or (3) subjecting a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or a salt thereof, to the formation reaction of a tetrazole group, to give a compound of the formula :
wherein R7, R2 and R3 are each as defined above, or a salt thereof, or (4) subjecting a compound of the formula :
wherein R1, R2 and R7 are each as defined above, and Ra is lower alkoxycarbonyl, or a salt thereof, to elimination reaction of the carboxy protective group, to give a compound of the formula :
wherein R1, R2 and R7 are each as defined above, or a salt thereof.
9. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848429710A GB8429710D0 (en) | 1984-11-23 | 1984-11-23 | Pharmaceutical composition |
| GB8429710 | 1984-11-23 | ||
| US712,435 | 1985-03-18 | ||
| US06/712,435 US4650804A (en) | 1984-03-30 | 1985-03-18 | Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents |
| US06/770,953 US4698349A (en) | 1984-03-30 | 1985-08-30 | Quinolizinone compounds, and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents |
| US770,953 | 1985-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1268458A true CA1268458A (en) | 1990-05-01 |
Family
ID=27262528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000491534A Expired - Fee Related CA1268458A (en) | 1984-11-23 | 1985-09-25 | Quinolizinone compound, processes for preparation thereof and pharmaceutical composition comprising the same |
Country Status (8)
| Country | Link |
|---|---|
| AU (1) | AU598446B2 (en) |
| CA (1) | CA1268458A (en) |
| DK (1) | DK165554C (en) |
| FI (1) | FI83518C (en) |
| GR (1) | GR852368B (en) |
| HU (1) | HU206710B (en) |
| NO (1) | NO162285C (en) |
| PH (1) | PH23064A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW17385A1 (en) * | 1984-11-06 | 1986-02-19 | Hoffmann La Roche | Tricyclic pyridine derivatives |
| AU616916B2 (en) * | 1987-11-20 | 1991-11-14 | Kissei Pharmaceutical Co. Ltd. | 4h-quinolizin-4-one compounds exhibiting therapeutic activities |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW17385A1 (en) * | 1984-11-06 | 1986-02-19 | Hoffmann La Roche | Tricyclic pyridine derivatives |
-
1985
- 1985-09-09 NO NO853525A patent/NO162285C/en unknown
- 1985-09-11 AU AU47341/85A patent/AU598446B2/en not_active Ceased
- 1985-09-19 PH PH32807A patent/PH23064A/en unknown
- 1985-09-25 CA CA000491534A patent/CA1268458A/en not_active Expired - Fee Related
- 1985-09-25 DK DK434185A patent/DK165554C/en not_active IP Right Cessation
- 1985-09-27 FI FI853731A patent/FI83518C/en not_active IP Right Cessation
- 1985-09-27 HU HU374085A patent/HU206710B/en unknown
- 1985-09-30 GR GR852368A patent/GR852368B/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4734185A (en) | 1986-05-29 |
| FI83518C (en) | 1991-07-25 |
| NO162285B (en) | 1989-08-28 |
| FI853731A0 (en) | 1985-09-27 |
| FI853731L (en) | 1986-05-24 |
| DK434185D0 (en) | 1985-09-25 |
| HUT38931A (en) | 1986-07-28 |
| PH23064A (en) | 1989-03-27 |
| HU206710B (en) | 1992-12-28 |
| GR852368B (en) | 1985-12-12 |
| NO853525L (en) | 1986-05-26 |
| AU598446B2 (en) | 1990-06-28 |
| NO162285C (en) | 1989-12-06 |
| DK165554B (en) | 1992-12-14 |
| DK434185A (en) | 1986-05-24 |
| DK165554C (en) | 1993-04-26 |
| FI83518B (en) | 1991-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4698349A (en) | Quinolizinone compounds, and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents | |
| CA1103246A (en) | Thiazine derivatives | |
| CA2102137A1 (en) | Heterocyclic compounds | |
| CA2180253A1 (en) | Pyrazolopyridine adenosine antagonists | |
| RU2238937C2 (en) | Derivatives of imidazole, pharmaceutical composition and method for prophylaxis and/or treatment based on thereof | |
| CA2108971A1 (en) | Quinoline derivatives | |
| CA2127365A1 (en) | Amino acid derivatives as paf-receptor antagonists | |
| NO874904L (en) | PROCEDURE FOR THE PREPARATION OF NEW IMIDAZOPYRIDINE COMPOUNDS. | |
| JPH11508267A (en) | Pyrazole compounds and pharmaceutical compositions | |
| RU2124017C1 (en) | Indane condensed derivatives, method of their synthesis and composition showing antitumor effect | |
| US4831030A (en) | Diphenylpyridine compounds, processes for the preparation thereof and composition comprising the same | |
| US5464849A (en) | N-hydroxyurea derivatives as antiallergy and antiinflammatory agents | |
| CA2127367A1 (en) | Heterocyclic sulfonamide derivatives as antagonists of paf and angiotensin ii | |
| KR19990072053A (en) | Pyrido (2,3-B) pyrazine Derivatives | |
| CA1268458A (en) | Quinolizinone compound, processes for preparation thereof and pharmaceutical composition comprising the same | |
| AU769890B2 (en) | Sulfonamide compounds and uses thereof as medicines | |
| KR870001362B1 (en) | Process for the preparation of tetrahydro imidazoquinazoline derivatives | |
| FR2488609A1 (en) | NOVEL DERIVATIVES OF THIOFORMAMIDE, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM | |
| KR930001413B1 (en) | Process for preparing quinolizinone compounds | |
| JPS60222482A (en) | Quinolizinone compound, its preparation, and drug composition containing it | |
| CA1201436A (en) | Diamino isothiazole-1-oxides and -1,1- dioxides as gastric secretion inhibitors | |
| WO1993001184A1 (en) | Imidazoles inhibitors as acat and thromboxane txa2 | |
| JPS62135473A (en) | Condensed heterocyclic imidazole compound | |
| KR800000851B1 (en) | Process for preparing thiazolo(3,4-b)isoquinoline derivatives | |
| JPH10120681A (en) | New azaindole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |